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Strange is our situation here upon Earth. Each of us comes for a short visit, not knowing why, 
yet sometimes seeming to a divine purpose. From the standpoint of daily life, however, there 
is one thing we do know: that man is here for the sake of other men…for the countless 
unknown souls with whose fate we are connected by a bond of sympathy. Many times a day I 
realize how much my own outer and inner life is built upon the labors of my fellowmen, both 
living and dead, and how earnestly I must exert myself in order to  
give in return as much as I have received. 
-Albert Einstein 
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STATEMENT OF DISSERTATION 
 
My doctoral research has focused on (i) using organocatalysis to prepare 
enantioenriched pharmaceutically relevant scaffolds and (ii) preparing isoenzyme 
selective inhibitors of phospholipase D. My training has mainly focused on the synthetic 
aspects of the projects that are presented. While I had a part in analysis of the assays 
performed with the different compounds, I did not perform the assays myself. 
(i) Methodologies for asymmetric chlorination and fluorination of aldehydes have recently 
been reported; the potential of such building blocks in organic synthesis, however, were yet 
be exploited.
1–4
 A main project of mine was to fully unveil the synthetic potential of 
enantioenriched chlorinated and fluorinated aldehydes or alcohols as chiral building blocks 
toward the synthesis of various pharmaceutically relevant scaffolds. Morpholines, 
piperazines, azetidines, and aziridines are biologically relevant scaffolds and are often used 
as important synthetic intermediates. These scaffolds, however, are often difficult to prepare 
in enantioenriched form. 
By utilizing 
organocatalysis to arrive at 
chiral β-chloro alcohols, I 
was able to generate all of 
these scaffolds through a 
novel and facile manifold 
of reactions in good overall 
yields and excellent 
xxv 
 
enantiomeric excess (Fig. I).
5–7
 Importantly, these synthetic methods provide access to these 
enantioenriched scaffolds from achiral aldehydes, of which hundreds are commercially 
available. In a similar vein, I found that organocatalytic asymmetric fluorination methods 
provide access to fluoro-aldehydes from achiral aldehydes. Fluorination is a common method 
used to improve a compounds metabolic stability, bioavailability, ancillary pharmacology 
profile, protein-ligand interactions, and CNS exposure.
8–10
 Using organocatalysis to generate 
enantioenriched β-fluoro alcohols, I was able to utilize a general reaction pathway towards 
chiral fluorinated scaffolds of pharmaceutical relevance (Fig. I).
11
  Of note, the chiral 
fluorinated scaffolds would have previously been accessed through alternate chemistry that is 
frequently plagued with low yields, rearrangements, and dehydration products. Our method 
offers a considerable advantage compared to past literature precedent. 
 
(ii) Phospholipase D (PLD)—an enzyme that catalyzes the hydrolysis of phosphatidyl 
choline to phosphatidic acid (PA)—has two mammalian isoforms that share 53% sequence 
homology. PA is a lipid second messenger involved in various signaling cascades. Aberrant 
PLD activity—and atypical PA concentrations—have been implicated in a number of human 
diseases.
12
 Until recently, there were no ways to chemically modulate either PLD isoenzyme 
selectively; therefore, it was difficult to distinguish between phenotypes driven by aberrant 
PLD1 or PLD2 activity. Prior to my work, a highly potent and selective PLD1 inhibitor was 
discovered in the Lindsley lab,
13,14
 but PLD2 inhibitors with enhanced selectivity profiles 
remained highly desirable.
15,16
 Therefore, I spearheaded a medicinal chemistry campaign to 
discover selective PLD2 inhibitors with improved physiochemical and DMPK properties. 
This effort produced compounds with enhanced potency and selectivity.
17
 Moreover, a key 
xxvi 
 
stereocenter was identified during the process that immensely increases PLD1 potency with 
IC50 amplifications of 200 to 590-fold (Fig. II). Modifications to incorporate a pyridyl group 
delivered the most selective PLD2 inhibitor, and the 
scaffold was found to have significantly improved in 
vivo properties compared to previous compounds (Fig. 
II).
18
 These lead compounds were screened in a wide 
range of in vitro anticancer and antiviral assays and 
were found to significantly affect pathogenic 
phenotypes. My compounds are now being applied to 
delineate the role of PLD2 function in various disease 
states. 
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CHAPTER I 
 
APPLICATION OF ORGANOCATALYSIS TO THE SYNTHESIS OF CHIRAL 
MORPHOLINES, PIPERAZINES, AZIRIDINES, AZETIDINES,  
β-FLUOROAMINES, AND γ-FLUOROAMINES 
 
1.1 Access to chiral, C2-functionalized morpholines and piperazines from prochiral 
aldehydes using organocatalysis 
1.1.1 Privileged structures in drug discovery 
Throughout the process of modern drug discovery, a key observation was made 
involving different chemical scaffolds. While some small molecule chemotypes were found 
to be highly selective for a single target of interest, other scaffold types were promiscuous. In 
essence, compounds derived from promiscuous scaffolds were not always active on a single 
biological target; instead, compound libraries derived from promiscuous scaffolds were 
capable of acting as ligands for a diverse array of biological targets. These promiscuous 
scaffolds were termed “privileged structures” by Evans in the late 1980s,1 and while the 
initial work dealt solely with the benzodiazepine scaffold, that work has expanded to a large 
assortment of small organic molecules that have been validated as privileged structures.
2,3
 
Privileged structures are widely utilized in the drug discovery process because while the core 
of the privileged structure provides activity at a range of biological targets, substitution to the 
scaffold can enable selective activity at targets of therapeutic relevance.
2,3
 For instance, 
piperazine 1.1—a frequently utilized privileged structure—can be elaborated to Dropropizine 
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1.2, Fleroxacin 1.3, or Mepiprazole 1.4, showing the piperazine privileged structure to induce 
antitussive, antibacterial, and tranquilizer effects respectively (Figure 1.1.1.1). 
  
If the Molecular Design Limited Drug Data Report (MDDR), a database containing 
biologically active compounds from the journal and patent literature, is consulted, it provides 
additional evidence for the idea of privileged structures. For piperazines specifically, the 
database found 2,271 N-aryl piperazine scaffolds with broad bioactive properties. This 
expansive set of piperazine molecules includes 16 FDA approved pharmaceuticals and 23 
piperazines in phase II or III clinical trials.
4
 Compounds derived from this privileged 
structure cover 18 therapeutic indications, showing the piperazine moiety to be active at a 
wide range of therapeutic targets. One additional advantage of utilizing privileged structures 
in the search for novel drugs and probe compounds involves their validated in vivo 
properties. Essentially, since privileged structures are a key moiety in a large number of 
approved drugs, that illustrates their chemotypes have the inherent physical properties 
biasing them towards optimal compound absorption, distribution, and circulation, which will 
likely provide these molecules access to the desired biological target of interest. 
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Since compounds based on privileged structures can be biologically active at more 
than one target, it is important that chemists have the synthetic means of providing these 
molecules with any desired molecular framework. Indeed, synthetic means of selectively 
accessing different enantiomers, diastereomers, or regioisomers of the desired compounds are 
necessary to make the promiscuous privileged structure selective for the target of interest. 
Morpholines and piperazines are two privileged structures that, despite their presence in a 
large assortment of approved pharmaceuticals, lack a general asymmetric approach for 
synthesis. A considerable portion of my dissertation involved developing a common 
approach to synthesize chiral, C2-functionalized morpholines and piperazines from prochiral 
aldehydes.  
1.1.2 Biological significance of morpholines and piperazines 
Morpholines and piperazines are 6-membered heterocycles with either an oxygen or 
nitrogen in the 1 and 4 positions of the ring (Figure 1.1.2.1). The biological activity of 
morpholine and piperazine based scaffolds is extremely diverse;
4,5
 an incomplete sampling of 
their pharmaceutical applications show morpholines and piperazines to be a key chemical 
moiety in antidepressants 1.5,
6
 antibiotics 1.6,
7
 antipsychotics 1.7,
8
 anticancer agents 1.8,
9
 
and antihypertensive agents 1.9 (Figure 1.1.2.1)
10
. 
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While Figure 1.1.2.1 shows examples of biologically active chiral, carbon substituted 
morpholines and piperazines, this class of privileged structures is underrepresented in 
approved drugs. In fact, FDA approved morpholine and piperazine containing compounds 
are almost entirely restricted to those substituted only at the heteroatoms. These FDA 
approved drugs are mainly achiral, therefore, and this stems partially from the difficulty 
related to preparing these carbon substituted morpholines and piperazines as single 
enantiomers. Indeed, the patent literature is rife with carbon substituted morpholine and 
piperazine scaffolds synthesized, biologically tested, and patented as racemic mixtures.
11–13
 
This deficiency illustrates the need for novel synthetic methods of preparing morpholine and 
piperazine scaffolds as single enantiomers. 
1.1.3 Synthetic precedent for carbon substituted morpholines 
This section details the most successful synthetic methods to access chiral 
morpholines. When considering morpholines retrosynthetically, disconnections result 
between the heteroatoms and the neighboring carbons of the ring. Three possibilities result 
from these disconnections providing (i) an aminoalcohol and a bifunctional electrophile, (ii) 
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amine and alcohol functional groups each containing embedded electrophiles, or (iii) a 
monosubstituted amine and a bifunctional electrophile containing an ether (Figure 1.1.3.1).  
 
To synthesize morpholines as a single enantiomer, retrosynthetic disconnection (i) is the 
most common. Indeed, chiral aminoalcohols are frequently commercially available since they 
can be easily derived from chiral pool reagents. All amino acids are aminoalcohol precursors 
after simple synthetic manipulations, so the field has taken advantage of the chiral pool when 
in need of chiral morpholines. This approach, however, limits the supply of chiral 
morpholines since they must be derived from available chiral aminoalcohols. An approach 
not reliant on the chiral pool, therefore, would be advantageous. 
The most useful method based on retrosynthetic disconnection (i) was developed in 
2008 by Aggarwal and coworkers.
14
 They developed a vinyl diphenyl sulfonium triflate salt 
that reacts with aminoalcohols to generate morpholines in excellent yields. To generate the 
salt, they performed a substitution reaction with diphenyl sulfide and the bromo 
trifluoromethanesulfonate 1.10.  With bromide salt 1.11 in hand, an elimination reaction 
afforded the vinyl diphenyl sulfonium triflate salt 1.12, which is the reactive species driving 
their morpholine forming method (Scheme 1.1.3.1A). With that reactive specie in hand, 
chiral aminoalcohols 1.13 were added to the vinyl diphenyl sulfonium triflate salt 1.12 to 
form morpholines 1.14 through an annulation reaction (Scheme 1.1.3.1B).  
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Mechanistically, the diphenyl sulfonium triflate salt is proposed to act as a Michael acceptor 
while the disubstituted amine adds as a nucleophile to the β-position. This forms an ylide 
which takes part in a proton transfer with the hydroxyl group. That hydroxyl anion can then 
nucleophilically displace diphenyl sulfide by way of an intramolecular backside attack, 
forming the morpholine product as a result (Scheme 1.1.3.2). 
 
One of the subtle drawbacks of this method was the instability of the vinyl diphenyl 
sulfonium triflate salt 1.12. It is sensitive to decomposition, especially on large scale. To 
remove this liability, Aggarwal and coworkers improved their method to utilize the bromide 
salt 1.11—a stable crystalline compound—in the morpholine forming reaction. They 
substitute sodium hydride for triethylamine in the last step of their sequence, which facilitates 
elimination to the vinyl diphenyl sulfonium triflate salt 1.12 in situ prior to the aminoalcohol 
annulation.
15
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While this method employing the vinyl diphenyl sulfonium triflate salt has been 
widely utilized to efficiently prepare morpholines, it lacks any asymmetric steps. Preparation 
of an enantioenriched morpholine, therefore, relies on the ability to obtain it from the chiral 
pool. This limits the broad accessibility of morpholine substrates to what one can find 
commercially, which is the major liability of this successful method.  
Myers and coworkers utilized retrosynthetic disconnection (ii) while accessing 
morpholines.
16
 Following those disconnection, they envisioned access to chiral morpholines 
using a chiral epoxide and aminoalcohol after various synthetic manipulations (Figure 
1.1.3.2). 
 
To bring this envisioned route to fruition, chiral epoxide 1.15 was nucleophilically opened by 
alanine derived chiral aminoalcohol 1.16 to furnish diol 1.17 in 99% yield. The amine had to 
be protected with a tosyl group to eliminate unwanted reactions in future steps, and this 
synthetic manipulation afforded the tosyl trisubstituted amine 1.18 in 77% yield. Sodium 
hydride and tosyl imidazole was then utilized to promote sulfonylation of the primary alcohol 
and displacement of that tosyl leaving group with the chiral secondary alcohol to provide 
morpholine 1.19 in near quantitative yield. Removal of the tosyl group was then enacted with 
sodium in liquid ammonia to provide the desired, unprotected, chiral morpholine 1.20 in 
quantitative yield (Scheme 1.1.3.3).
16
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While this method provided chiral morpholine 1.20 in an excellent 75% overall yield, there 
were some deficiencies when the reactions were utilized with different substrates. 
Specifically, when the reaction sequence was attempted with phenyl or benzyl substituted 
aminoalcohols, it was ineffective and modifications to the route were necessary to provide 
the corresponding morpholines. Even with the route modifications, the morpholine substrates 
were still prepared in high overall yield; however, the method cannot be considered general if 
it needs to be modified for substrates with slight modifications and only three morpholine 
substrates were synthesized in the letter. Additionally, this method does not generate 
asymmetry since all the chirality in the product morpholine is derived from the chiral epoxide 
and chiral aminoalcohol. Akin to the method using the vinyl diphenyl sulfonium triflate salt, 
this method is dependent on the chiral pool of reagents and/or methods to obtain chiral 
epoxides. With the limitations noted, this powerful method generates morpholines in high 
yields with preservation of chirality, enabling access to optically active morpholines.
16
 
 Retrosynthetic disconnection (iii) is least common among methods to generate 
morpholines, but it is possible to use sugar derivatives and primary amines to generate chiral 
morpholines. Overhand and coworkers utilized D-ribose to arrive at the elaborated azido 
acetal starting material 1.21 in 57% overall yield. At that stage, they cleaved the acetal with 
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hydrochloric acid in 82% yield, and cleaved diol 1.22 to dial 1.23 in 95% yield, which was in 
equilibrium with the hemiacetal 1.24. This species underwent a double reductive amination 
with an assortment of primary amines to fashion morpholine type 1.25 in poor to moderate 
yields.
17
 This reaction manifold can tolerate various sugar starting materials and amines, 
providing access to various morpholines through this reaction pathway (Scheme 1.1.3.4).  
 
This method suffers from a number of shortcomings. Low yields in the final step make this 
approach difficult to generate large quantities of the morpholines, and the approach requires 
more steps when compared to other existing methods. This reaction pathway—and all 
methods reviewed—rely heavily on the chiral pool. Therefore, the substitution pattern and 
absolute configuration is determined at the outset by the commercially available chiral 
sugars. 
 It is clear that a common method of accessing carbon substituted optically active 
morpholines would be advantageous for synthetic chemists. The methods highlighted are 
state of the art, but it is obvious that they share a common deficiency. Namely, they all rely 
on optically active precursors to provide the chiral building blocks that will lead to chiral 
morpholines. Additionally, most of these methods are solely for morpholines (Aggarwal and 
coworkers showed their method can be applied to piperazines
14
), and it would be 
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advantageous to have a common method to apply for both morpholines and piperazines, 
since these types of scaffold are privileged structures known to have diverse biological 
activities. Before detailing our progress making common methods to synthesize morpholines 
and piperazines, a short discussion of known methods of chiral piperazine synthesis will be 
discussed.  
1.1.4 Synthetic precedent for carbon substituted piperazines 
Just as the methods for chiral morpholine synthesis largely rely on the chiral pool, the 
same pattern holds true for chiral piperazine synthesis. Essentially every method that makes 
carbon functionalized piperazines use precursors from the chiral pool. Additionally, 
piperazine synthesis frequently uses amino acids and results in diketopiperazines. If the 
piperazine is desired, therefore, the diketopiperazines must undergo additional functional 
group interconversions that can complicate synthesis. The most common, state of the art, and 
relevant methods of piperazine synthesis will be explored.  
The Ugi reaction is a one pot, four component reaction utilizing an acid, aldehyde, 
amine, and isonitrile. This method has been employed to make diverse libraries of 
diketopiperazines since any of the four components can be altered to yield a different 
reaction product. Campbell and coworkers used a resin to make this reaction sequence 
extraordinarily facile.
18
 The amine 1.26 was coupled to an insoluble resin, and through 
sequential addition of the aldehyde 1.27, isonitrile 1.28, and acid 1.29, Boc protected amine 
1.30 is produced. This acyclic substrate was treated with acid to cleave the Boc group, and 
refluxing in toluene allowed for cyclization with concomitant cleavage from the resin to form 
diketopiperazines 1.31 (Scheme 1.1.4.1). 
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This procedure allows access to chiral diketopiperazines that could be further reduced to 
form piperazines. Unfortunately, this—and essentially all Ugi processes—result in mixtures 
of stereoisomers. Different Ugi reaction protocols have been created to access many types of 
diketopiperazines, 
19–21
 but any enantioenrichment is a result of using chiral pool reagents, 
which limits the scope of these methods. 
 An additional method by Husson and coworkers makes use of a chiral auxiliary to 
ultimately obtain an enantioenriched piperazine. The ketopiperazine, with the chiral auxiliary 
on the amide nitrogen, is deprotonated to form an enolate, which can alkylate in high 
diastereomeric excess.
22
 To synthesize the ketopiperazines to be used in asymmetric C-
alkylation, chiral aminoalcohol 1.32 and Boc-glycine 1.33 were coupled using standard 
amide coupling conditions in 95% yield to obtain amide 1.34. The amide was reduced to a 
disubstituted amine and the alcohol was protected as silyl ether 1.35 in 70% yield. 
Bromoacetic acid was coupled to disubstituted amine 1.35 to obtain trisubstituted amine 1.36 
in 80% yield, and the material was subjected to a base induced cyclization and silyl ether 
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cleavage to afford ketopiperazines 1.37 in 64% yield, which is the substrate for the 
asymmetric C-alkylation. The enolate was formed with 
t
BuLi, and it was reacted with methyl 
iodide, benzyl bromide, and allyl bromide forming those chiral ketopiperazines 1.38 in yields 
from 60-80% and all greater than 95:5 dr (Scheme 1.1.4.2).  
 
Chiral ketopiperazines 1.38 are essentially differentially protected since the chiral auxiliary 
can be removed under reductive conditions and the Boc group can be removed with acid. 
Reduction of the amide would provide the chiral piperazine, an elusive chiral privileged 
structure. Unfortunately, this method is not without its deficiencies. It cannot be considered 
general since only three substrates were made, and the product must be modified reductively 
to arrive at the chiral piperazine. Additionally, a method would be desirable that required far 
less forcing conditions in the last step. With all of those considerations stated, this is a viable 
route to a number of enantioenriched piperazines following chiral auxiliary cleavage. 
 While the previous method allows for enantioenriched material to be prepared, a 
number of groups have applied a palladium catalyzed carboamination reaction to rapidly 
prepare piperazines in high dr.
23,24
 Wolfe and coworkers begin with chiral Boc-amino acids 
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1.39 and couple disubstituted allyl amines, reducing the resultant amide to the diamine 1.40 
in moderate yields. The Boc group is cleaved with acid and the amine is coupled to an aryl 
group under Buchwald-Hartwig conditions to furnish the aniline 1.41 in moderate yields.  A 
final diastereoselective carboamination reaction with migratory insertion into the alkene 
provided cis-piperazine 1.42 in excellent dr (Scheme 1.1.4.3).   
 
This approach is limited by the substituents that are necessary in each position, and it can 
only make cis-disubstituted N-aryl piperazines. The final configuration, once again, is set by 
the stereocenter present in the chiral starting materials. We can consider this approach, 
therefore, reliant on the chiral pool to induce its desired stereochemistry.  
 An additional carboamination approach was discovered by Michael and coworkers. 
Unlike the chemistry above resulting in favored diequatorial stereochemistry, this 
carboamination chemistry results in axial and equatorial substituents.
24
 Opening of 
sulfamidate 1.43 with allylamine and cleavage of the sulfamic acid provided diamine 1.44 in 
good yields. Similar to the previous method, palladium mediated hydroamination—using 
these specific protecting groups—provides the trans disubstituted piperazine 1.45 in 
excellent yield and good to excellent diastereoselectivity (Scheme 1.1.4.4).  
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A crystal structure was procured of the trans-dimethyl piperazine, and it had adopted the 
twist-boat conformation. While this conformation is usually disfavored in a cyclohexane by 
5.3 kcal/mol,
25
 that value would be slightly less for a piperazine with partially sp
2
 hybridized 
heteroatoms as part of the ring system. Additionally, the Cbz protecting group experiences 
allylic strain with the methyl groups in the chair conformation, shifting the equilibrium 
toward the more favorable twist-boat (Figure 1.1.4.1).  
 
While this additional method of synthesizing piperazines increases the substrate scope 
available using current methods, it also relies on the chiral pool to generate its 
diastereoselectivity, and its substrate scope is limited.
24
  
 All things considered, there are available methods to obtain piperazines, but they all 
rely on either the chiral pool or chiral auxiliaries to drive their stereoselectivity.
26–30
 We can 
clearly state, therefore, that various methods exist to access both morpholines and piperazines 
in the literature.  The precedent for forming these privileged structures, however, is limited to 
specific substitution patterns and is fragmented into discrete methodologies to access either 
morpholines or piperazines using the chiral pool. Thus, we determined this area was ripe for 
15 
 
the development of a general new methodology with a unified approach toward chiral 
morpholines and piperazines starting from achiral materials. 
1.1.5 Envisioned rationale to access chiral morpholines and piperazines 
The Jørgensen and MacMillan groups concurrently discovered an organocatalytic 
method to asymmetrically chlorinate aldehydes.
31,32
 The research groups used different small 
molecule amine containing organic catalysts that could be used substoichiometrically. These 
amines work by condensing on the aldehyde to form an enamine, which enantioselectively 
chlorinates by way of electrophilic chloride sources, and hydrolysis of the organocatalyst 
imine provides the free catalyst and the α-chloro aldehyde (Figure 1.1.5.1A). This reaction 
system is clean and efficient yielding the chloroaldehyde product in high yield and excellent 
enantiomeric excess (ee). Lindsley and coworkers applied the α-chlorination technology 
while developing a one-pot synthesis of aziridines (Figure 1.1.5.1B).
33
 Their method utilizes 
 
the α-chloroaldehyde as a bifunctional electrophile. In the method, a monosubstituted amine 
undergoes a reductive amination with the aldehyde functionality followed by a stereospecific 
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backside intramolecular displacement inverting the stereocenter. This reaction cascade 
delivered aziridines in good overall yields and moderate to excellent enantioselectivity.
33
  
 While considering the asymmetric synthesis of morpholines and piperazines from 
achiral precursors, we reasoned the α-chloroaldehyde could be used as a chiral bifunctional 
electrophile that could be reacted with aminoalcohols or diamines to fashion C-
functionalized morpholines and piperazines (Scheme 1.1.5.1A). Indeed, we envisioned 
enantioselectively chlorinating achiral aldehydes 1.46 using diphenylpyrrolidine catalyst 1.47 
to arrive at α-chloroaldehydes 1.48. An aminoalcohol or diamine would be used to perform a 
chemoselective reductive amination fashioning β-chloro aminoalcohols or β-chloro diamines 
1.49. Next, we would develop conditions to facilitate the 6-exo-tet cyclization providing the 
desired chiral morpholines or piperazines 1.50 (Scheme 1.1.5.1B). 
 
We determined this route to be desirable and advantageous compared to state of the art 
methods because (i) morpholines and piperazines could be synthesized following a common 
method, (ii) chiral precursors are not necessary to fashion enantioenriched morpholines and 
piperazines since any achiral aldehyde can be used, and (iii) an organocatalytic approach is 
favorable compared to approaches utilizing chiral auxiliaries or the chiral pool.  
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1.1.6 General access to chiral C2 substituted morpholines and piperazines—1st 
generation method 
To follow our envisioned method for access to chiral C2 substituted morpholines and 
piperazines, we began the reaction sequence using a racemic proline catalyst. Racemic 
proline facilitated the aldehyde chlorination giving a racemic mixture of the α-
chloroaldehyde, which was used in subsequent reactions to validate the reaction pathway. 
Additionally, the racemic compound allowed chiral separatory conditions to be discovered 
using chiral supercritical fluid chromatography (SFC), which were necessary for later 
determinations of % ee. Since our lab was able to utilize a similar reaction pathway to 
synthesize chiral aziridines in a one pot protocol only requiring purification at the last step,
33
 
we began these studies attempting to generate conditions where only a single purification 
step was necessary. We began our studies with dodecanal 1.51, which was chlorinated with 
DL-proline and N-chlorosuccinimide in DCM (Scheme 1.1.6.1). Addition of pentanes and 
cold filtration provided the racemic α-chloroaldehyde 1.52 in relatively high purity, which 
was subjected to reductive amination conditions developed for the aziridine chemistry.
33
 
After workup, the reductive amination product was subjected to basic cyclization conditions 
in polar aprotic solvents to furnish morpholine 1.53. 
 
While isolation of product morpholine 1.53 from the reaction sequence was encouraging, 
significant optimization was necessary to improve the 11% overall yield. At this point, effort 
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transitioned to analysis of each step in the reaction sequence to potentially improve the 
overall yield.  
 Regarding the asymmetric chlorination step of the reaction sequence, our research 
group spent great effort extensively screening organocatalysts to ensure that the diphenyl 
pyrrolidine catalyst was ideal.
33
 To ensure that the use of racemic proline was not responsible 
for the low overall yield, 5-phenyl pentanal 1.54 was chlorinated under standard reaction 
conditions using DL-proline. Following the aforementioned cold pentanes wash and 
filtration, which removed insoluble succinimide and proline, we found that the α-
chloroaldehyde 1.55 was produced in 90% yield and was effectively pure for successive 
reactions (Scheme 1.1.6.2).  
 
 Moving our efforts to examine the reductive amination of the chloroaldehyde, we 
found that analysis of the reaction by TLC and 
1
H NMR showed complete consumption of 
the starting material. Upon aqueous workup and column chromatography, however, an 
excess of 30% of the starting material aldehyde was isolated. Since consumption of the 
chloroaldehyde was observed using 
1
H NMR, through disappearance of the characteristic 
aldehyde peak, we reasoned that it must be temporarily transformed into a chemical species 
distinct by TLC and 
1
H NMR analysis. The aldehyde, therefore, could be reformed from this 
distinct species during the process of aqueous workup and flash column chromatography. We 
proposed that the presumed iminium ion 1.56 that forms in the first step of the reaction could 
have two simultaneous mechanistic pathways, one of which would act to mask the aldehyde 
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as a different functionality. Essentially, the expected pathway consists of a hydride from 
sodium triacetoxyborohydride adding to the iminium ion to provide the desired β-chloro 
aminoalcohol 1.57. The undesirable pathway, we proposed, involved the tethered ethanol 
moiety acting as a latent nucleophile, which could add to the iminium ion to form 
oxazolidine 1.58. This reaction pathway was confirmed by 
1
H NMR of the crude material. 
The oxazolidine proton, indicated in Scheme 1.1.6.3, was observed as doublets, consistent 
with the described theory.  
 
 Since greater than 30% of our material was being shuttled to the oxazolidine during 
this reaction, alternative strategies or conditions were necessary to circumvent this problem.  
Two approaches were pursued to prevent formation of the oxazolidine. Silyl ether protection 
of ethanolamine’s alcohol functionality would render the alcohol unreactive towards 
nucleophilic addition; therefore, the reductive amination was performed with TBS protected 
ethanolamine. Treatment of the silyl ether 1.59 with TBAF facilitated cleavage of the TBS 
group, affording the β-chloro aminoalcohol 1.60 in 45-65% yield over three steps from the 
aldehyde 1.46 (Scheme 1.1.6.4). While we were satisfied with the improved yield using the 
silyl protecting group, we also decided to seek alternative reductive amination conditions to 
obtain protecting group free conditions. In essence, we reasoned that oxazolidine byproduct 
1.61 is in equilibrium with the iminium ion precursor 1.62. If we could find conditions to 
catalyze the interconversion between these species, therefore, the iminium ion form should 
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be trapped by hydride addition. If this was the case, the reaction should be driven to 
completion as hydride addition reduces the iminium ion/oxazolidine species to the β-chloro 
aminoalcohol 1.60.   After exhaustively screening conditions, sodium cyanoborohydride and 
acetic acid in THF was found to facilitate this transformation protecting group free in 
comparable yields, and the two step protocol was advantageous because it removed the 
previously necessary silyl cleavage step (Scheme 1.1.6.4). With the ideal reductive 
amination conditions in hand, efforts turned toward optimization of the cyclization 
transformation. 
 
 Considering the final cyclization step toward morpholines, the original conditions 
(KO
t
Bu, DMF, rt) led to full consumption of the starting material, but appreciable 
decomposition was noted. Before screening other conditions, we thought it prudent to 
examine those original conditions to determine what side products were forming. After 
examining the 
1
H NMR of the crude material following aqueous workup, we observed a 
considerable amount of aldehyde. Because no aldehyde is present throughout the desired 
reaction, we considered side reactions that could produce aldehydes given the known 
reaction conditions (Scheme 1.1.6.5). We rationalized that a common reaction competing 
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with substitution is elimination, and deprotonating the hydrogen vicinal to the trisubstituted 
amine 1.60 to eliminate chloride forms an enamine 1.63. Consequently, enamine 1.63 can 
protonate upon aqueous workup to form iminium ion 1.64, which can hydrolyze to form 
aldehyde 1.46 and N-benzyl ethanolamine. This undesired reaction pathway explains the 
observed aldehyde, and by measuring the molar quantity of aldehyde formed we determined 
that greater than 30% of the starting material was shunted into this undesired reaction 
pathway. 
 
After extensively screening bases, solvents, and temperatures, we determined the optimal 
cyclization conditions to be five molar equivalents of KO
t
Bu in acetonitrile at -20 ⁰C.  
 We applied the optimized set of conditions to a limited substrate scope. The 
conditions successful converted achiral aldehydes into C2 substituted morpholines in 
moderate to excellent enantioselectivity (Scheme 1.1.6.6). Oddly, the racemic analogs had 
uniformly higher yields than their asymmetric cohorts. This may have been due to the initial 
chlorination being lower yielding.  Moreover, the pentane wash was not as effective at 
removing the chiral catalyst compared to proline from the reaction. The diphenylpyrrolidine 
catalyst, therefore, could have competed in the reductive amination or caused other unwanted 
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side reactions. These issues aside, we were able to successfully convert achiral starting 
materials into chiral morpholines using this easy three step method.
34
 
 
With this reaction sequence in hand, efforts now focused on applying it to the synthesis of 
chiral piperazines.  
  To apply the conditions developed for morpholines to piperazine synthesis, the ideal 
diamine source had to be chosen for the reductive amination, cyclization sequence. Related 
to that diamine choice, the final piperazine product, if synthesized for a medicinal chemistry 
project, may need to be derivatized on the differential amine components. To form a 
piperazine where further chemistry can be performed on the nitrogen atom of choice, the 
final piperazine—arising from the diamine—needs to be differentially protected, such that 
each protecting group can be removed selectively. To that end, ethylene diamine with Boc 
and benzyl protecting groups would allow for selective protecting group cleavage with acidic 
or reductive conditions respectively. This allows the piperazine products to take part in 
library synthesis with controlled access to either amine (Figure 1.1.6.1) 
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. 
This diamine protecting group strategy distinguishes the amines by varying their 
nucleophilicity. Since the Boc protected amine has sp
2
 character, it is less nucleophilic than 
the benzyl amine. This discrepancy in nucleophilicity allows the benzyl amine to participate 
chemoselectively in the reductive amination step without side reactions caused by the Boc 
amine. This permits the original reductive amination conditions to be utilized instead of the 
modified conditions used during morpholine synthesis. Using dodecanal 1.51 in the reaction 
protocol without column chromatography until piperazine 1.66, we observed formation of the 
β-chloro diamine 1.67 by LC-MS, but the basic cyclization conditions optimized for 
morpholine synthesis were ineffective for piperazine synthesis (Scheme 1.1.6.7).  
 
While it would have been advantageous to have a single set of conditions for both 
morpholine and piperazine synthesis, it is not surprising that the cyclization of the Boc amine 
required different conditions compared to a hydroxyl group.  
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 While we considered cleaving the Boc group prior to cyclization, which we reasoned 
would increase the nucleophilicity of the amine, potentially facilitating an in situ cyclization, 
we first screened cyclization conditions with the intact Boc amine. By simply varying the 
base and solvent, we found that changing from acetonitrile to DMF facilitated full conversion 
of the starting material (Table 1.1.6.1).  
 
Through further optimization efforts, the best conditions were determined to be 5 equivalents 
of KO
t
Bu in DMF at -20 ⁰C. 
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 With ideal conditions in hand, the method was applied to several piperazine analogs 
(Scheme 1.1.6.8). The yields for the three step method of forming piperazines were 
uniformly better than for their analogous morpholines. 
 
This new methodology presents a unified approach toward both morpholines and piperazines 
and generates these scaffolds in moderate to excellent % ee.  While the conditions to 
synthesize morpholines and piperazines are not exact, the method only varies (i) the hydride 
source and solvent in the reductive amination step and (ii) the solvent during the cyclization 
step. Importantly, the method allows highly enantioenriched chiral morpholines and 
piperazines to be synthesized from achiral aldehydes.  
1.1.7 1st generation method review 
After considering the state of the art methods to access morpholines and piperazines, 
we knew improvements could be made by developing a method that (i) did not rely on the 
chiral pool, (ii) did not utilize chiral auxiliaries, and (iii) was broadly applicable to 
morpholines and piperazines. Fortunately, since the method allowed chiral morpholines and 
piperazines to be synthesized from readily available achiral aldehydes, all of these conditions 
were met.
34
 Additionally, the new method provided morpholines and piperazines with 
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handles that gave easy access to further derivatization. Cleavage of the benzyl or Boc 
protecting groups on either morpholines or piperazines could be performed in near 
quantitative yields, which provides easy access to library synthesis. With those clearly 
advantageous attributes of the new method noted, there were also numerous weaknesses. 
While the reaction cascade could be scaled up to generate gram quantities of the morpholines 
or piperazines, the 26% average overall yield was suboptimal. Moreover, variable 
enantioselectivity was a formidable problem. We attributed the variability to the acidity of 
the α-chloroaldehyde’s α-proton, which is deprotonated during the keto/enol tautomerization, 
destroying the newly formed stereocenter. And finally, synthetic methods are best—and most 
often employed—when they lack extreme temperatures and long reaction times. Running the 
reductive amination at -78 ⁰C overnight made this reaction sequence less desirable. 
Therefore, while we saw this method as a success that could be directly implemented in 
industry to generate molecular diversity in a hit-to-lead campaign, we knew that there were 
improvements that could be realized. 
1.1.8 General access to chiral C2 substituted morpholines and piperazines—2nd  
generation method 
To address the variable enantioselectivity of our previous method, we had to 
determine what was causing the problem. Based on literature precedent,
32
 we knew that the 
chlorination was occurring in excellent enantioselectivity, but working with the 
chloroaldehyde resulted in decreased selectivity. We observed this while performing trials of 
our morpholine synthesis on the same substrate. Essentially, if the chloroaldehyde is not used 
immediately in the reductive amination, the % ee erodes. Experimentally, we have used 
dodecanal and made the resultant morpholine in 95% ee, but if α-chloro dodecanal is left at 
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room temperature for several hours we have observed the enantiomeric excess to decrease to 
55% (Figure 1.1.8.1).  We believed that excellent enantiomeric excess could be retained, 
therefore, that if the α-chloroaldehyde is simply used immediately after synthesis and kept at 
low temperatures. After performing the reaction sequence an additional four times with this 
experimental understanding, however, we observed the % ee to vary from 78-94% ee 
(Figure 1.1.8.1). 
 
To improve the method and remove the possibility for variable % ee, a modification 
to the reaction protocol was necessary. To address this issue while keeping the envisioned 
method in mind, we imagined modifying the α-chloro aldehyde to a different 
configurationally stable bifunctional electrophile (Figure 1.1.8.2). With this modification to 
the method, we could continue to use aminoalcohols or diamines to consecutively react with 
a single electrophilic unit.  
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 Following this synthetic plan, we reasoned that reduction of α-chloro aldehydes to 
alcohols would provide (i) a new molecular species that was configurationally stable and (ii) 
a functional group allowing for facile modification to a wide variety of leaving groups. Since 
methanesulfonyl chloride is widely used  to convert hydroxyl groups into leaving groups,
35
 
we reasoned that modification of β-chloro alcohols to β-chloro mesylates would provide a 
reactive intermediate capable of facilitating substitution reactions with aminoalcohols and/or 
diamines. To this end, dodecanal 1.51 was chlorinated, reduced to chloroalcohol 1.68, and 
reacted with MsCl to provide β-chloromesylate 1.69, which was stable to aqueous workup 
and column chromatography, in 80% overall yield (Scheme 1.1.8.1).  
 
We reasoned this species could be the bifunctional electrophile necessary to facilitate 
alkylation with either aminoalcohols or diamines, and various solvent systems and 
temperatures were screened to facilitate this transformation (Table 1.1.8.1). Unfortunately, 
the β-chloromesylate—under all conditions screened —did not deliver the desired product. It 
was either unreactive showing no reaction progress at room temperature or the material 
decomposed to a complex mixture of products when enough energy was applied. All things 
considered, since the β-chloro mesylate gave way to no desired products under classical 
alkylation conditions, we turned our efforts to the synthesis of other bifunctional 
electrophiles to slightly perturb the reactivity of the system.  
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 Transforming the β-chloroalcohol to β-chlorohalides retained the same reactivity 
patterns as the aforementioned β-chloromesylate. Therefore, we rationalized that a leaving 
group more reactive than the mesylate may be necessary to facilitate the desired reaction. By 
consulting the literature,
36
 we saw that while mesylate and tosylate leaving groups have 
similar reactivity rates in substitution reactions, a chloride is far slower and a 
trifluoromethanesulfonate (triflate) leaving group is far more reactive (Table 1.1.8.2).  Since 
halides and mesylates were not reactive enough for the desired substitution reaction with 
diamines, therefore, we reasoned that triflates may be suitable leaving groups to permit the 
desired reaction.  
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 Gratifyingly, we were able to develop a one-pot reaction to form the triflate from β-
chloroalcohols and displace the triflate in situ with either a differentially protected diamine or 
N-benzyl ethanolamine. At this point, the β-chloro aminoalcohols or β-chloro diamines were 
identical to those developed using the 1
st
 generation method, so base mediated cyclization 
was possible using the same conditions. To show the new methods utility—and superiority 
compared to the last method—we prepared several chiral β-chloroalcohols (Scheme 
1.1.8.2).
32,37
 Importantly, these chiral alcohols could be prepared from an enormous number 
of achiral readily available aldehydes. Treatment of these aldehydes 1.46 with the chiral 
organocatalyst 1.47 and electrophilic chlorine facilitated the transformation to the chiral α-
chloro aldehyde 1.48, and reduction of that aldehyde with NaBH4 provided the 
configurationally stable β-chloro alcohols 1.70 in good yields (72-83%) with excellent 
asymmetric induction. 
 
 With the chloroalcohols in hand, we applied the newly developed displacement 
conditions. Triflic anhydride was added to the chloroalcohols 1.70 with 2,6-lutidine in DCM 
at -78 ⁰C followed by the addition of either N-benzyl ethanolamine 1.71 or N-benzyl-N’-boc-
ethylenediamine 1.72, which were allowed to react overnight. These conditions facilitated β-
chloro triflate formation followed by chemoselective alkylation in a one pot protocol giving 
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way to β-chloro aminoalcohols 1.73 or β-chloro diamines 1.74 in moderate to good yield (63-
87%), delivering the intermediates one step away from chiral morpholines and piperazines 
(Scheme 1.1.8.3).  
 
 With substrates 1.73A-D and 1.74A-D in hand, we utilized our optimized cyclization 
conditions for morpholines (KO
t
Bu, MeCN, -20 ⁰C) and piperazines (KOtBu, DMF, -20 ⁰C) 
generating C2-functionalized, chiral morpholines 1.75A-D and piperazines 1.76A-D in 
uniformly greater overall yield and enantioselectivity compared to the 1
st
 generation method 
(Scheme 1.1.8.4).
34,37
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Importantly, no % ee variability (less than experimental error) existed for individual 
substrates, illustrating the α-chloro aldehyde to be responsible for the % ee inconsistency 
during the 1
st
 generation method. The only substrate where moderate enantioselectivity was 
problematic was the silyl ether morpholine and piperazine, and the lower % ee was due to the 
initial α-chlorination step, which was expected based on literature precedent.32,38 Regarding 
the overall yields, this new method generates morpholines in 35-46% overall yield, a 
considerable improvement compared to the 13-19% overall yield of the 1
st
 generation 
approach. The improvement for piperazines was also noteworthy with overall yields of 36-
60% compared to the 15-50% yields of the 1
st
 generation method.  
 To illustrate the synthetic relevance of our newly developed method, we looked into 
the patent literature for biologically active compounds that could be accessed through our 
synthetic manifold. A chiral C2-substituted morpholine 1.77—directly related to one of the 
compounds in our substrate scope—was reported to be a specific dopamine subtype 4 (D4) 
antagonist, which is a target of relevance for antipsychotic therapeutics. While the patent 
claimed a single enantiomer of 1.77 to be more active at D4, it did not disclose the absolute 
stereochemistry at C2. Ambiguous stereochemistry in the patent is likely the result of their 
racemic synthesis (Scheme 1.1.8.5). They began with racemic epoxide 1.78, which they 
opened with aminosulfate 1.79 to generate racemic morpholine 1.80 in 38% yield. Alkylation 
of the morpholine nitrogen with 2-chloromethyl benzimidazole 1.81 provided them racemic 
1.77, which was resolved into its two enantiomers using HPLC with a chiral column. This 
synthesis resulted in a less than 10% yield of their final enantioenriched material, and the 
final stereochemical information was unknown.  
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 We saw the unknown absolute configuration and low overall yield surrounding this 
D4 antagonist as an opportunity to showcase our new morpholine/piperazine method while 
also investigating these compounds for enantiospecific activity at D4. To do this, we utilized 
previously synthesized morpholine 1.75C, which contained the exact phenylethyl R-group 
that is a substituent of the D4 antagonist. By starting with this material, which was 
synthesized in 43% overall yield, we cleaved the benzyl group with hydrogenolysis and 
followed that with 2-chloromethyl benzimidazole alkylation of the morpholine to arrive at D4 
antagonist 1.77 in 35% overall yield and 98% ee—a significant improvement compared to 
the literature precedent (Scheme 1.1.8.6).  
 
 Fortunately, our method allowed us to prepare D4 antagonist 1.77 as the racemate and 
as each enantiomer so that they could each be tested for their activity at the different 
dopamine receptor subtypes. They were tested in a radio ligand binding assay where 1.77—if 
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it binds the receptor—will displace radioactive dopamine from the receptor. Displaced 
dopamine can be detected and quantified to calculate a binding constant (Ki) for the 
compound of interest. This assay showed the two enantiomers of 1.77 to be devoid of activity 
at D1 and D2 while being highly selective for D4 compared to D3. There is clear 
enantiospecific activity since S-1.77 is inactive at D4 and has extremely modest activity at D3, 
compared to R-1.77, which is twice as potent compared to the racemate at D4, indicating all 
of the racemate’s activity at D4 is coming solely from the R enantiomer. This data further 
underscores the power of our method to synthesize chiral, C2-functionalized morpholines 
and piperazines.  
 
 In summary, our 2
nd
 generation method to access chiral morpholines and piperazines 
circumvents many of the limitations of our initial approach. This novel route fills a void in 
the synthetic chemistry literature, giving us access to chiral morpholines and piperazines 
from achiral starting materials, while literature precedent always involves either the chiral 
pool or stoichiometric chiral auxiliaries. In essence, our 2
nd
 generation method is a three pot 
protocol allowing access to enantioenriched C2 substituted morpholines and piperazines, and 
it avoids the weaknesses of the 1
st
 generation approach. Namely, by modifying the reaction 
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protocol to reduce the α-chloro aldehyde to a β-chloroalcohol, the critical chloro stereocenter 
was rendered configurationally stable, which allowed us to avoid large deviations in % ee. 
Additionally, this reaction protocol increases the average overall yields from 26% to 45% 
and avoids long term extreme reaction conditions, since the previous reductive amination 
step was run at -78 ⁰C for greater than 16 hours. The notable advantage of our novel 
approach to morpholines and piperazines is illustrated in our synthesis of morpholine D4 
antagonist, and optimization of this scaffold for activity at D4 is currently underway in our 
laboratory 
1.2 General access to chiral β-fluoroamines and γ-fluoroamines from prochiral 
aldehydes using organocatalysis 
1.2.1 Fluorine in the pharmaceutical industry 
While 5-fluorouracil, the first fluorine containing drug, was discovered in 1957, 
fluorinating biologically active compounds did not become commonplace until the 1970s.
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Since that time, the unique qualities of organofluorine compounds have intrigued 
chemists,
40,41
 and fluorinating biologically active compounds to augment their biological and 
physical properties is now commonplace. In fact, 20-25% of compounds in the 
pharmaceutical pipeline,
42
 20% of approved drugs, and 30% of agrochemicals contain at least 
one fluorine atom.
43,44
 These fluorinated compounds are not isolated to treating specific 
disease states; instead, fluorine is an essential component of leading drugs targeting heart 
disease (atorvastatin, Lipitor),
44
 depression (fluoxetine, Prozac),
45
 cancer (fulvestrant, 
Faslodex),
46
 bacterial infection (ciprofloxacin, Ciprobay),
47
 and viral infection (efavirenz),
48
 
to name a few (Figure 1.2.1.1).  
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 Fluorine is often added to biologically active compounds to decrease ancillary 
pharmacology, block metabolic liabilities, increase bioavailability, and modulate 
protein:ligand interactions.
42,49
 It is possible to alternate fluorine for different atoms because 
the C-F bond is inert, and fluorine has a relatively small size. Fluorine is most commonly 
used to replace hydrogen atoms, hydroxyl groups, or the oxygen of carbonyls since fluorine’s 
atomic radius, the C-F bond length, and the bond polarity is comparable to a C-H or C-O.
50
  
Fluorine’s incorporation into molecules generally increases hydrophobicity, but fluorine is 
polar possessing the highest electronegativity value of all elements. The C-F bond is the 
strongest of all carbon single bonds; formation of the bond, therefore, is thermodynamically 
favorable.
43
  Table 1.2.1.1 displays atomic radii, electronegativity, bond length, and bond 
strength data for fluorine and atoms fluorine commonly replaces.
41
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1.2.2 Biological effects of organic fluorination 
 When a drug is introduced orally into the body, it must (i) be stable enough to 
survive the acidic environment in the stomach, (ii) have the necessary physical properties to 
be absorbed into the blood stream, (iii) have chemical characteristics providing for a 
reasonable half-life, (iv) have a limited number of off target effects rendering it safe, and (v) 
be potent and efficacious at its anticipated biological target to provoke the desired biological 
effect. Since the human body is xenophobic, attempting to rid itself of foreign substances for 
its own safety, designing a compound that meets all of these criteria is difficult. The drug 
discovery process, therefore, is based on a multidimensional optimization (MDO) 
approach.
40
 This means that potency, selectivity, and efficacy cannot be the only compound 
characteristics studied during the lead optimization process. Instead, physiochemical 
properties such as absorption, distribution, metabolism, excretion (ADME), and safety of the 
lead compounds must be considered equally compared to potency and efficacy while 
designing the molecule. Fortunately, fluorine chemistry has been a central instrument in the 
medicinal chemist’s toolbox to balance all of these properties in MDO.42,44,49,51 
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While practicing MDO for a cholesterol uptake inhibitor, scientists at Schering-
Plough had to consider how their lead compounds were metabolized.
52,53
 Generally, prior to 
compound elimination from the body, a class of enzymes called Cytochrome P450s oxidize 
the compound making it more water soluble and therefore easier to remove from the body. If 
oxidation by these enzymes can be prevented, it results in a longer half-life giving the 
compounds more time to affect their molecular targets. In this case, the scientists realized 
that their lead compound SCH 48461 was being metabolized too rapidly. By isolating the 
metabolites, they realized phenyl oxidation and methoxy demethylation were decreasing the 
half-life to unacceptable levels while other metabolites actually resulted in a more potent 
compound. To address the metabolites resulting in a low half-life, they substituted fluorine 
atoms in those positions—effectively blocking metabolism—while they pre-activated the 
metabolism resulting in benzylic oxidation and demethylation, which resulted in a more 
potent compound (Figure 1.2.2.1).  
 
This MDO process resulted in Ezetimib, which is an FDA approved drug that can be dosed 
at a fifty-five-fold lower dose than the previous lead compound.  
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 Many factors contribute to C-F bonds having low metabolic liabilities, and it has 
become common practice to substitute a fluorine atom onto a molecule to prevent 
metabolism. In the case of anti-inflammatory celecoxib (Celebrex), a lead compound 
contained both a trifluoromethyl group and a 4-fluorophenyl ring (Figure 1.2.2.2). While this 
compound was potent and efficacious, it suffered from an unusual problem. Most 
biologically active compounds to be used in vivo require intense effort to obtain a suitable 
half-life. Celecoxib’s precursor, however, had a half-life of 9 days, much longer than what is 
safe and desirable. To increase metabolism, therefore, they substituted a metabolically labile 
methyl group in the position of a fluorine atom (Figure 1.2.2.2), which decreased the half-
life of the FDA approved drug to a desirable 3.5 hours.
49,54
 This example illustrates the 
stability of the C-F bond to metabolism in vivo.   
 
Besides having an impact on metabolism, fluorine can have a significant impact on 
the binding interactions between the ligand and protein.
42,49
 The extra lipophilicity gained by 
replacing a hydrogen with a fluorine usually results in slightly increased binding affinity by 
way of nonspecific nonpolar interactions.
55
 Additionally, fluorine can take part in polar 
interactions with the amino acid backbone or negatively charged side chains of its binding 
partner. These interactions commonly result from C-F---C=O or C-F---H-N of the amino acid 
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backbone,
56
 and while they are not usually termed hydrogen bonds, they are strong 
interactions that can result in conformational changes within the binding pocket. In an 
attempt to discover novel serine protease inhibitors, Böhm and coworkers solved crystal 
structures of two compounds only differing in an aryl H or F (Figure 1.2.2.3).
49
 They found 
the two compounds to have different conformations, and they hypothesize this to be the 
result of the fluorine atom having a polar interaction with an N-H side chain. Importantly, the 
fluorinated congener was six times more potent than the des-fluoro compound.  
 
The majority of FDA approved drugs contain basic amine functionalities, and this 
functional group contributes in a major way to all aspects of the MDO process.
40
 Amine 
protonation state can have major impacts on protein binding, bioavailability,
57,58
 off target 
effects,
59,60
 and generally all physiochemical properties of small molecules. Fluorine, through 
induction, has a major impact on the pKa of adjacent functional groups.
40
 To modulate the 
basicity of amine containing small molecules, therefore, fluorine is often added to the 
41 
 
molecule in close proximity to the amine, modulating its pKa and impacting those 
physiochemical properties. Since fluorine is the most electronegative element, its effect on 
nearby amines is substantial, changing their pKa on a logarithmic scale. To fully optimize 
amine containing small molecules for ideal physiochemical properties and potency, rational 
and structure based modulation of amine basicity gives the medicinal chemist fine-tuned 
control during MDO.   
While the pKa of an aliphatic protonated amine is 10.7, addition of fluorine in the γ-
position decreases that value to 9.7. Moving the fluorine into the β-position shifts the pKa to 
9.0, addition of γ-geminal difluoro atoms decreases it further to 8.7, and β-geminal 
difluorination decreases the pKa to 7.3 (Figure 1.2.2.4).  
 
Fluorine substitution allows the medicinal chemist to access a wide range of pKa values, 
allowing powerful control over protonation state, which is essential when simultaneously 
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optimizing a compound for potency, bioavailability, metabolism, and safety—the standard 
process of MDO.
40,42,49
 
 Chemists at Merck utilized this strategy while optimizing a compound to treat 
migraines.
61
 They prepared a series of piperidinyl indoles to be selective for the 5-HT1D 
receptor, but bioavailability and CNS penetrance were issues with lead compound 1.82. To 
modify the protonation state of the piperidine, they added a β-fluorine, which decreased the 
pKa of the conjugate acid more than 1 unit. This had little effect on binding or selectivity, but 
it dramatically increased bioavailability to acceptable levels (Figure 1.2.2.5).
42,61
  
 
 In another case, γ-fluorination of another piperidinyl indole increased oral 
bioavailability. This effort was to discover a selective 5-HT2 antagonist for the treatment of 
schizophrenia.
62
 While the lead compound 1.84 was a potent and efficacious antagonist, oral 
dosing of 1.84 showed only trace amounts to be absorbed and circulated through the body. 
To decrease the basicity of the piperidine, a γ-fluorine was introduced to the piperidine to 
make compound 1.85. That scaffold modification resulted in a modest potency increase and 
allowed 18% of the dosed compound to reach circulation. Following that modification, they 
found the major metabolite to be indole oxidation, which again was limiting compound 
bioavailability. To address that, they added another fluorine atom to the site of oxidation to 
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make antagonist 1.86, and that modification resulted in a seven-fold increase in potency and 
made the compound 80% bioavailable (Figure 1.2.2.6).  
 
1.2.3 Synthetic methods for compound fluorination 
While fluorinating biologically relevant compounds can benefit the physical and 
biological properties of the molecules, medicinal chemists—and nature—have not mastered 
the synthesis of organofluorine chemistry. Fluorine is the thirteenth most abundant element 
on Earth, yet only 21 fluorine containing natural products have been isolated compared to 
thousands of natural products containing the heavier halogens.
63,64
 While there are many 
known haloperoxidases that catalyze the addition of chlorine and bromine, there are no 
fluoroperoxidases known. Additionally, natural fluoride is a hard anion, which causes it to 
form a very tight hydration shell decreasing its nucleophilicity and general reactivity. Natural 
fluoride, with its hydration shell, is so unreactive that the first known fluorinating enzyme—
reported in 2002—must dehydrate fluoride in the active site prior to the subsequent 
substitution reaction. 
65,66
 These qualities, along with those already stated, make selective 
fluorination of organic compounds exceedingly difficult. 
Since fluorine carbon bonds are difficult to form, conditions for C-F bond 
construction are extremely valuable. Medicinal chemists, therefore, appreciate commercially 
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available reagents that facilitate formation of this bond. That being said, there are several 
types of commercial reagents available for this purpose, and they can be largely divided into 
nucleophilic and electrophilic fluorine sources (Figure 1.2.3.1).
44,51
  
 
Nucleophilic fluorination sources generally react with alcohols, carbonyls, good 
leaving groups, epoxides, and sometimes activated olefins. DAST, Deoxofluor
®
, and DFI 
react with carbonyls and alcohols to form difluoro and monofluoro alkyl compounds. DAST 
and Deoxofluor
® 
are commercially available and DFI is readily available from other 
commercial materials.
67
 While these reagents form achiral difluoro alkyl compounds from 
achiral ketones or aldehydes, they form chiral monofluoro alkyl compounds with inversion of 
stereochemistry when reacted with chiral secondary alcohols (Scheme 1.2.3.1).
51,68
 
Tetraalkylammonium fluorides are more often used to displace reactive leaving groups,
61
 
open halonium ions or epoxides,
69
 or they can be used to trifluoromethylate in a process 
termed oxidative desulfurization—fluorination (Scheme 1.2.3.1).70 These nucleophilic 
45 
 
reagents provide access to a wide assortment of fluorination patterns, and in some cases they 
can deliver chiral organofluorine compounds. 
 
 The electrophilic fluorine sources generally deliver “F+” from an N-F bond,71 and 
they are most frequently employed to add fluorine to a carbanion generated from a carbonyl 
species, a lithiated aryl ring, or to nucleophilic heterocycles (Scheme 1.2.3.2).
44,51
  
 
While all of these sources of fluorine are achiral, whether they are nucleophilic or 
electrophilic, they can be utilized simultaneously with a chiral additive to prepare 
enantioenriched fluorinated materials. The ability to synthesize C—F bonds asymmetrically 
is valuable since (i) differential biological activity is frequently observed for different 
enantiomers, (ii) chiral syntheses avoid otherwise necessary and tedious chiral 
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chromatography, and (iii) asymmetric synthesis provides knowledge of the absolute 
stereochemistry, which is desirable and useful while developing intellectual property.  
 To prepare chemical scaffolds containing chiral fluorine, DAST is most frequently 
utilized with a chiral secondary alcohol, which is thought to undergo an enantiospecific SN2 
mechanism resulting in an organofluorine compound with inversion of configuration. For 
example, treatment of the α-hydroxy amide 1.87 with DAST follows that pattern of reactivity 
resulting in inversion of configuration to fluoride 1.88 (Scheme 1.2.3.3A).
72
 Unfortunately, 
the reagent sometimes proves to be unreliable, and reaction of hydroxyl-sterol derivative 1.89 
with DAST resulted in conversion to the fluoride 1.90 in high yield with retention of 
configuration, likely through an SN1 reaction mechanism (Scheme 1.2.3.3B).
73
 Additionally, 
reaction of alcohol 1.91 with DAST went through an SN1 pathway, which resulted in an 
undesired rearrangement to the tertiary carbocation that was trapped by the nucleophilic 
fluoride to generate tertiary achiral fluoride 1.92 (Scheme 1.2.3.3C).
74
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Further complicating matters, one must generate a chiral alcohol, which is not a trivial 
endeavor, prior to reaction with DAST to produce the chiral fluorine. A single 
enantioselective reaction installing the chiral fluorine would be advantageous to this reaction 
protocol. 
 While a variety of other asymmetric fluorination reactions exist, after considering the 
importance of β and γ-fluoroamines as discussed above, we saw a need for methods to 
effectively and consistently synthesize these amines from readily available and achiral 
starting materials. Prior to efforts in the Lindsley Lab, the only methods facilitating access to 
β or γ-fluoroamines relied predominantly on the classical DAST technology.68 From 2005 to 
2006, organocatalytic asymmetric fluorination of aldehydes emerged as a powerful method to 
prepare chiral fluoro aldehydes directly from achiral aldehydes.
75
 In fact, four separate 
research groups reported enantioselective organocatalytic fluorination of aldehydes during 
this time period. The Enders group was first to report the fluorination reaction, but their 
catalyst and conditions only gave modest yield and enantioselectivity (Figure 1.2.3.2).
76
 
Shortly thereafter, the Barbas,
77
 Jørgensen,
78–81
 and MacMillan
82,83
 groups simultaneously 
disclosed catalyst systems that enabled enantioselective fluorination of achiral aldehydes. 
Each of their methods drastically improved upon the % ee from Ender’s method, and each set 
of reaction conditions had a very similar substrate scope (Figure 1.2.3.2).  
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Since these methods facilitated rapid access to chiral fluoro aldehydes, the Lindsley 
lab envisioned these α-fluoro aldehydes could be useful intermediates in a reaction pathway 
leading to chiral β-fluoroamines. Essentially, this was done through a two-step protocol 
consisting of α-fluorination of an achiral aldehyde following MacMillan’s protocol,82 then 
standard reductive amination conditions to arrive at β-fluoroamines in high yields and 
enantioselectivity (Scheme 1.2.3.4).
84
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This route also facilitated access to β,β-difluoroamines; therefore, this chemistry can be used 
to modulate the pKa of basic amines in biologically active compounds from 10.7 (des-fluoro) 
to 9.0 (β-fluoroamine) to 7.3 (β,β-difluoroamine). This chemistry represented a considerable 
improvement in the art of preparing diverse chiral β-fluoroamines from readily available 
precursors. Since the α-fluoro aldehyde was used in this reaction pathway, however, storage 
of that intermediate would lead to immediate deterioration of % ee. Additionally, access to γ-
fluoroamines was not possible through this reaction manifold. With those aspects of this 
method in mind, a route capable of accessing both β and γ-fluoroamines would be 
advantageous. 
1.2.4 Envisioned access to β and γ-fluoroamines 
Our labs previous work preparing chiral β-fluoroamines,84 aziridines,33 
morpholines,
34
 and piperazines were all based on utilizing an epimerizable α-halo aldehyde. 
In all cases, if the chiral halogenated aldehyde was left at room temperature, the % ee would 
deteriorate. To circumvent this problem while accessing morpholines and piperazines, we 
modified our procedure to reduce the epimerizable α-chloro aldehyde to the configurationally 
stable β-chloro alcohol.37 That adjustment resulted in further modification of the reaction 
procedure; namely, the hydroxyl group was transformed to a reactive leaving group, which 
was displaced by aminoalcohols or diamines instead of the reductive amination from the 
former reaction sequence. This result led our lab to reflect on our β-fluoroamine reaction 
protocol. Specifically, we imagined a modification to the reaction sequence providing more 
reliable access to enantioenriched β-fluoroamines and β,β-difluoroamines while also giving a 
reaction path to γ-fluoroamines and a variety of other fluorinated scaffolds. 
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Analogous to our modification to the morpholine/piperazine synthesis, we envisioned 
an enantioselective organocatalytic fluorination of achiral aldehydes 1.93 followed by 
reduction of the aldehyde to provide configurationally stable β-fluoroalcohol 1.94. At this 
point, the hydroxyl could be converted into a leaving group and substitution with amines 
would generate β-fluoroamines 1.95. In a similar vein, if the leaving group was instead 
displaced by cyanide, that would generate β-fluoronitrile 1.96. This intermediate is useful 
because of its high oxidation state, a molecular species poised to access a variety of 
fluorinated scaffolds. Importantly, full reduction of the nitrile would give access to the 
desired γ-fluoroamine 1.97, but nitrile 1.96 could also be (i) hydrolyzed to the carboxylic 
acid, (ii) hydrolyzed to the carboxylic amide, (iii) partially reduced to the aldehyde, (iv) 
hydrolyzed to amide oxime 1.98, or (v) reacted with sodium azide, facilitating a formal 3 + 2 
addition to form the tetrazole 1.99 (Scheme 1.2.4.1) 
. 
1.2.5 General access to β and γ-fluoroamines 
To validate our envisioned approach, we prepared a number of β-fluoroalcohol 
substrates using MacMillan’s organocatalytic approach.82 Treatment of aldehyde 1.93 with 
20 mol % organocatalyst 1.100 and NFSI facilitated the transformation to α-fluoroaldehydes. 
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At this point, workup and a solvent change allowed the aldehydes to be treated with sodium 
borohydride to reduce them to chiral β-fluoroalcohols 1.94. As expected, these conditions 
allowed for the preparation of β-fluoroalcohols 1.94A-G in good yields and excellent 
enantioselectivity (Scheme 1.2.5.1). 
 
 At this point, application of the previously developed aminoalcohol/diamine 
alkylation conditions to β-fluoroalcohols (triflic anhydride, DCM, then nucleophilic amine) 
allowed for clean conversion to the β-fluoroamines. This reaction pathway provided β-
fluoroalcohols 1.101A-C in high yield and excellent enantioselectivity (Scheme 1.2.5.2).  
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While overall yield and enantioselectivity is only slightly better than the previous Lindsley 
Lab method,
84
 this new strategy sets the key stereocenter in a configurationally stable way, 
preventing any loss of % ee, leading to reproducibly high enantioselectivity.
85
 This method 
allows pKa perturbation of the amine’s conjugate acid from 10.7 to 9.0. 
 To further decrease the basicity of amines, sometimes β,β-difluoro substitution results 
in optimized physiochemical properties. To illuminate whether this approach would allow 
access to the difluoroamine variant, organocatalytic difluorination of aldehyde 1.102 with 
excess NFSI and proline organocatalyst followed by sodium borohydride reduction led to 
β,β-difluoroalcohol 1.103 in 77% yield. Treatment of this compound with triflic anhydride 
and benzylamine facilitated substitution to the β,β-difluoroamine 1.104 (Scheme 1.2.5.3), 
which would result in a pKa shift from 10.7 to 7.3.
85
  
 
 While the ability to access β-fluoroamines and β,β-difluoroamines from this reaction 
manifold was gratifying, with noted benefits compared to former methods, we now focused 
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our attention on γ-fluoroamines, a very difficult chemotype to access. We initially examined 
the possibility of alkylating cyanide using fluoro-tosylates. β-fluoroalcohol congener 1.105 
was treated with tosyl chloride to generate β-fluoro tosylate 1.106 in good yield. An 
assortment of solvents and temperatures were then screened for their ability to facilitate the 
SN2 transformation generating β-fluoronitrile 1.107 (Table 1.2.5.1). 
 
While sodium cyanide in DMSO was found to fully consume β-fluoro tosylate 1.106, the 
product formed was not β-fluoronitrile 1.107. Instead, a double displacement occurred with 
cyanide leading to bis-cyano adduct 1.108 and none of the desired β-fluoronitrile 1.107 
(Scheme 1.2.5.4). 
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In hopes of only undergoing a single SN2 reaction with cyanide, the reaction 
conditions were modified to only use a single equivalent of sodium cyanide. Essentially, if 
only one equivalent was available, we postulated that it would be fully consumed by the first 
substitution reaction of the tosylate, and there would be no cyanide remaining for the second 
displacement of the fluoride. Unfortunately, we observed 50% conversion of the starting 
material to the bis-cyano adduct 1.108 under these conditions, leaving 50% of the starting 
material unreacted.
85
 At this point, we reasoned that the β-fluorine was inductively 
withdrawing from the tosylate, decreasing its reactivity as a leaving group by way of δ+ 
delocalization across vicinal carbon atoms. This made an SN2 reaction of the tosylate 
kinetically more unfavorable than the second displacement of the fluoride. Essentially, when 
the activation energy barrier of one displacement was breached, the second displacement was 
less energetically demanding leading to the bis-cyano product. This led us to consider 
different leaving groups to modulate the energetics of this single displacement. 
 We next assessed the β-fluoro triflate for the desired single displacement, since 
triflate leaving groups are orders of magnitude more reactive than tosylates.
36
 We treated β-
fluoroalcohols with triflic anhydride to form β-fluoro triflate 1.109, which was remarkably 
stable when compared to known triflates from literature precedent. In fact, β-fluoro triflate 
1.109 could be chromatographed with conventional normal phase silica gel chromatography, 
a technique that usually results in triflate hydrolysis. Solvents, temperatures, cyanide 
equivalents, and additives were screened to assess the reactivity of the β-fluoro triflate 
(Table 1.2.5.2). Optimal conditions were found that resulted in single displacement of β-
fluoro triflate 1.109 and formation of β-fluoronitrile 1.96. Catalytic 18-crown-6 with 10 
equivalents of potassium cyanide in acetonitrile were the optimal conditions to facilitate the 
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transformation.
85
 This protocol resulted in full conversion without any formation of bis-
cyano adduct. 
 
 Following these conditions, we applied the reaction to the set of β-fluoro alcohols 
(1.94A-G) we had synthesized. The cyanide substitution conditions were general for all the 
substrates, yielding β-fluoronitriles 1.96A-G with an average yield of 82% (Scheme 1.2.5.5).  
 
With these β-fluoronitriles in hand, effort turned toward ascertaining optimal reduction 
conditions to generate the desired γ-fluoroamines.  
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 Normally, reduction of nitriles can be accomplished using lithium aluminum hydride 
or Pd/C with hydrogenation conditions. Unfortunately, these conditions resulted in low yields 
of the desired amine and were accompanied by decomposition and/or defluorination. 
Ultimately, we found milder conditions using InCl3/NaBH4 in THF, which forms InCl2H in 
situ. These conditions facilitated clean reduction of the β-fluoronitriles 1.96A-G to the γ-
fluoroamines 1.97A-G with an 85% average yield (Scheme 1.2.5.6).
85
  
 
This three-pot process (aldehyde fluorination/reduction, cyanide substitution, and nitrile 
reduction) smoothly provided chiral γ-fluoroamines in excellent enantioselectivity (87-96% 
ee) and good overall yields (40-58%). Importantly, this process utilizes a commercial 
organocatalyst that is available as both enantiomers, which provides access to γ-fluoroamines 
as a single desired enantiomer from achiral aldehydes in a quick reaction protocol.  
 Importantly, this reaction manifold provides a method to modulate the pKa of 
biologically active amine containing ligands. It offers the ability to fine tune pKa from 10.7 of 
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the parent amine, to 9.7 (γ-fluorine), to 9.0 (β-fluorine), to 7.3 (β,β-difluoro), giving control 
over 3.5 logarithmic pKa units. We also desired to access γ,γ-difluoroamines, to add an 
additional level of control; however, we were unable to facilitate SN2 reaction of the β,β-
difluorotriflate with cyanide despite surveying a broad array of reaction conditions (Table 
1.2.5.3).
85
 
 
1.2.6 β-fluoronitriles: access to diverse fluorinated scaffolds 
While planning this method to access β and γ-fluoroamines, we envisioned the β-
fluoronitrile as an intermediate poised to access a variety of fluorinated scaffolds using the 
nitrile as a handle. We reasoned that any reaction conditions we found to perform functional 
group conversions on the nitrile would be directly applicable to our β-fluoronitriles. 
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Unfortunately, we observed the fluorine atom to be more reactive than expected. Standard 
hydrolysis conditions leading to fluoro carboxylic acids or fluoro carboxylic amides also 
facilitated elimination of fluoride as a leaving group. Additionally, we followed literature 
precedent to facilitate (i) 3 + 2 addition of azide to the nitrile forming the tetrazole 1.99 and 
(ii) hydroxylamine hydrolysis of the nitrile to the amide oxime 1.98, which is a precursor for 
oxadiazole synthesis.
86–88
 Unfortunately, these conditions predominantly led to defluorination 
presumably through elimination. By decreasing the temperatures of both reactions, however, 
we facilitated both reactions without accompanied elimination, albeit over extended reaction 
times (Scheme 1.2.6.1).
85
 
 
We determined, therefore, that β-fluoronitriles are multifunctional intermediates poised to 
access a large number of fluorinated scaffolds, but reaction conditions must be optimized for 
each β-fluoronitrile modification, since literature precedent frequently results in C-F bond 
cleavage.  
In summary, this fluorination method was a powerful extension of the previous β-
fluoroamine method,
84
 providing access to the same chiral β-fluoroamines and β,β-
difluoroamines through a reaction manifold eliminating the possibility for racemization of 
the key stereocenter. Additionally, this work generates a pathway to chiral γ-fluoroamines, a 
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chemotype difficult to prepare and something our previous method lacked entirely. These 
chiral γ-fluoroamines can be accessed in good overall yields (40-58%) and excellent 
enantioselectivity (87-96% ee) from achiral commercial aldehydes. Importantly, outside of 
classical DAST chemistry, this work provides the only pathway to chiral γ-fluoroamines, to 
the best of our knowledge. Moreover, the chiral β-fluoronitrile lynchpin can provide access 
to numerous fluorinated functional groups and heterocyclic ring systems with slight 
perturbations of pKa and electronic properties, which can have substantial impact on the 
compound’s physiochemical properties.  
1.3 Preliminary access to chiral N-alkyl aziridines and chiral C2-functionalized 
azetidines from prochiral aldehydes using organocatalysis 
1.3.1 Importance of aziridine and azetidine heterocycles 
Aziridines represent an important class of nitrogen containing heterocycles since (i) 
they are part of numerous natural products and (ii) they are powerful chiral intermediates that 
can impart their chirality on more advanced intermediates through ring opening reactions.
89
 
Aziridines 1.108 are 3-membered nitrogen containing rings, which results in considerable 
ring strain (27 kcal/mol) that can be relieved through nucleophilic ring opening. The 
synthetic utility of these heterocycles is derived from the ability to open chiral aziridines 
regioselectively.
89,90
 While numerous methods exist for the synthesis of chiral aziridines 
including chiral pool approaches,
90
 asymmetric catalysis,
91,92
 and chiral auxiliaries,
93
 the 
generality of these methods is limited while considering the carbon and nitrogen substituents 
tolerated by each approach. After considering the available methods, it becomes clear that 
general routes to access chiral 1,2-disubstituted terminal aziridines 1.109 remain rare, and 
asymmetric access to this aziridine subtype, as a result, is limited (Figure 1.3.1.1).
33,94
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 Azetidines 1.110 are 4-membered nitrogen containing heterocycles that have received 
little attention from the synthetic community despite their presence in biologically active 
compounds.
95–97
 One possible explanation for this fact is azetidines are much less frequently 
found in natural products compared with larger aza-heterocycles, and it is kinetically and 
thermodynamically unfavorable to form the 4-membered ring system. Compared to the 
smaller 3-membered or larger 5 and 6-membered aza-heterocycles, there are far fewer 
synthetic methods for their enantiopure preparation, especially when considering general 
methods.
98
 Among the different methods to synthesize azetidines, access to chiral C2 
substituted azetidines 1.111 are rare (Figure 1.3.1.2).  
 
After using organocatalysis to make chiral morpholines, piperazines, and fluorinated 
scaffolds, we saw the potential of using similar chemistry to extend the reaction pathway to 
aziridines and azetidines. Prior research in our lab had focused on using organocatalysis to 
access chiral aziridines.
33
 By coupling that chemistry to the reactions described earlier in this 
chapter,
34,85
 we reasoned that access to chiral aziridines and azetidines was possible. 
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1.3.2 Envisioned access to aziridines and azetidines 
In 2010, Fadeyi, Schulte, and Lindsley developed access to chiral N-alkyl terminal 
aziridines.
33
 They utilized a short reaction cascade involving asymmetric chlorination, 
reductive amination, and base-induced cyclization to generate aziridines in good overall 
yields and moderate to excellent enantioselectivity (scheme 1.3.2.1).  
 
This chemistry was a major improvement compared to the literature precedent for 
synthesizing chiral 1,2-disubstituted terminal aziridines. The method, however, suffered from 
variable enantioselectivity, since the α-chloroaldehyde taking part in the reductive amination 
was not configurationally stable.  Since this methods deficiency was shared by our first 
generation chiral morpholine and piperazine method,
34
 we reasoned that the same approach 
leading to consistent enantioinduction for morpholines and piperazines could be utilized to 
improve the aziridine methodology. Namely, if we could remove the reductive amination 
from the reaction sequence and instead make the bifunctional electrophile configurationally 
stable, there would no longer be deterioration of enantiomeric excess.  
 To improve the method, we reasoned that the same asymmetric chlorination and 
reduction of aldehyde 1.112 would deliver enantioenriched β-chloroalcohols 1.113 that were 
configurationally stable. At that point, we could utilize the conditions that were developed to 
make β-chloro aminoalcohols, β-chloro diamines, and β-fluoroamines by forming the β-
chloro triflate and facilitating substitution reaction with primary amines. At that point, we 
would have a β-chloroamine, which could be cyclized to form aziridines 1.114 in the same 
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way as was previously reported (Scheme 1.3.2.2).
33
 Additionally, the β-chloro triflate could 
be displaced by cyanide, just as in the γ-fluoroamine reaction pathway, to form β-
chloronitrile 1.115, which could be used to access chiral C2-substituted azetidines 1.116 after 
reduction of the nitrile and cyclization of the resultant amine.
85
 
 
1.3.3 Preliminary access to chiral N-alkyl aziridines 
To validate the approach toward chiral N-alkyl terminal aziridines, we began work 
with three standard achiral aldehydes.  Treatment of aldehydes 1.112 with 
diphenylpyrrolidine catalyst and N-chlorosuccinimide in DCM followed by sodium 
borohydride reduction facilitated conversion to the chiral β-chloroalcohols 1.113 in moderate 
to excellent yields. We then performed a one-pot triflate formation, benzylamine alkylation, 
and base induced cyclization to form aziridines 1.114A-C in a 3-step yield ranging from 69-
82% overall. The overall yields for this sequence were at the high end compared to substrates 
from the previous aziridine methodology,
33
 and the enantioselectivity was consistently over 
90% ee (Scheme 1.3.3.1).
99
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1.3.4 Preliminary access to chiral C2-functionalized azetidines  
To access azetidines, we had to access the γ-chloroamines prior to optimizing the 
cyclization reaction. As these steps had been optimized during our work with fluoroamine 
chemistry,
85
 all of the reactions progressed as expected, giving us rapid access to a small 
assortment of chiral γ-chloroamines (Scheme 1.3.4.1). 
 
While we initially tried the conditions successfully facilitating 3-exo-tet cyclization of 
β-chloroamines to aziridines (KOH, THF/H2O, 65 °C), these conditions led to minimal 
consumption of the γ-chloroamine starting material. Additionally, when other conditions 
were tried, we observed substantial elimination of the chloride to the olefin. To find optimal 
conditions, we performed a broad screening of different bases, solvents, temperatures, and 
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additives to determine what would best facilitate this cyclization transformation and 
minimize the undesired elimination (Table 1.3.4.1).  
 
Fortunately, we found conditions that were able to promote ring closure in a 3:1 ratio with 
the elimination pathway. KOH in THF/H2O (1:1) with forcing thermal conditions promoted 
γ-chloroamine 1.117 cyclization to azetidine 1.116, and we were able to apply these 
conditions to a preliminary set of aldehydes. While we were able to isolate product azetidine 
from the mixture, the yields were rather low, ranging from 30-38% (Scheme 1.3.4.2).  
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While the single step yield was low, the overall yields were—in many cases—higher than 
literature precedent (21-28% overall); and, despite forcing thermal conditions the reaction 
proceeded stereospecifically, maintaining high levels of enantioinduction (>90% ee). 
 To highlight the practicality of the azetidine reaction pathway, we looked to the 
patent literature for C2-substituted azetidines with interesting biological activity. We found 
that azetidine 1.118 is a subunit of a calcium sensing receptor antagonist, and literature 
precedent prepared 1.118 in 7 steps and 8.7% overall yield.
100
  We decided to make this 
compound using our method, to emphasize its advantages. Beginning with commercially 
available aldehyde 1.119, we performed our chlorination and reduction in 84% yield to 
generate β-chloroalcohol 1.120. Triflate formation and cyanide alkylation went smoothly in 
74% yield, and β-chloronitrile 1.121 was reduced to the amine and cyclized to the azetidine 
1.118 in 28% yield (Scheme 1.3.4.3). Our route, therefore, resulted in an asymmetric 
synthesis of 1.118 in 18% overall yield—double the literature method—and 91% ee in fewer 
steps than the known method.
99
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In summary, this reaction pathway represents a major advantage over the previous 
aziridine method since there is no possibility for erosion of enantioselectivity. While we are 
in the process of generating more examples for the substrate scope, the aziridines that have 
been made are in good overall yields (51-63%) and excellent enantioselectivity (94-94% ee). 
Additionally, this reaction manifold gives access to chiral C2-substituted azetidines, a 
heterocycle that is historically difficult to prepare. This method prepares azetidines in yields 
from 18-28% overall and in excellent enantioselectivity (>90% ee). Investigation of the 
reaction scope is underway, and refinements may result in increased yields. 
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Experimental for chiral C2-subsituted morpholines and piperazines 
All reagents were purchased from Sigma-Aldrich Corp., TCI America, Rieke Metals, Inc. 
and were used without purification. Analytical thin-layer chromatography (TLC) was 
performed on 250 µm silica plates from Sorbent Technologies.  Visualization was 
accomplished via UV light, and/or the use of ninhydrin, iodine, and potassium permanganate 
solutions followed by application of heat.  Chromatography was performed using Silica Gel 
60 (230-400 mesh) from Sorbent Technologies or Silica RediSep Rf flash columns on a 
CombiFlash Rf automated flash chromatography system.  All 
1
H and 
13
C NMR spectra were 
recorded on a Bruker AV-400 (400 MHz) instrument.  Chemical shifts are reported in ppm 
relative to residual solvent peaks as an internal standard set to δ 7.26 and δ 77.16 (CDCl3).  
Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, 
q = quartet, p = pentet, br = broad, dd = doublet of doublets, dq = doublet of quartets, td = 
triplet of doublets, pd = pentet of doublets, m = multiplet), coupling constat (Hz), integration. 
Low resolution mass spectra (LCMS) were recorded on an Agilent 1200 LCMS with 
electrospray ionization.  High resolution mass spectra (HRMS) were recorded on a Waters 
Qtof-API-US plus Acuity system with ES as the ion source. Analytical high performance 
liquid chromatography (HPLC) was performed on an Agilent 1200 analytical LCMS with 
UV detection at 214 nm and 254 nm along with ELSD detection.  Chiral separations were 
performed on a Thar Investigator II supercritical fluid chromatograph (SFC) utilizing 
Chiralcel
® 
OD, OD-Cl, OJ, and Chiralpak
®
 IA columns. Optical rotations were acquired on a 
Jasco P-2000 polarimeter at 23 ⁰C and 589 nm.  The specific rotations were calculated 
according to the equation [α]23/D = 100α/l x c where l is the path length in decimeters and c 
is the concentration in g/100 mL.   
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Procedure for Chiral Chloro-alcohol Synthesis 
 
To a solution of aldehyde (1 mmol) and (2R, 5R)-2,5-diphenylpyrrolidine (0.1 eq., 0.1 mmol) 
in DCM (2.0 mL) was added N-chlorosuccinimide (173 mg, 1.3 mmol, 1.3 eq.) at 0 ⁰C.  The 
reaction was kept at 0 ⁰C for 1 hour at which point it was allowed to warm to ambient 
temperature.  It was then stirred until the aldehyde was completely consumed as determined 
by 
1
H NMR spectroscopy of the reaction mixture. The reaction was then cooled to 0 ⁰C and 
diluted with methanol (10 mL).  NaBH4 (189 mg, 5 mmol, 5 eq) was added in several 
portions and the mixture was stirred for 30 minutes and quenched via the addition of water.  
The reaction was extracted 3X with EtOAc, dried with MgSO4, and concentrated.  
 
 
The product was prepared according to the chiral chloro-alcohol synthesis procedure and 
purified by silica chromatography (6:1 Hexanes/EtOAc) to afford the product as a clear oil 
(159.5 mg, 72.2%). 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 3.99 (s, br, 1H); 3.78-3.75 (m, 
1H); 3.67-3.62 (m, 1H); 2.37-2.27 (m, 1H); 1.80-1.64 (m, 2H); 1.55-1.46 (m, 1H); 1.42-1.36 
(m, 1H); 1.25 (s, br, 14H); 0.87 (t, J = 6.5 Hz,  3H).  
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 
66.92, 65.22, 34.18, 31.81, 29.49, 29.46, 29.34, 29.23, 29.03, 26.24, 22.59, 14.01. Specific 
rotation [ =  -41.0⁰ (c = 100, MeOH). 
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The product was prepared according to the chiral chloro-alcohol synthesis procedure and 
purified by silica chromatography (6:1 Hexanes/EtOAc) to afford the product as a clear oil 
(154 mg, 83%). 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 7.33-7.20 (m, 5H); 4.02-3.96 (m, 
1H); 3.82-3.67 (m, 2H); 2.94-2.87 (m, 1H); 2.80-2.73 (m, 1H); 2.09-1.99 (m, 3H).
 13
C NMR 
(100.6 MHz, CDCl3) δ (ppm): 140.61, 128.49, 128.47, 126.17, 66.92, 64.02, 35.75, 32.30. 
Specific rotation [ =  -43.1⁰ (c = 100, MeOH). 
 
 
The product was prepared according to the chiral chloro-alcohol synthesis procedure and 
purified by silica chromatography (6:1 Hexanes/EtOAc) to afford the product as a clear oil 
(157 mg, 82%). 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 5.36-5.23 (m, 2H); 3.97-3.91 (m, 
1H); 3.74-3.68 (m, 1H); 3.65-3.59 (m, 1H); 2.87 (s, br, 1H); 2.03-1.95 (m, 4H); 1.79-1.60 (m, 
2H); 1.56-1.47 (m, 1H); 1.43-1.28 (m, 3H); 0.91 (td, J1 = 1.97 Hz, J2 = 7.50, 3H). 
13
C NMR 
(100.6 MHz, CDCl3) δ (ppm): 131.86, 128.52, 68.81, 64.80, 34.07, 29.10, 26.73, 25.83, 
20.41, 14.23.  Specific rotation [ =  -31.3⁰ (c = 100, MeOH). 
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The product was prepared according to the chiral chloro-alcohol synthesis procedure and 
purified by silica chromatography (9:1 Hexanes/EtOAc) to afford the product as a clear oil 
(199 mg, 79%). 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 4.10-4.04 (m, 1H); 3.83-3.77 (m, 
1H); 3.71-3.63 (m, 3H); 2.11-2.06 (m, 1H); 1.94-1.85 (m, 1H); 1.81-1.71 (m, 2H); 1.68-1.53 
(m, 1H); 0.89 (S, 9H); 0.047 (S, 6H). 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 66.85, 64.86, 
62.30, 30.70, 29.25, 25.83, 18.21, -5.43. HRMS (TOF, ES+) C11H25ClO2Si [M+H]
+
 calc. 
mass 253.1391, found 253.1393.  Specific rotation [  = -13.8 (c = 100, MeOH). 
 
General Procedure for Chiral Chloro-Aminoalcohol Synthesis 
 
Lutidine (10 eq.) was added to a solution of chloro alcohol (1 eq.) in DCM (0.1 M) in a flame 
dried flask under an argon atmosphere and the reaction was cooled to -78 ⁰C.  Triflic 
Anhydride (1.3 eq.) was added dropwise to the reaction and it was allowed to stir for 30 
minutes.  To this reaction, still at -78 ⁰C, was added the aminoalcohol (2 eq.) dropwise, 
dissolved in 1 mL of DCM. This reaction was allowed to warm to room temperature over the 
next 4 hours and was quenched with water and brine.  It was extracted 3X with EtOAc, dried 
with MgSO4, and concentrated before purification. 
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The product was prepared according to the chloro amino alcohol procedure on a 0.36 mmol 
scale and purified by silica chromatography (9:1 Hexanes/EtOAc) to afford the product as a 
clear oil (94 mg, 0.27 mmol, 74%). 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 7.39-7.32 (m, 
4H); 7.31-7.26 (m, 1H); 4.0-3.9 (m, 1H); 3.79-3.65 (m, 2H); 3.65-3.53 (m, 2H), 2.90-2.62 
(m, 5H); 1.81-1.70 (m, 1H); 1.66-1.45 (m, 2H); 1.29 (s, br, 15H); 0.92 (t, J = 6.81).  
13
C 
NMR (100.6 MHz, CDCl3) δ (ppm): 138.29, 128.97, 128.38, 127.34, 61.44, 61.21, 59.43, 
58.75, 56.27, 35.98, 31.84, 29.53, 29.49, 29.39, 29.26, 29.06, 26.14, 22.63, 14.07. HRMS 
(TOF, ES+) C21H37NOCl [M+H]
+
 calc. mass 354.2564, found 354.2563.  Specific rotation 
[ =  -8.8⁰ (c = 100, MeOH). 
 
The product was prepared according to the chloro amino alcohol procedure on a 0.38 mmol 
scale and purified by silica chromatography (9:1 Hexanes/EtOAc) to afford the product as a 
clear oil (91 mg, 0.29 mmol, 76%). 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 7.40-7.20 (m, 
10H); 3.99-3.90 (m, 1H); 3.76-3.53 (m, 4H); 2.96-2.63 (m, 7H); 2.18-2.07 (m, 1H); 1.99-
1.88 (m, 1H). 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 140.85, 138.20, 128.97, 128.49, 
128.46, 128.42, 127.38, 126.11, 61.14, 60.30, 59.34, 58.82, 56.28, 37.60, 32.30. HRMS 
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(TOF, ES+) C19H25ClNO [M+H]
+
 calc. mass 318.1625, found 318.1624. Specific rotation 
[ =  -15.1⁰ (c = 100, MeOH). 
 
 
The product was prepared according to the chloro amino alcohol procedure on a 0.29 mmol 
scale and purified by silica chromatography (9:1 Hexanes/EtOAc) to afford the product as a 
clear oil (71 mg, 0.22 mmol, 76%). 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 7.39-7.30 (m, 
4H); 7.30-7.24 (m, 1H); 5.43-5.26 (m, 2H); 3.98-3.88 (m, 1H); 3.78-3.63 (m, 2H); 3.63-3.50 
(m, 2H); 2.87-2.61 (m, 5H); 2.09-1.97 (m, 4H); 1.80-1.69 (m, 1H); 1.64-1.45 (m, 2H); 1.43-
1.22 (m, 4H); 0.96 (s, J = 7.53, 3H).  
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 138.24, 
131.87, 128.96, 128.63, 128.39, 128.35, 61.33, 61.15, 59.39, 58.73, 56.24, 35.87, 29.14, 
26.14, 25.76, 20.45, 14.30. HRMS (TOF, ES+) C19H31ClNO [M+H]
+
 calc. mass 324.2094, 
found 324.2094. Specific rotation [ =  -9.5⁰ (c = 100, MeOH). 
 
 
The product was prepared according to the chloro amino alcohol procedure on a 0.37 mmol 
scale and purified by silica chromatography (9:1 Hexanes/EtOAc) to afford the product as a 
clear oil (106 mg, 0.27 mmol, 74%). 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 7.36-7.23 (m, 
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5H); 4.03-3.93 (m, 1H); 3.78-3.49 (m, 6H); 2.83-2.69 (m, 4H); 2.68-2.59 (m, 1H); 1.95-1.83 
(m, 1H); 1.79-1.67 (m, 1H); 1.66-1.51 (m, 2H); 0.89 (s, 9H); 0.04 (s, 6H). 
13
C NMR (100.6 
MHz, CDCl3) δ (ppm): 138.24, 128.95, 128.38, 127.33, 62.30, 61.24, 61.20, 59.40, 58.77, 
56.20, 32.45, 29.33, 25.88, 18.24, -5.38. HRMS (TOF, ES+) C20H37NO2ClSi [M+H]
+
 calc. 
mass 386.2282, found 386.2282. Specific rotation [ =  -5.7⁰ (c = 100, MeOH).  
 
General Procedure for Chiral Chloro-Diamine Synthesis 
 
Lutidine (10 eq.) was added to a solution of chloro alcohol (1 eq.) in DCM (0.1 M) in a flame 
dried flask and the reaction was cooled to -78 ⁰C.  Triflic Anhydride (1.3 eq.) was added 
dropwise to the reaction and it was allowed to stir for 30 minutes.  To this reaction, still at -
78 ⁰C, was added the diamine (2 eq.) dropwise, dissolved in 1 mL of DCM. This reaction 
was allowed to warm to room temperature over the next 4 hours and was quenched with 
water and brine.  It was extracted 3X with EtOAc, dried with MgSO4, and concentrated 
before purification. 
 
 
The product was prepared according to the chloro diamine procedure on a 0.23 mmol scale 
and purified by silica chromatography (9:1 Hexanes/EtOAc) to afford the product as a clear 
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oil (78 mg, 0.17 mmol, 75%). 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 7.34-7.30 (m, 4H); 
7.29-7.24 (m, 1H); 5.04 (s, br, 1H); 3.94-3.86 (m, 1H); 3.71-3.61 (m, 2H); 3.27-3.10 (m, 2H); 
2.81-2.69 (m, 2H); 2.67-2.55 (m, 2H); 1.85-1.74 (m, 1H); 1.61-1.55 (m, 1H); 1.44 (s, 9H); 
1.28 (s, 16H); 0.90 (t, J = 7.01, 3H). 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 156.07, 138.59, 
128.87, 128.28, 127.18, 78.84, 61.32, 59.42, 54.01, 38.13, 35.94, 31.82, 29.51, 29.48, 29.39, 
29.24, 29.06 (one set of coincident signals), 28.33, 26.11, 22.60, 14.04. HRMS (TOF, ES+) 
C26H46N2O2Cl [M+H]
+
 calc. mass 453.3248, found 453.3245.  Specific rotation [ =  -7.0⁰ 
(c = 100, MeOH). 
 
The product was prepared according to the chloro diamine procedure on a 0.27 mmol scale 
and purified by silica chromatography (9:1 Hexanes/EtOAc) to afford the product as a clear 
oil (97 mg, 0.23 mmol, 87%). 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 7.37-7.19 (m, 10H); 
5.00 (s, br, 1H); 3.91-3.83 (m, 1H); 3.60 (s, 2H); 3.25-3.08 (m, 2H); 2.92-2.83 (m, 1H); 2.81-
2.68 (m, 3H); 2.64-2.51 (m, 2H); 2.23-2.12 (m, 1H); 1.93-1.82 (m, 1H); 1.47 (s, 9H).
 13
C 
NMR (100.6 MHz, CDCl3) δ (ppm): 155.94, 140.97, 138.62, 128.88, 128.47, 128.33, 127.21, 
126.06, 78.84, 61.28, 60.18, 54.00, 39.20, 37.53, 32.29, 28.42. HRMS (TOF, ES+) C24H-
34N2O2Cl [M+H]
+
 calc. mass 417.2309, found 417.2308.  Specific rotation [ =  -5.5⁰ (c = 
100, MeOH). 
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The product was prepared according to the chloro diamine procedure on a 0.41 mmol scale 
and purified by silica chromatography (9:1 Hexanes/EtOAc) to afford the product as a clear 
oil (138 mg, 0.33 mmol, 80%). 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 7.35-7.28 (m, 4H); 
7.28-7.23 (m, 1H); 5.41-5.26 (m, 2H); 4.97 (s, br, 1H); 3.92-3.84 (m, 1H); 3.69-3.60 (m, 2H); 
3.26-3.09 (m, 2H); 2.79-2.66 (m, 2H); 2.66-2.52 (m, 2H); 2.08-1.98 (m, 4H); 1.84-1.74 (m, 
1H); 1.63-1.46 (m, 2H); 1.43 (s, 9H); 1.41-1.22 (m, 3H); 0.96 (t, J = 7.5, 3H). 
13
C NMR 
(100.6 MHz, CDCl3) δ (ppm): 155.93, 138.69, 131.80, 128.85, 128.68, 128.28, 127.16, 
78.79, 61.32 (one set of coincident signals), 59.43, 54.05, 38.19, 35.81, 29.18, 28.36, 26.83, 
25.75, 20.46, 14.32.  HRMS (TOF, ES+) C24H40N2O2Cl [M+H]
+
 calc. mass 423.2778, found 
423.2779.  Specific rotation [ =  -7.0⁰ (c = 100, MeOH). 
 
 
The product was prepared according to the chloro diamine procedure on a 0.37 mmol scale 
and purified by silica chromatography (9:1 Hexanes/EtOAc) to afford the product as a clear 
oil (113 mg, 0.23 mmol, 63%). 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 7.35-7.22 (m, 5H); 
5.00 (s, br, 1H); 3.99-3.90 (m, 1H); 7.73-3.55 (m, 4H); 3.26-3.09 (m, 2H); 2.83-2.68 (m, 2H); 
2.67-2.53 (m, 2H); 1.96- 1.88 (m, 1H); 1.79-1.68 (m, 1H); 1.66-1.54 (m, 2H); 1.43 (s, 9H); 
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0.90 (s, 9H); 0.05 (s, 6H). 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 155.97, 138.66, 128.84, 
128.30, 127.15, 78.87, 62.43, 61.40, 61.31, 59.41, 53.95, 38.21, 32.51, 29.41, 28.35, 25.87, 
18.24, -5.37. HRMS (TOF, ES+) C25H46N2O3ClSi [M+H]
+
 calc. mass 485.2966, found 
485.2970.  Specific rotation [ =  -2.7⁰ (c = 100, MeOH). 
 
General Procedure for Chiral Morpholine Synthesis 
\ 
Potassium tert-butoxide (5 eq) was added to a solution of chloro-diamine (1 eq) in MeCN 
(0.02 M) at -20 ⁰C. This reaction was followed via TLC, and upon consumption of starting 
material, diethyl ether followed by water was added to the reaction.  It was extracted 3X with 
diethyl ether, dried with MgSO4, and concentrated before purification. 
 
 
The product was prepared according to the cyclization to morpholines procedure on a 0.19 
mmol scale and was purified by silica chromatography (9:1 Hexanes/EtOAc) to afford the 
product as a clear oil (39 mg, 0.12 mmol, 65%), which was determined to have an ee of 92% 
by chiral SFC analysis (Chiralpak IA, tR (major) = 2.76 min, tR (minor) = 2.12 min, traces 
shown below). 
1
H NMR (400.1 MHz, CDCl3) δ (ppm):
 
7.32-7.24 (m, 5H); 3.84 (dq, J1 = 11.5 
Hz, J2 = 1.8, 1H); 3.65 (td, J1 = 11.5, J2 = 2.5, 1H); 3.52-3.45 (m, 3H); 2.74-2.71, (m, 1H); 
2.65 (dq, J1 = 11.4, J2 = 1.8, 1H); 2.14 (td, J1 = 11.4, J2 = 3.3, 1H); 1.87-1.82 (m, 1H); 1.5-
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1.25 (m, 18H); 0.87 (t, J = 7.1, 3H).  
13
C NMR (100.6 MHz, CDCl3) δ (ppm):  137.76, 
129.11, 128.17, 127.03, 75.76, 66.73, 63.29, 58.80, 53.12, 33.67, 31.83, 29.60, 29.52, 29.51, 
29.45, 29.24, 25.33, 22.60, 14.04. HRMS (TOF, ES+) C21H36NO [M+H]
+
 calc. mass 
318.2797, found 318.2795.   Specific rotation [ =  +13.04⁰ (c = 100, MeOH). 
 
 
The product was prepared according to the cyclization to morpholines procedure on a 0.15 
mmol scale and was purified by silica chromatography (9:1 Hexanes/EtOAc) to afford the 
product as a clear oil (31 mg, 0.11 mmol, 74%), which was determined to have an ee of 95% 
by chiral SFC analysis (Chiralpak IB, tR (major) = 3.36 min, tR (minor) = 2.57 min, traces 
shown below). 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 7.39-7.25 (m, 7H); 7.24-7.18 (m, 
3H); 3.92 (d, J = 11.12, 1H); 3.70 (td, J1 = 2.38, J2 = 11.12, 1H); 3.58-3.50 (m, 3H); 2.86-
2.63 (m, 4H); 2.21 (td, J1 = 3.18, J2 = 11.12, 1H); 1.92 (t, J = 10.73, 1H); 1.89-1.78 (m, 1H); 
1.74-1.63 (m, 1H). 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 141.97, 137.72, 129.12, 128.40, 
128.27, 128.20, 127.07, 125.70, 74.82, 66.70, 63.27, 58.62, 53.16, 35.30, 31.54. HRMS 
(TOF, ES+) C19H24NO [M+H]
+
 calc. mass 282.1858, found 282.1857.   Specific rotation 
[ =  +25.2⁰ (c = 100, MeOH). 
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The product was prepared according to the cyclization to morpholines procedure on a 0.13 
mmol scale and was purified by silica chromatography (9:1 Hexanes/EtOAc) to afford the 
product as a clear oil (26 mg, 0.09 mmol, 68%), which was determined to have an ee of 98% 
by chiral SFC analysis (Chiralpak IA, tR (major) = 2.68 min, tR (minor) = 1.79 min, traces 
shown below). 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 7.38-7.25 (m, 5H); 5.43-5.28 (m, 
2H); 3.89-3.83 (m, 1H); 3.67 (td, J1 = 11.34, J2 = 2.39, 1H); 3.56-3.46 (m, 3H); 2.75 (d, J = 
11.72, 1H); 2.67 (d, J = 11.73, 1H); 2.16 (td, J1 = 11.62, J2 = 3.66, 1H); 2.09-1.98 (m, 4H); 
1.87 (t, J = 10.39, 1H); 1.56-1.21 (m, 7H); 0.97 (t, J = 7.95, 1H). 
13
C NMR (100.6 MHz, 
CDCl3) δ (ppm): 137.76, 131.62, 129.10, 128.95, 128.17, 127.03, 75.69, 66.74, 63.28, 58.77, 
53.12, 33.56, 29.73, 26.90, 24.99, 20.42, 14.29.   HRMS (TOF, ES+) C19H30NO [M+H]
+
 
calc. mass 288.2327, found 288.2328.   Specific rotation [ =  +10.8⁰ (c = 100, MeOH). 
 
 
The product was prepared according to the cyclization to morpholines procedure on a 0.13 
mmol scale and was purified by silica chromatography (9:1 Hexanes/EtOAc) to afford the 
product as a clear oil (26 mg, 0.09 mmol, 68%), which was determined to have an ee of 80% 
by chiral SFC analysis (Chiralpak IA, tR (major) = 3.08 min, tR (minor) = 2.66 min, traces 
shown below). 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 7.35-7.23 (m, 5H); 3.84 (dd, J1 = 
1.69, J2 = 11.33, 1H); 3.69-3.55 (m, 3H); 3.54-3.44 (m, 3H); 2.74 (d, J = 10.79, 1H); 2.65 (d, 
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J = 11.26, 1H); 2.15 (td, J1 = 3.13, J2 = 11.21, 1H); 1.86 (t, J = 10.69, 1H); 1.70-1.58 (m, 
1H); 1.58-1.40 (m, 3H); 0.89 (s, 9H); 0.039 (s, 6H). 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 
137.76, 129.08, 128.18, 127.03, 75.56, 66.71, 63.27, 63.01, 58.75, 53.10, 29.97, 28.64, 25.91, 
18.27, -5.36. HRMS (TOF, ES+) C20H36NO2Si [M+H]
+
 calc. mass 350.2515, found 
350.2514.   Specific rotation [ =  +11.1⁰ (c = 100, MeOH). 
 
General Procedure for Cyclization to Piperazines 
 
Potassium tert-butoxide (5 eq) was added to a solution of chloro-diamine (1 eq) in DMF 
(0.02 M) at -20 ⁰C. This reaction was followed via TLC and was typically done within 2 
hours.  Upon consumption of starting material, diethyl ether followed by water was added to 
the reaction.  It was extracted 3X with diethyl ether, dried with MgSO4, and concentrated 
before purification. 
 
 
The product was prepared according to the cyclization to piperazines on a 0.12 mmol scale 
and was purified by silica chromatography (9:1 Hexanes/EtOAc) to afford the product as a 
clear oil (33mg, 0.08 mmol, 66%), which was determined to have an ee of 89% by chiral 
SFC analysis (Lux Cellulose-4, tR (major) = 4.49 min, tR (minor) = 3.78 min, traces shown 
below). 
1
H NMR (400.1 MHz, CDCl3) δ (ppm):
 
7.32-7.21 (m, 5H); 3.99 (s, br, 1H); 3.90-
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3.82 (m, 1H); 3.53 (d, J = 13.2, 1H); 3.37 (d, J = 13.3, 1H); 3.05 (t, J = 12.5, 1H); 2.75-2.65 
(m, 2H); 2.06-2.00 (m, 2H); 1.78-1.73 (m, 1H); 1.66-1.61 (m, 1H); 1.45 (s, 9H); 1.30-1.15 
(m, 16H); 0.88 (t, J = 7.5, 3H).  
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 154.81, 138.39, 
128.68, 128.12, 126.93, 79.18, 62.80, 55.39, 53.29, 51.37, 39.24, 31.84, 29.74, 29.59, 29.56, 
29.53, 29.50, 29.27, 28.38, 26.20, 22.52, 14.04. HRMS (TOF, ES+) C26H45N2O2 [M+H]
+
 
calc. mass 417.3481, found 417.3480.  Specific rotation [ =  -34.68⁰ (c = 100, MeOH). 
 
 
The product was prepared according to the cyclization to piperazines on a 0.165 mmol scale 
and was purified by silica chromatography (9:1 Hexanes/EtOAc) to afford the product as a 
clear oil (42mg, 0.11 mmol, 67%), which was determined to have an ee of 95% by chiral 
SFC analysis (Chiralpak IA, tR (major) = 4.77 min, tR (minor) = 4.29 min, traces shown 
below) . 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 7.40-7.26 (m, 7H); 7.25-7.17 (m, 3H); 4.14 
(s, br,  1H); 3.96 (s, br, 1H); 3.60 (d, J = 13.4, 1H); 3.40 (d, J = 13.4, 1H); 3.15 (t, J = 12.8, 
1H); 2.86-2.73 (m, 2H); 2.62-2.45 (m, 2H); 2.20-1.99 (m, 4H); 1.50 (s, 9H). 
13
C NMR (100.6 
MHz, CDCl3) δ (ppm): 154.81, 142.11, 138.37, 128.78, 128.39 (set of two coincident 
signals), 128.21, 127.05, 125.70, 79.41, 62.84, 55.10, 53.39, 51.35, 39.45, 32.65, 31.68, 
28.40. HRMS (TOF, ES+) C24H33N2O2 [M+H]
+
 calc. mass 381.2542, found 381.2545. 
Specific rotation [ =  -41.0⁰ (c = 100, MeOH). 
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The product was prepared according to the cyclization to piperazines on a 0.15 mmol scale 
and was purified by silica chromatography (9:1 Hexanes/EtOAc) to afford the product as a 
clear oil (53mg, 0.137 mmol, 91%), which was determined to have an ee of 95% by chiral 
SFC analysis (Chiralpak IC, tR (major) = 4.62 min, tR (minor) = 4.10 min, traces shown 
below). 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 7.37-7.23 (m, 5H); 5.42-5.27 (m, 2H); 4.03 
(s, br, 1H); 3.89 (d, J = 11.03, 1H); 3.56 (d, J = 13.42, 1H); 3.40 (d, J = 13.42, 1H); 3.08 (t, J 
= 10.90, 1H); 2.77 (d, J = 10.9, 1H); 2.68 (d, J = 11.32, 1H); 2.11-1.98 (m, 6H); 1.86-1.74 
(m, 1H); 1.72-1.60 (m, 1H); 1.47 (s, 9H); 1.43-1.31 (m, 2H); 1.26-1.16 (m, 2H); 0.97 (t, J = 
7.53, 3H). 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 154.79, 138.38, 131.57, 129.00, 128.69, 
128.13, 126.94, 79.23, 62.79, 60.31, 55.41, 53.28, 51.31, 39.07, 29.61, 28.38 (one set of 
coincident signals), 27.01, 25.82, 20.44, 14.31.  HRMS (TOF, ES+) C24H39N2O2 [M+H]
+
 
calc. mass 387.3012, found 387.3009. Specific rotation [ =  -45.4⁰ (c = 100, MeOH). 
 
 
The product was prepared according to the cyclization to piperazines on a 0.19 mmol scale 
and was purified by silica chromatography (9:1 Hexanes/EtOAc) to afford the product as a 
clear oil (68.5mg, 0.15 mmol, 78%), which was determined to have an ee of 75% by chiral 
SFC analysis (Lux Cellulose-2 (OZ), tR (major) = 6.54 min, tR (minor) = 5.73 min, traces 
shown below). 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 7.34-7.20 (m, 5H); 4.02 (s, br, 1H); 
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3.93-3.81 (m, 1H); 3.61 (t, J = 6.14, 2H); 3.52 (d, J = 13.09, 1H); 3.38 (d, J = 13.59, 1H); 
3.05 (t, J = 11.58, 1H); 2.73 (d, J = 10.32, 1H); 2.66 (d, J = 11.27, 1H); 2.11-1.96 (m, 2H); 
1.94-1.82 (m, 1H); 1.71-1.59 (m, 1H); 1.50-1.35 (m, 11H); 0.89 (s, 9H); 0.04 (s, 6H). 
13
C 
NMR (100.6 MHz, CDCl3) δ (ppm): 154.78, 138.41, 129.31, 128.65, 126.94, 79.28, 62.99, 
62.76, 55.68, 53.22, 51.24, 38.91, 29.53, 28.37, 26.20, 25.89, 18.25, -5.32. HRMS (TOF, 
ES+) C25H45N2O3Si [M+H]
+
 calc. mass 449.3199, found 449.3198. Specific rotation [ =  
-29.9⁰ (c = 100, MeOH). 
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Procedure for Debenzylation and Formation of Dopamine Antagonist 
 
To a solution of benzyl protected morpholine (435 mg, 1.54 mmol) in methanol (31 mL, 0.05 
M) under an argon atmosphere was added 0.2 eq of 10% Pd/C. The flask was then purged 
with H2 and was left to react under a hydrogen atmosphere and followed via TLC and LC-
MS until consumption of the starting material was determined.  Upon consumption of the 
starting material, the reaction was filtered through celite, concentrated, and resuspended in 
MeCN (7.7 mL, 0.2 M).  To this solution was added potassium carbonate (1,064 mg, 7.7 
mmol) and 2-(chloromethyl) benzimidazole (256.6 mg, 1.54 mmol) and the reaction was left 
to stir overnight. The reaction was then quenched with water and was extracted 3X with ethyl 
acetate.  The organic layer was dried with magnesium sulfate, filtered, and was concentrated.  
It was purified using flash column chromatography (5% methanol in dichloromethane) to 
afford the product as a waxy solid (376 mg, 1.17 mmol, 76%). 
1
H NMR (400.1 MHz, CDCl3) 
δ (ppm): 7.62 (s, br, 2H); 7.31-7.23 (m, 4H); 7.21-7.12 (m, 3H); 3.90-3.77 (m, 3H); 3.57 (td, 
J1 = 11.63, J2 = 2.10, 1H); 3.42-3.44 (m, 1H); 2.78-2.56 (m, 4H); 2.34 (td, J1 = 11.65, J2 = 
3.43, 1H); 2.04 (t, J = 10.28, 1H); 1.84-1.73 (m, 1H); 1.63-1.53 (m, 1H). 
13
C NMR (100.6 
MHz, CDCl3) δ (ppm): 151.82, 141.73, 138.69, 128.43, 128.35, 125.82, 122.45, 114.94, 
74.68, 66.50, 58.69, 56.60, 53.35, 35.04, 31.36. HRMS (TOF, ES+) C20H24N3O [M+H]
+
 calc. 
mass 322.1919, found 322.1917.   Specific rotation [ =  +38.3⁰ (c = 100, MeOH). 
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Experimental for chiral β and γ-fluoroamines  
All reagents were purchased from commercial suppliers and were purified as needed 
according to the procedures of Armarego and Chai.
1
  Analytical thin-layer chromatography 
(TLC) was performed on 250 µm silica plates from Sorbent Technologies.  Visualization was 
accomplished via UV light, and/or the use of ninhydrin, iodine, and potassium permanganate 
solutions followed by application of heat.  Chromatography was performed using Silica Gel 
60 (230-400 mesh) from Sorbent Technologies or Silica RediSep Rf flash columns on a 
CombiFlash Rf automated flash chromatography system.  All 
1
H and 
13
C NMR spectra were 
recorded on a Bruker AV-400 (400 MHz) instrument.  Chemical shifts are reported in ppm 
relative to residual solvent peaks as an internal standard set to δ 7.26 and δ 77.16 (CDCl3) or 
δ 3.31 and δ 49.00 (MeOD).  Data are reported as follows: chemical shift, multiplicity (s = 
singlet, d = doublet, t = triplet, q = quartet, p = pentet, sx = sextet, sp = septet, br = broad, dd 
= doublet of doublets, dq = doublet of quartets, td = triplet of doublets, pd = pentet of 
doublets, m = multiplet), coupling constant (Hz), integration. Low resolution mass spectra 
(LCMS) were recorded on an Agilent 1200 LCMS with electrospray ionization.  High 
resolution mass spectra (HRMS) were recorded on a Waters QToF-API-US plus Acuity 
system with ES as the ion source. Analytical high performance liquid chromatography 
(HPLC) was performed on an Agilent 1200 analytical LCMS with UV detection at 214 nm 
and 254 nm along with ELSD detection.  Chiral separations were performed on a Thar 
Investigator II supercritical fluid chromatograph (SFC) utilizing Chiralcel
® 
OD, OD-Cl, OJ, 
and Chiralpak
®
 IA columns. Optical rotations were acquired on a Jasco P-2000 polarimeter at 
23 ⁰C and 589 nm.  The specific rotations were calculated according to the equation [α]23/D 
= 100α/l x c where l is the path length in decimeters and c is the concentration in g/100 mL.   
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General Procedure A—for fluorination and reduction of aldehydes. 
 
To a round-bottom flask equipped with a magnetic stir bar and charged with (R)-5-benzyl-
2,2,3-trimethylimidazolidin-4-one dichloro acid salt (139 mg, 0.400 mmol) and N-
fluorobenzenesulfonimide (3.15 g, 10.0 mmol) was added THF (8.0 mL) and iPrOH (1.0 
mL).  The mixture was stirred at room temperature until all solids were dissolved and was 
then cooled to -20⁰ C.  The aldehyde substrate (2 mmol) was then slowly added to the 
reaction mixture dissolved in THF (1.0 mL) and the mixture was left to stirred for 16 hours.  
The reaction was then diluted with Et2O (20 mL), cooled to -78⁰C, and filtered through a pad 
of silica gel, eluting with cold Et2O (~50 mL).  The resultant organic layer was washed with 
saturated NaHCO3 (3 x 75 mL), saturated brine (75 mL), dried over MgSO4, filtered, and 
concentrated.  The resultant oil was the dissolved in DCM (12 mL) and EtOH (8 mL) and 
NaBH4 (189 mg, 5.0 mmol) was added at room temperature, all at once.  After 30 minutes, 
the reaction was cooled to 0⁰ C and was quenched with saturated NH4Cl (~100 mL).  The 
mixture was stirred vigorously and allowed to warm to room temperature and stirred for an 
additional 30 minutes. 75 mL DCM was added to the suspension when it was extracted with 
DCM (3 x 75 mL).  The combined organic extracts were then washed with NaHCO3 (3 x 75 
mL) and brine (75 mL), dried with MgSO4, filtered and concentrated.  Purification of the 
resultant oil was performed by flash column chromatography. 
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The product was prepared according general procedure A, purified via flash column 
chromatography (15% ethyl acetate in hexanes) to afford the product was a clear oil (200 mg, 
65% yield).  
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 7.36-7.20 (m, 5H); 4.78 (dm, J = 49.0 
Hz); 3.84-3.63 (m, 2H); 3.10-2.89 (m, 2H); 1.92 (s, br, 1H). 
13
C NMR (100.6 MHz, CDCl3) δ 
(ppm): 136.52 (d, J = 5.5 Hz), 129.33, 128.58, 126.75, 95.70 (d, J = 171.9 Hz), 64.01 (d, J = 
21.7 Hz), 37.45 (d, J = 21.2 Hz). Specific rotation [ =  +14.9⁰ (c = 100, CHCl3). HRMS 
(TOF, ES+) C9H11OFNa [M+Na]
+
 calc. mass 177.0692, found 177.0692.   
 
 
The product was prepared according general procedure A, purified via flash column 
chromatography (25% ethyl acetate in hexanes) to afford the product was a waxy solid (291 
mg, 73% yield).  
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 7.13 (d, J = 8.6 Hz, 2H); 6.86 (d, J 
= 8.6 Hz, 2H); 4.56 (dm, J = 49.9 Hz, 1H); 3.79 (s, 3H); 3.74-3.59 (m, 2H); 2.92 (s, br, 1H); 
2.82-2.56 (m, 2H); 2.07-1.92 (m, 1H); 1.89-1.71 (m, 1H). 
13
C NMR (100.6 MHz, CDCl3) δ 
(ppm): 157.89, 133.12, 129.33, 113.89, 93.72 (d, J = 168.7 Hz), 64.75 (d, J = 21.9), 55.20, 
32.84 (d, J = 20.7), 30.11 (d, J = 4.7). Specific rotation [ =  +24.2⁰ (c = 100, CHCl3). 
HRMS (TOF, ES+) C11H15O2FNa [M+Na]
+
 calc. mass 221.0956, found 221.0954.   
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The product was prepared according general procedure A, purified via flash column 
chromatography (10% ethyl acetate in hexanes) to afford the product as a clear oil (365 mg, 
77% yield). 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 4.52 (dm, J = 49.4 Hz, 1H); 3.70-3.53 
(m, 4H); 3.31 (s, br, 1H); 1.69-1.48 (m, 4H); 0.84 (s, 9H); 0.00 (s, 6H). 
13
C NMR (100.6 
MHz, CDCl3) δ (ppm): 94.12 (d, J = 169.2 Hz), 64.28 (d, J = 22.2 Hz), 62.47, 27.97 (d, J = 
4.2 Hz), 27.37 (d, J = 20.8 Hz), 25.72, 18.04, -5.60. Specific rotation [ =  5.9⁰ (c = 100, 
CHCl3). HRMS (TOF, ES+) C11H26O2FSi [M+H]
+
 calc. mass 237.1686, found 237.1688.   
 
 
The product was prepared according general procedure A, purified via flash column 
chromatography (10% ethyl acetate in hexanes) to afford the product as a clear oil (249 mg, 
74% yield, 1:1 dr).  
1
H NMR—Diastereomer A (less polar) (400.1 MHz, CDCl3) δ (ppm): 
7.39-7.23 (m, 5H); 4.62 (dm, J = 49.1 Hz, 1H); 3.66-3.47 (m, 2H); 3.16-2.97 (m, 2H); 1.43 
(d, J = 7.1 Hz, 3H). 
1
H NMR—Diastereomer B (more polar) (400.1 MHz, CDCl3) δ (ppm): 
7.36-7.20 (m, 5H); 4.69 (dm, J = 48.5 Hz, 1H); 3.81-3.51 (m, 2H); 3.16-3.02 (m, 2H); 1.83 
(s, br, 1H); 1.35 (d, J = 7.2 Hz, 3H). 
13
C NMR—Diastereomer A (less polar)  (100.6 MHz, 
CDCl3) δ (ppm): 142.32 (d, J = 7.7 Hz), 128.66, 127.59, 126.89, 98.02 (d, J = 175.5 Hz), 
63.02 (d, J = 21.6 Hz), 40.93 (d, J = 20.5 Hz), 17.19 (d, J = 4.9 Hz).
 13
C NMR—
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Diastereomer B (more polar) (125 MHz, CDCl3) δ (ppm): 141.94, 128.63, 128.08, 127.02, 
97.57 (d, J = 174.1 Hz), 63.60 (d, J = 22.6 Hz), 41.13 (d, J = 20.1 Hz), 17.54 (d, J = 6.1 Hz). 
Specific rotation—Diastereomer A (less polar) [ =  +12.3⁰ (c = 100, CHCl3). Specific 
rotation—Diastereomer B (more polar) [ =  +6.1⁰ (c = 100, CHCl3). HRMS (TOF, 
ES+)–Diastereomer A (less polar): C10H13OFNa [M+Na]
+
 calc. mass 191.0848, found 
191.0848.  HRMS (TOF, ES+)–Diastereomer B (more polar): C10H13OFNa [M+Na]
+
 calc. 
mass 191.0848, found 191.0847.   
 
 
 
 
The product was prepared according general procedure A,  purified via flash column 
chromatography (10% ethyl acetate in hexanes) to afford the product was a waxy solid (282 
mg, 69% yield).  
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 4.524 (dm, J = 51.3 Hz, 1H); 3.77-
3.50 (m, 3H); 1.71-1.16 (m, 18H); 0.85 (t, J = 6.6 Hz, 3H).
13
C NMR (100.6 MHz, CDCl3) δ 
(ppm): 94.83 (d, J = 168.1 Hz), 64.96 (d, J = 22.1 Hz), 31.99, 31.08 (d, J = 20.6 Hz), 29.69, 
29.65, 29.57, 29.54, 29.42, 25.02 (d, J = 4.8 Hz), 22.76, 14.14. Specific rotation [ =  
+9.6⁰ (c = 100, CHCl3). HRMS (TOF, ES+) C12H25OFNa [M+Na]
+
 calc. mass 227.1787, 
found 227.1787.   
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The product was prepared according general procedure A, purified via flash column 
chromatography (15% ethyl acetate in hexanes) to afford the product was a clear oil (236 mg, 
81% yield).  
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 4.20 (dm, J = 49.2 Hz, 1H); 3.70-3.57 
(m, 2H); 3.21 (s, br, 1H); 1.79 (dm, br, J = 12.7, 1H); 1.73-1.49 (m, 5H); 1.26-0.93 (m, 5H). 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 98.38 (d, J = 169.6 Hz), 62.84 (d, J = 22.2 Hz), 
38.79 (d, J = 18.8 Hz), 28.11 (dd, J1 = 51.2 Hz, J2 = 5.6 Hz), 26.14, 25.67 (d, J = 17.4 Hz). 
Specific rotation [ =  2.4⁰ (c = 100, CHCl3). HRMS (TOF, ES+) C8H15O2FNa [M+Na]
+
 
calc. mass 169.1005, found 169.005.   
 
General procedure B—procedure for preparation of difluoro-alcohols 
 
To a round-bottom flask equipped with a magnetic stir bar and charged with DL proline 
(103.5 mg, 0.9 mmol) and N-fluorobenzenesulfonimide (7.568 g, 24.0 mmol) was added 
THF (27 mL).  The mixture was stirred at room temperature until all solids were dissolved 
and the aldehyde substrate (649.2 mg, 3 mmol) was then slowly added to the reaction 
mixture dissolved in THF (3.0 mL) and the mixture was stirred for 16 hours.  The reaction 
was then diluted with Et2O (20 mL), cooled to -78⁰C, and filtered through a pad of silica gel, 
eluting with cold Et2O (~75 mL).  The resultant organic layer was washed with saturated 
NaHCO3 (3x), saturated brine (1x), dried over MgSO4, filtered, and concentrated.  The 
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resultant oil was the dissolved in DCM (18 mL) and EtOH (12 mL) and NaBH4 (283.7 mg, 
7.5 mmol) was added at room temperature, all at once.  After 30 minutes, the reaction was 
cooled to 0⁰C and was quenched with saturated NH4Cl (~100 mL).  The mixture was stirred 
vigorously and allowed to warm to room temperature and stir for an additional 30 minutes.  
About 75 mL of DCM was added to the suspension and it was extracted with DCM (3x).  
The combined organic extracts were then washed with NaHCO3 (3x) and brine (1x), dried 
with MgSO4, filtered and concentrated.  Purification of the resultant oil was performed by 
flash column chromatography. 
 
 
 
 
The product was prepared according general procedure B, purified via flash column 
chromatography (10% ethyl acetate in hexanes) to afford the product as a clear oil (586 mg, 
77% yield). 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 3.73-3.60 (m, 4H); 3.49 (s, br, 1H); 
2.03-1.85 (m, 2H); 1.75-1.63 (m, 2H); 0.87 (s, 9H); 0.03 (s, 6H). 
13
C NMR (100.6 MHz, 
CDCl3) δ (ppm): 123.52 (t, J = 241.5 Hz), 63.85 (t, J = 31.8 Hz), 62.59, 29.89 (t, J = 24.2 
Hz), 25.97, 25.14 (t, J = 4.3 Hz), 18.39, -5.34. HRMS (TOF, ES+) C11H25O2F2Si [M+H]
+
 
calc. mass 255.1592, found 255.1592. 
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General Procedure C—procedure for preparation of fluoro-nitriles 
 
To a flame dried round-bottom flask equipped with a magnetic stir bar and charged with the 
chiral fluoro-alcohol (1 mmol) and lutidine (535 mg, 5.0 mmol) was added DCM (5 mL), and 
the mixture was cooled to 0⁰C with stirring.  Trifluoromethanesulfonic anhydride (339 mg, 
1.2 mmol) was added to the reaction dropwise, and the mixture was left to stir for 30 
minutes.  The reaction was then diluted with Et2O and water was added to quench the 
reaction.  The mixture was extracted with Et2O (3x), dried with MgSO4, filtered, and 
concentrated.  The resultant oil was transferred to a round-bottom flask equipped with a 
magnetic stir bar where it was dissolved in acetonitrile (4 mL), and 18-crown-6 (53 mg, 0.2 
mmol) was added and allowed to dissolve with stirring.  Potassium cyanide (651 mg, 10 
mmol) was added to the reaction at room temperature and the reaction was left with vigorous 
stirring for the following 16 hours.  The reaction was then quenched via the addition of 
saturated NaHCO3 and it was extracted with DCM (3x).  The organic extract was dried with 
MgSO4, filtered, and concentrated and the resultant crude oil was purified via flash column 
chromatography. 
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The product was prepared according general procedure C, purified via flash column 
chromatography (15% ethyl acetate in hexanes, visualized TLC with KMnO4) to afford the 
product was a clear oil (126 mg, 77% yield). 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 7.41-
7.23 (m, 5H); 4.93 (dp, J1 = 46.7 Hz, J2 = 5.6 Hz, 1H); 3.21-2.97 (m, 2H); 2.75-2.52 (m, 2H). 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 134.77 (d, J = 5.6 Hz), 129.39, 128.86, 127.37, 
116.07 (d, J = 5.4 Hz), 88.70 (d, J = 180.9 Hz), 40.17 (d, J = 20.8), 23.11 (d, J = 24.7 Hz). 
Specific rotation [ =  -12.3⁰ (c = 100, CHCl3). HRMS (TOF, ES+) C10H10NFNa 
[M+Na]
+
 calc. mass 186.0695, found 186.0692.   
 
 
 
The product was prepared according general procedure C, purified via flash column 
chromatography (20% ethyl acetate in hexanes, visualized TLC with KMnO4) to afford the 
product was a clear oil (190 mg, 92% yield).  
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 7.12 
(d, J = 8.6 Hz, 2H); 6.86 (d, J = 8.6 Hz, 2H); 4.69 (dsx, J1 = 47.5 Hz, J2 = 5.3 Hz, 1H); 3.8 (s, 
3H); 2.86-2.57 (m, 4H); 2.21-2.06 (m, 1H); 2.02-1.83 (m, 1H). 
13
C NMR (100.6 MHz, 
CDCl3) δ (ppm): 158.25, 132.05, 129.44, 114.97 (d, J = 6.1 Hz), 114.13, 87.49 (d, J = 177.9 
Hz), 55.33, 36.16 (d, J = 20.3 Hz), 29.90 (d, J = 4.2 Hz), 24.10 (d, J = 25.5 Hz). Specific 
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rotation [ =  +22.8⁰ (c = 100, CHCl3). HRMS (TOF, ES+) C12H14NFNa [M+Na]
+
 calc. 
mass 230.0957, found 230.0955.   
 
 
The product was prepared according general procedure C, purified via flash column 
chromatography (15% ethyl acetate in hexanes, visualized TLC with KMnO4) to afford the 
product was a clear oil (175 mg, 71% yield).  
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 4.76 
(dm, J = 47.5 Hz, 1H); 3.69-3.59 (m, 2H); 2.78-2.59 (m, 2H); 1.90-1.53 (m, 4H); 0.87 (s, 
9H); 0.03 (s, 6H).
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 116.03 (d, J = 5.8 Hz), 88.51 (d, J 
= 177.4 Hz), 62.24, 31.11 (d, J = 20.4 Hz), 27.85 (d, J = 4.2 Hz), 25.94, 24.09 (d, J = 25.3 
Hz), 18.30, -5.35. Specific rotation [ =  +4.0⁰ (c = 100, CHCl3). HRMS (TOF, ES+) 
C12H25NOFSi [M+H]
+
 calc. mass 246.1689, found 246.1690.   
 
 
The product (diastereomer A) was prepared according to general procedure C, purified via 
flash column chromatography (10% ethyl acetate in hexanes, visualized TLC with KMnO4) 
to afford the product was a clear oil (164 mg, 93% yield). The product (diastereomer B) was 
prepared according to general procedure C, purified via flash column chromatography (10% 
ethyl acetate in hexanes, visualized TLC with KMnO4) to afford the product was a clear oil 
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(137 mg, 77% yield).    
1
H NMR—Diastereomer A (less polar) (400.1 MHz, CDCl3) δ 
(ppm): 7.39-7.20 (m, 5H); 4.72 (dm, J = 46.9 Hz, 1H); 3.17-3.05 (m, 1H); 2.65-2.33 (m, 2H); 
1.45 (dd, J1 = 6.9 Hz, J2 = 1.3 Hz, 3H). 
1
H NMR—Diastereomer B (more polar) (400.1 
MHz, CDCl3) δ (ppm): 7.40-7.26 (m, 5H); 4.89 (dm, J = 46.9 Hz, 1H); 3.18-3.03 (m, 1H); 
2.65-2.44 (m, 2H); 1.44 (d, J = 7.3 Hz, 3H). 
13
C NMR—Diastereomer A (less polar) (100.6 
MHz, CDCl3) δ (ppm): 140.72 (d, J = 8.3 Hz), 129.23, 127.76, 127.59, 116.15 (d, J = 3.3 
Hz), 92.21 (d, J = 184.5 Hz), 44.07 (d, J = 20.0 Hz), 22.56 (d, J = 23.7 Hz), 17.32 (d, J = 4.1 
Hz). 
13
C NMR—Diastereomer B (more polar) (100.6 MHz, CDCl3) δ (ppm): 139.65 (d, J = 
1.2 Hz), 128.78, 128.30, 127.53, 116.23 (d, J = 7.7 Hz), 91.58 (d, J = 183.6 Hz), 43.26 (d, J 
= 19.1 Hz), 22.04 (d, J = 26.9 Hz), 17.07 (d, J = 5.5 Hz). Specific rotation—Diastereomer A 
(less polar) [ =  -41.8⁰ (c = 100, CHCl3). Specific rotation—Diastereomer B (more 
polar)  [ =  +41.0⁰ (c = 100, CHCl3). HRMS—Diastereomer A (less polar)  (TOF, 
ES+) C11H13NF [M+H]
+
 calc. mass 178.1032, found 178.1033.  HRMS—Diastereomer B 
(more polar)   (TOF, ES+) C11H13NF [M+H]
+
 calc. mass 178.1032, found 178.1033.     
 
 
The product was prepared according to general procedure C, purified via flash column 
chromatography (10% ethyl acetate in hexanes, visualized TLC with KMnO4) to afford the 
product was a waxy solid (175 mg, 82% yield).  
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 4.69 
(dm, J = 47.7 Hz, 1H); 2.76-2.56 (m, 2H); 1.87-1.55 (m, 2H); 1.51-1.17 (m, 16H), 0.86 (t, J 
= 7.0 Hz, 3H). 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 116.11 (d, J = 6.1 Hz), 88.54 (d, J = 
177.4 Hz), 34.27 (d, J = 20.1 Hz), 31.92, 29.58, 29.51, 29.41, 29.33, 29.17, 24.66 (d, J = 4.4 
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Hz), 24.02 (d, J = 25.6 Hz), 22.70, 14.11. Specific rotation [ =  +8.5⁰ (c = 100, CHCl3). 
HRMS (TOF, ES+) C13H24NFNa [M+Na]
+
 calc. mass 236.1790, found 236.1790.   
 
The product was prepared according to general procedure C, purified via flash column 
chromatography (10% ethyl acetate in hexanes, visualized TLC with KMnO4) to afford the 
product was a clear oil (131 mg, 84% yield). 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 4.44 
(dq, J1 = 47.0 Hz, J2 = 6.2 Hz, 1H); 2.78-2.60 (m,, 2H); 1.95-1.88 (m, 1H); 1.84-1.56 (m, 
5H); 1.36-0.99 (m, 5H). 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 116.45 (d, J = 5.4 Hz), 
92.18 (d, J = 179.6 Hz), 41.31 (d, J = 18.7 Hz), 27.84 (dd, J1 = 78.4 Hz, J2 = 4.8 Hz), 26.05, 
25.55 (d, J = 26.3 Hz), 21.79 (d, J = 25.9 Hz). Specific rotation [ =  -4.2⁰ (c = 100, 
CHCl3). HRMS (TOF, ES+) C9H14NFNa [M+Na]
+
 calc. mass 178.1008, found 178.1007.   
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General procedure D—preparation of -Fluoroamines 
 
To a flame dried round-bottom flask equipped with a magnetic stir bar and charged with 
anhydrous InCl3 (111 mg, 0.50 mmol) and NaBH4 (56.7 mg, 1.50 mmol) was added 
anhydrous THF (1.2 mL) and the heterogeneous mixture was allowed to stir under argon for 
1 hour.  The nitrile substrate (0.5 mmol) was then slowly added to the reaction mixture in 
dissolved in THF (0.5 mL).  The reaction was then allowed to stir and was monitored by 
TLC until completion (approx. 4 hrs). The solution was quenched by the dropwise addition 
of water (2 mL).  This solution was then heated to 75 ⁰C for 30 minutes, then MeOH (2 mL) 
was added to the mixture and it was again heated to 75 ⁰C for an additional 30 minutes.  The 
solution was then filtered, eluting with MeOH to remove any solid reaction components and 
the filtrate was concentrated under reduced pressure.  The resultant crude material was 
purified via flash column chromatography (DCM/MeOH). 
 
 
The product was prepared according to general procedure D, purified via flash column 
chromatography (10% MeOH in DCM, visualize TLC with ninhydrin) to afford the product 
was a clear oil (73 mg, 87% yield), which was determined to have an ee of 94% by 
19
F NMR 
of the (R) mosher amide of the final amine (
19
F NMR (300 MHz, CDCl3) δ (ppm): δ  (minor) 
-180.70, δ  (major) -180.94, fluorine NMR of racemic and enantioenriched mosher amides 
106 
 
shown below. 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 7.33-7.18 (m, 5H); 4.81 (dm, J = 49.0 
Hz, 1H); 3.05-2.78 (m, 4H); 1.88-1.60 (m, 2H); 1.49 (s, br, 2H).
 13
C NMR (100.6 MHz, 
CDCl3) δ (ppm): 137.10 (d, J = 5.0 Hz), 129.42, 128.49, 126.65, 92.97 (d, J = 170.6 Hz), 
41.86 (d, J = 21.1 Hz), 38.40, 38.29 (d, J = 14.5 Hz). Specific rotation [ =  -2.1⁰ (c = 
100, CHCl3).HRMS (TOF, ES+) C10H15NF [M+H]
+
 calc. mass 168.1189, found 168.1190.   
 
 
The product was prepared according to general procedure D, purified via flash column 
chromatography (10% MeOH in DCM, visualize TLC with ninhydrin) to afford the product 
was a clear oil (89 mg, 84% yield) which was determined to have an ee of 87% by 
19
F NMR 
of the (R) mosher amide of the final amine (
19
F NMR (300 MHz, CDCl3) δ (ppm): δ  (minor) 
-184.15, δ  (major) -184.32, fluorine NMR of racemic and enantioenriched mosher amides 
shown below.  
1H NMR (400.1 MHz, MeOD) δ (ppm): 7.10 (d, J = 8.5 Hz, 2H); 6.82 (d, J = 
8.7 Hz, 2H);  4.55 (dsp, J1 = 49.8 Hz, J2 = 4.0 Hz, 1H); 3.75 (s, 3H); 2.83-2.56 (m, 4H); 1.98-
1.60 (m, 4H).
 13C NMR (100.6 MHz, MeOD) δ (ppm): 159.42, 134.76, 130.33, 114.87, 93.01 
(d, J = 166.7 Hz), 55.63, 39.12 (d, J = 20.4 Hz), 38.81 (d, J = 4.1 Hz), 38.61 (d, J = 20.6 Hz), 
31.40 (d, J = 4.6 Hz). Specific rotation [ =  +11.6⁰ (c = 100, CHCl3).HRMS (TOF, ES+) 
C12H19NOF [M+H]
+
 calc. mass 212.1451, found 212.1447.   
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The product was prepared according general procedure D, purified via flash column 
chromatography (10% MeOH in DCM, visualize TLC with ninhydrin) to afford the product 
was a clear oil (107 mg, 86% yield) which was determined to have an ee of 92% by 
19
F NMR 
of the (R) mosher amide of the final amine (
19
F NMR (300 MHz, CDCl3) δ (ppm): δ  (minor) 
-184.15, δ  (major) -184.32, fluorine NMR of racemic and enantioenriched mosher amides 
shown below.  
1H NMR (400.1 MHz, MeOD) δ (ppm): 4.60 (dm, J = 50.2 Hz, 1H); 3.71-
3.55 (m, 2H); 2.84-2.70 (m, 2H); 1.87-1.53 (m, 6H); 0.91 (s, 9H); 0.07 (s, 6H). 
13
C NMR 
(100.6 MHz, MeOD) δ (ppm): 93.73 (d, J = 166.4 Hz), 63.88, 39.27 (d, J = 20.5 Hz), 38.95 
(d, J = 4.4 Hz), 32.97 (d, J = 21.1 Hz), 29.49 (d, J = 4.1 Hz), 26.41, 19.13, -5.18. Specific 
rotation [ =  -4.2⁰ (c = 100, CHCl3). HRMS (TOF, ES+) C12H29NOFSi [M+H]
+
 calc. 
mass 250.2002, found 250.2001.   
 
The product (diastereomer A) was prepared according to general procedure D,  purified via 
flash column chromatography (10% MeOH in DCM, visualize TLC with ninhydrin) to afford 
the product was a clear oil (75 mg, 83% yield) which was determined to have an ee of 96% 
by 
19
F NMR of the (R) mosher amide of the final amine (
19
F NMR (300 MHz, CDCl3) δ 
(ppm): δ  (major) -186.34, δ  (minor) -186.39, fluorine NMR of racemic and enantioenriched 
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mosher amides shown below.  The product (diastereomer B) was prepared according to 
general procedure D,  purified via flash column chromatography (10% MeOH in DCM, stain 
visualize with ninhydrin) to afford the product was a clear oil (82 mg, 90% yield) which was 
determined to have an ee of 96% by 
19
F NMR of the (R) mosher amide of the final amine 
(
19
F NMR (300 MHz, CDCl3) δ (ppm): δ  (minor) -187.23, δ  (major) -187.43, fluorine NMR 
of racemic and enantioenriched mosher amides shown below.  
1
H NMR—Diastereomer A 
(less polar) (400.1 MHz, MeOD) δ (ppm): 7.33-7.26 (m, 2H); 7.25-7.18 (m, 3H); 4.65 (dm, J 
= 49.0 Hz); 2.97-2.83 (m, 1H); 2.79-2.61 (m, 2H); 1.81-1.44 (m, 2H); 1.35 (d, J = 7.0 Hz). 
1
H NMR—Diastereomer B (more polar) (400.1 MHz, MeOD) δ (ppm): 7.32-7.17 (m, 5H); 
4.71 (dm, J = 48.9 Hz, 1H); 2.99-2.85 (m, 1H); 2.83-2.69 (m, 2H); 1.78-1.58 (m, 2H); 1.33 
(d, J = 7.2 Hz, 3H). 
13
C NMR—Diastereomer A (less polar) (100.6 MHz, MeOD) δ (ppm): 
144.49 (d, J =6.8 Hz), 129.63, 128.89, 127.80, 97.34 (d, J = 173.3 Hz), 46.19 (d, J = 20.5 
Hz), 39.10 (d, J = 3.5 Hz), 37.32 (d, J = 20.7 Hz), 17.67 (d, J = 5.4 Hz). 
13
C NMR—
Diastereomer B (more polar) (100.6 MHz, MeOD) δ (ppm): 143.62 (d, 2.3 Hz), 129.37, 
129.28, 127.62, 96.81 (d, J = 172.8 Hz), 45.61 (d, J = 19.8 Hz), 38.98 (d, J = 4.0 Hz), 36.46 
(d, J = 20.8 Hz), 17.96 (d, J = 5.9 Hz).Specific rotation—Diastereomer A (less polar) 
[ =  -9.1⁰ (c = 100, CHCl3). Specific rotation— Diastereomer B (more polar) [ =  -
14.0⁰ (c = 100, CHCl3). HRMS—Diastereomer A (less polar)  (TOF, ES+) C11H17NF 
[M+H]
+
 calc. mass 182.1345, found 182.1343. HRMS—Diastereomer B (more polar)   
(TOF, ES+) C11H17NF [M+H]
+
 calc. mass 182.1345, found 182.1346. 
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The product was prepared according to general procedure D, purified via flash column 
chromatography (10% MeOH in DCM, visualize TLC with ninhydrin) to afford the product 
was a waxy solid (97 mg, 89% yield) which was determined to have an ee of 95% by 
19
F 
NMR of the (R) mosher amide of the final amine (
19
F NMR (300 MHz, CDCl3) δ (ppm): δ  
(minor) -181.97, δ  (major) -182.19, fluorine NMR of racemic and enantioenriched mosher 
amides shown below. 
1H NMR (400.1 MHz, MeOD) δ (ppm): 4.56 (dm, J = 49.7 Hz, 1H); 
2.83-2.70 (m, 2H); 1.81-1.42 (m, 5H); 1.41-1.24 (m, 15H); 0.90 (t, J = 7.1 Hz, 3H). 
13
C 
NMR (100.6 MHz, MeOD) δ (ppm): 93.81 (d, J = 166.3 Hz), 39.15 (d, J = 20.7 Hz), 38.95 
(d, J = 4.4 Hz), 36.53 (d, J = 20.7 Hz), 33.08, 30.75, 30.73, 30.70, 30.62, 30.49, 26.22 (d, J = 
4.6 Hz), 23.75, 14.47. Specific rotation [ =  -4.6⁰ (c = 100, CHCl3).HRMS (TOF, ES+) 
C13H29NF [M+H]
+
 calc. mass 218.2284, found 218.2283.   
 
 
The product was prepared according to general procedure D, purified via flash column 
chromatography (10% MeOH in DCM, visualize TLC with ninhydrin) to afford the product 
was a clear oil (58 mg, 73% yield), which was determined to have an ee of 96% by 
19
F NMR 
of the (R) mosher amide of the final amine (
19
F NMR (300 MHz, CDCl3) δ (ppm): δ  (minor) 
-187.84, δ  (major) -187.94, fluorine NMR of racemic and enantioenriched mosher amides 
110 
 
shown below.  
1H NMR (400.1 MHz, MeOD) δ (ppm): 4.30 (dm, J = 49.2 Hz, 1H); 2.89-
2.72 (m, 2H); 1.92-1.84 (m, 1H); 1.83-1.62 (m, 5H); 1.57-1.42 (m, 1H); 1.36-1.00 (m, 5H). 
13C NMR (100.6 MHz, MeOD) δ (ppm): 97.39 (d, J = 168.6 Hz), 43.61 (d, J = 19.3 Hz), 39.1 
(d, J = 3.8 Hz), 35.74 (d, J = 21.3 Hz), 29.20 (dd, J1 = 97 Hz, J2 = 5.7 Hz), 27.30 (d, J = 35.7 
Hz), 29.94. Specific rotation [ =  -19.0⁰ (c = 100, CHCl3).HRMS (TOF, ES+) C9H19NF 
[M+H]
+
 calc. mass 160.1502, found 160.1502.   
 
General Procedure E—preparation of β-fluoroamines or β,β-difluoroamines 
 
Triflic anhydride (339 mg, 1.2 mmol) was added dropwise to a flame dried round bottom 
flask equipped with a magnetic stir bar and charged with the chiral fluoro alcohol or difluoro 
alcohol (1 mmol) and lutidine (535 mg, 5 mmol) in DCM (5 mL) under argon at 0⁰C. The 
reaction mixture was allowed to stir for 30 minutes before it was removed from the stir plate 
while still being kept at 0⁰C. A separate round bottom flask equipped with a magnetic stir bar 
and charged with benzylamine (1.07 g, 10.0mmol) in 2 mL of DCM was stirred at 0⁰C.  The 
solution of the triflate was then added slowly to this new flask taking care to keep everything 
at 0⁰C, and after addition was complete, the flask was washed with an additional 2 mL of 
DCM and that was then added to the reaction to bring the total volume of DCM to 9 mL.  
The reaction was then allowed to warm to room temperature over the next hour and left to 
stir overnight (14-16 hours). The β,β-difluoroamines were allowed to react for 24 hours. A 
solution of saturated NaHCO3 was added to quench the reaction and it was transferred to a 
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separatory funnel.  There it was extracted 3X with DCM and the combined organic extracts 
were dried with MgSO4, filtered, and concentrated under reduced pressure.  The crude oil 
was then purified via flash column chromatography (hexanes/ethyl acetate). 
 
 
The product was prepared according to general procedure E, purified via flash column 
chromatography (20-50% ethyl acetate in hexanes, visualize TLC with ninhydrin) to afford 
the product was a clear oil (204 mg, 84% yield), which was determined to have an ee of 94% 
by chiral HPLC analysis (Chiralpak IA, tR (major) = 4.87 minutes, tR (minor) = 5.74 minutes, 
traces shown below).
 1
H NMR (400.1 MHz, CDCl3) δ (ppm): 7.42-7.23 (m, 10H); 4.91 (dm, 
J = 48.9 Hz, 1H); 3.91-3.81 (m, 2H); 3.13-2.78 (m, 4H); 1.86 (s, br, 1H). 
13
C NMR (100.6 
MHz, CDCl3) δ (ppm): 140.09, 136.96 (d, J = 5.5 Hz), 129.40, 128.55, 128.50, 128.18, 
127.10, 126.70, 94.07 (d, J = 171.2 Hz), 53.83, 52.38 (d, J = 21.0 Hz), 39.45 (d, J = 21.2 
Hz). Specific rotation [ =  -2.3⁰ (c = 100, CHCl3). HRMS (TOF, ES+) C16H19NF [M+H]
+
 
calc. mass 244.1502, found 244.1503.   
 
 
The product was prepared according to general procedure E, purified via flash column 
chromatography (20-50% ethyl acetate in hexanes, visualize TLC with ninhydrin) to afford 
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the product was a clear oil (277 mg, 96% yield), which was determined to have an ee of 90% 
by chiral HPLC analysis (Chiralpak IB, tR (major) = 6.56 minutes, tR (minor) = 5.93 minutes, 
traces shown below).
 1
H NMR (400.1 MHz, CDCl3) δ (ppm): 7.41-7.25 (m, 5H); 7.14 (d, J = 
8.6 Hz, 2H); 6.87 (d, J = 8.6 Hz, 2H); 4.68 (dm, J = 50.0 Hz, 1H); 3.85 (s, 2H); 3.81 (s, 3H); 
2.94-2.63 (m, 4H); 2.10-1.95 (m, 1H); 1.93-1.80 (m, 1H); 1.78 (s, br, 1H). 
13
C NMR (100.6 
MHz, CDCl3) δ (ppm): 157.97, 140.10, 133.30, 129.40, 128.47, 128.13, 127.07, 113.92, 
93.05 (d, J = 167.8 Hz), 55.26, 53.83, 53.07 (d, J = 20.9 Hz), 35.00 (d, J = 20.6 Hz), 30.36 
(d, J = 4.6 Hz). Specific rotation [ =  +11.8⁰ (c = 100, CHCl3). HRMS (TOF, ES+) 
C18H23NOF [M+H]
+
 calc. mass 288.1764, found 288.1762.   
 
 
The product was prepared according to general procedure E, purified via flash column 
chromatography (20-50% ethyl acetate in hexanes, visualize TLC with ninhydrin) to afford 
the product was a clear oil (314 mg, 96% yield), which was determined to have an ee of 94% 
by chiral HPLC analysis (Chiralpak ID, tR (major) = 9.74 minutes, tR (minor) = 10.65 
minutes, traces shown below).
 1
H NMR (400.1 MHz, CDCl3) δ (ppm): 7.39-7.22 (m, 5H); 
4.68 (dm, J = 50.0 Hz, 1H); 3.87-3.79 (m, 2H); 3.69-3.58 (m, 2H); 2.90-2.68 (m, 2H); 1.81-
1.54 (m, 5H); 0.90 (s, 9H); 0.06 (s, 6H).  
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 140.18, 
128.54, 128.19, 127.12, 93.89 (d, J = 167.8 Hz), 62.76, 53.90, 53.24 (d, J = 20.9 Hz), 29.62 
(d, J = 20.7 Hz), 28.43 (d, J = 4.3 Hz), 26.06, 18.43, -5.20. Specific rotation [ =  +0.6⁰ (c 
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= 100, CHCl3). HRMS (TOF, ES+) C18H33NOFSi [M+H]
+
 calc. mass 326.2315, found 
326.2318.   
 
The product was prepared according to general procedure E, purified via flash column 
chromatography (20-50% ethyl acetate in hexanes, visualize TLC with ninhydrin) to afford 
the product was a clear oil (277 mg, 81% yield). 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 
7.39-7.24 (m, 5H); 3.88 (s, 2H); 3.67 (t, J = 6.3 Hz, 2H); 2.95 (t, J = 14.1 Hz, 2H); 2.10-1.95 
(m, 2H); 1.75-1.66 (m, 2H); 1.62 (s, 1H); 0.93 (s, 9H); 0.09 (s, 6H). 
13
C NMR (100.6 MHz, 
CDCl3) δ (ppm): 139.96, 128.55, 128.17, 127.23, 127.87 (t, J = 240.9 Hz), 62.52, 53.78, 
52.70 (t, J = 28.4), 31.27 (t, J = 24.6 Hz), 26.04, 25.57 (t, J = 4.3 Hz) , 18.41, -5.23. HRMS 
(TOF, ES+) C18H32NOF2Si [M+H]
+
 calc. mass 344.2221, found 344.2219.   
 
Procedure F—preparation of β-fluoro tetrazoles 
 
The mixture of fluoro-nitrile 1.107 (354 mg, 2 mmol), sodium azide (244 mg, 6 mmol), and 
triethylamine hydrochloride (517 mg, 6 mmol) in toluene (6 mL), in a round-bottomed flask 
equipped with a magnetic stir bar, was stirred and heated to 70 ⁰C for 48 hours. After cooling 
to room temperature, the product was extracted with water (2 X 6 mL), and the aqueous layer 
was acidified with 1 mL of concentrated hydrochloric acid (38%). If a white solid did not 
immediately crash out of solution upon acidification, air was blown on the water for to 
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partially concentrate the water, and the β-fluoro-tetrazole then crashed out of solution as a 
white solid, which was collected using a Buchner funnel and was dried under reduced 
pressure. The solid was purified via reverse phase chromatography. 
 
 
The product was prepared according to general procedure F, and was purified via reverse 
phase chromatography (10-90% MeCN in water (0.1% TFA), to afford the product as a white 
solid (339 mg, 77% yield). 
1H NMR (400.1 MHz, MeOD) δ (ppm): 7.28-7.22 (m, 2H); 7.21-
7.12 (m, 3H); 4.84 (dm, J = 48.8 Hz, 1H); 3.40-3.21 (m, 2H); 2.86-2.66 (m, 2H); 2.04-1.86 
(m, 2H). 
13C NMR (100.6 MHz, MeOD) δ (ppm):154.38, 142.11, 129.50, 129.41, 127.11, 
91.62 (d, J = 172.0 Hz), 37.43 (d, J = 20.5 Hz), 31.92 (d, J = 4.3 Hz), 30.2 (d, J = 22.3 Hz). 
HRMS (TOF, ES+) C11H14N4F [M+H]
+
 calc. mass 221.1202, found 221.1201.   
 
Procedure G—preparation of β-fluoro amide oxime 
 
A mixture of fluoro-nitrile 1.107 (177 mg, 1 mmol) and aqueous hydroxylamine (66 mg, 2 
mmol, from 50% aqueous solution) in methanol (1 mL) was added to a round-bottomed flask 
equipped with a magnetic stir bar and was heated to 50⁰C for 5 hours with stirring.  The 
reaction was then concentrated under reduced pressure to evaporate all solvents and reagents.  
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Crude product was pure enough for use in future reactions, but was purified via reverse phase 
chromatography to obtain spectroscopically pure material. 
 
 
The product was prepared according to general procedure G, and was purified via reverse 
phase chromatography (10-90% MeCN in water (0.1% TFA), to afford the product as a white 
solid (191 mg, 91% yield). 
1H NMR (400.1 MHz, MeOD) δ (ppm): 7.31-7.24 (m, 2H); 7.23-
7.15 (m, 3H); 4.79 (dm, J = 49.0 Hz, 1H); 2.89-2.63 (m, 4H); 2.09-1.85 (m, 2H).
 13
C NMR 
(100.6 MHz, MeOD) δ (ppm): 161.66, 141.94, 129.57, 129.46, 127.23, 90.89 (d, J = 174.6), 
37.66 (d, J = 20.1 Hz), 35.9 (d, J = 22.3 Hz),  = 22.3 Hz), 31.82 (d, J = 3.9 Hz). HRMS 
(TOF, ES+) C11H16N2OF [M+H]
+
 calc. mass 211.1247, found 211.1245.   
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Experimental for chiral aziridines and azetidines  
All reagents were purchased from Sigma-Aldrich Corp., TCI America, Rieke Metals, Inc. 
and were used without purification. Analytical thin-layer chromatography (TLC) was 
performed on 250 µm silica plates from Sorbent Technologies.  Visualization was 
accomplished via UV light, and/or the use of ninhydrin, iodine, and potassium permanganate 
solutions followed by application of heat.  Chromatography was performed using Silica Gel 
60 (230-400 mesh) from Sorbent Technologies or Silica RediSep Rf flash columns on a 
CombiFlash Rf automated flash chromatography system.  All 
1
H and 
13
C NMR spectra were 
recorded on a Bruker AV-400 (400 MHz) instrument.  Chemical shifts are reported in ppm 
relative to residual solvent peaks as an internal standard set to δ 7.26 and δ 77.16 (CDCl3).  
Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, 
q = quartet, p = pentet, br = broad, dd = doublet of doublets, dq = doublet of quartets, td = 
triplet of doublets, pd = pentet of doublets, m = multiplet), coupling constat (Hz), integration. 
Low resolution mass spectra (LCMS) were recorded on an Agilent 1200 LCMS with 
electrospray ionization.  High resolution mass spectra (HRMS) were recorded on a Waters 
Qtof-API-US plus Acuity system with ES as the ion source. Analytical high performance 
liquid chromatography (HPLC) was performed on an Agilent 1200 analytical LCMS with 
UV detection at 214 nm and 254 nm along with ELSD detection.  Chiral separations were 
performed on a Thar Investigator II supercritical fluid chromatograph (SFC) utilizing 
Chiralcel
® 
OD, OD-Cl, OJ, and Chiralpak
®
 IA columns. Optical rotations were acquired on a 
Jasco P-2000 polarimeter at 23 ⁰C and 589 nm.  The specific rotations were calculated 
according to the equation [α]23/D = 100α/l x c where l is the path length in decimeters and c 
is the concentration in g/100 mL.   
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((S)-2-chloro-4-(4-methoxyphenyl)butan-1-ol) To a flame dried round-bottomed flask 
equipped with a magnetic stir bar, aldehyde (0.25 g, 1.40 mmol) was dissolved in DCM (2.81 
mL) at 0 °C. To the stirred solution was added diphenylpyrrolidine catalyst (31 mg, 0.14 
mmol) followed by N-chlorosuccinimide (0.24 g, 1.82 mmol). The solution was allowed to 
warm to rt over the next hour, and it was checked by 
1
H NMR for consumption of the 
starting material (8 hrs). The reaction was then diluted with methanol (7.0 mL), cooled to 0 
°C, and sodium borohydride (0.26 g, 7.02 mmol) was slowly added with stirring. The 
reaction was stirred for an additional 30 minutes, and was then quenched with water (30 mL). 
It was extracted into EtOAc (3 X 50 mL), the combined organic layer was dried with 
magnesium sulfate, filtered, and concentrated under reduced pressure. The crude material 
was then purified by flash column chromatography (4:1 Hex/EtOAc) to yield the desired 
product as a clear oil. (0.21 g, 77%). 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 7.12 (d, J = 8 
Hz, 2H); 6.84 (d, J = 8 Hz, 2H); 3.97 (m, 1H); 3.79 (s, 3H); 3.68 (dd, J1 = 11.5 Hz, J2 = 6.5 
Hz, 1H); 2.84 (dt, J1 = 14 Hz, J2 = 6.5 Hz, 1H); 2.71 (dt, J1 = 14 Hz, J2 = 8 Hz, 1H); 2.01 (m, 
2H); 1.9 (br s, 1H). 
 
 
((S)-N-benzyl-2-chloro-4-(4-methoxyphenyl)butan-1-amine) To a flame dried round-
bottomed flask equipped with a magnetic stir bar, starting material alcohol (0.18 g, 0.82 
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mmol) and lutidine (0.44 g, 4.09 mmol) were dissolved in DCM (4.1 mL) and the reaction 
was cooled to 0 °C. Triflic anhydride was added (0.28 g, 0.98 mmol) dropwise, and the 
solution was left to stir at 0 °C for 30 minutes. At that time, the triflate solution was taken up 
in a syringe and added dropwise to a stirring solution of benzylamine (0.88 g, 8.17 mmol) in 
DCM (1.5 mL) at 0 °C. The flask containing the triflate solution was washed 2 times with 
DCM (1 mL total) and added to the reaction. The solution was then allowed to warm to room 
temperature over an hour before leaving it to stir overnight. The reaction was quenched with 
saturated sodium bicarbonate (30 mL), diluted with DCM (25 mL), and extracted with DCM 
(3 X 30 mL). The organic layers were combined and washed with brine (1 X 100 mL), and 
the combined organic was dried with magnesium sulfate, filtered, and concentrated under 
reduced pressure to provide a crude yellow oil. The product was purified by flash column 
chromatography (9:0.9:0.1 DCM/MeOH/NH4OH) to provide the product as a pale yellow oil 
(0.22 g, 88%). 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 7.33 (m, 4H); 7.26 (m, 1H); 7.10 (d, J 
= 9 Hz, 2H); 6.83 (d, J = 9 Hz, 2H); 4.03 (m, 1H); 3.80 (dd, J1 = 14 Hz, J2 = 13 Hz, 2H); 
3.79 (s, 3H); 2.86 (dd, J1 = 6 Hz, J2 = 3 Hz, 2H); 2.80 (m, 1H); 2.01 (m, 2H). 
13
C NMR 
(100.6 MHz, CDCl3) δ (ppm): 157.94, 132.82, 129.39, 129.22, 128.42, 128.15, 128.07, 
127.06, 120.12, 113.86, 113.80, 62.48, 55.34, 55.21, 53.25, 37.97, 31.52, 24.41. 
 
 
((R)-1-benzyl-2-(4-methoxyphenethyl)aziridine) In an open assimilation vial equipped 
with a magnetic stir bar, starting material amine (0.18 g, 0.82 mmol) was dissolved in 1:1 
THF/water (4.1 mL), followed by the addition of KOH (0.25 g, 4.40 mmol). The vial was 
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sealed and stirred overnight at 65 °C. The reaction mixture was allowed to cool to ambient 
temperature prior to diluting with ethyl acetate (25 mL) and water (25 mL). The mixture was 
extracted with ethyl acetate (3 X 25 mL), and the combined organic was dried with 
magnesium sulfate, filtered, and concentrated under reduced pressure to provide a crude oil. 
The crude material was purified by flash column chromatography (1:1 H/E) to deliver the 
product as a pale yellow oil (0.18 g, 99%). 
 
 
((S)-3-chloro-5-(4-methoxyphenyl)pentanenitrile) To a flame dried round-bottomed flask 
equipped with a magnetic stir bar, starting material alcohol (0.19 g, 0.89 mmol), and 2,6-
lutidine (0.48 g, 4.44 mmol) was added DCM (4.4 mL) and the solution was cooled to 0 °C. 
Triflic anhydride (0.30 g, 1.07 mmol) was added to the mixture dropwise, and the solution 
was left to stir for 30 minutes. The reaction was then diluted with DCM (20 mL) and was 
washed with water (25 mL). the organic fraction was washed with brine (25 mL), dried with 
magnesium sulfate, filtered, and concentrated under reduced pressure. The crude oil was then 
dissolved in acetonitrile (4.4 mL) and 18-crown-6 (0.05 g, 0.18 mmol) followed by KCN 
(0.578 g, 8.88 mmol) was added to the mixture and it was allowed to stir at rt for 12 hours. 
The reaction was then quenched with saturated sodium bicarbonate (60 mL) and was 
extracted with DCM (3 X 50 mL). the combined organic fractions were dried with 
magnesium sulfate, filtered, and concentrated under reduced pressure. The crude oil was then 
purified by flash column chromatography (4:1 Hex/EtOAc) affording the desired product as a 
rose colored oil (0.15 g, 75%).  
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 7.11 (d, J = 8.5 Hz, 
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2H); 6.85 (d, J = 8.5 Hz, 2H); 3.97 (q, J = 6.5 Hz, 1H); 3.79 (s, 3H); 2.84 (m, 1H); 2.80 (dd, 
J1 = 5.6 Hz, J2 = 5.6 Hz, 2H); 2.72 (m, 1H); 2.12 (dd, J1 = 14 Hz, J2 = 7 Hz, 2H). 
 
 
((R)-2-(4-methoxyphenethyl)azetidine) To a flame dried microwave vial with magnetic stir 
bar was added InCl3 (0.12 g, 0.54 mmol) and NaBH4 (0.06 g, 1.63 mmol). Anhydrous THF 
(1.2 mL) was added and the heterogeneous mixture was stirred under argon for 1 hour. The 
starting material nitrile was added to that reaction mixture, and it was allowed to stir at room 
temperature for 4 hours. The reaction was then quenched by dropwise addition of water (1.5 
mL), and the reaction was stirred vigorously and heated to 75 °C for 30 minutes. KOH (0.16 
g, 2.86 mmol) was then added and the vial was sealed and submitted to microwave 
irradiation at 170 °C for 1 hour. The biphasic solution was extracted with EtOAc (3 X 10 
mL), and the combined organic was washed with brine (1 X 30 mL). The combined organic 
was dried with magnesium sulfate, filtered, and concentrated under reduced pressure. The 
crude material was purified by flash column chromatography (9.0:0.9:0.1 
DCM/MeOH/NH4OH) to afford the desired product as a light yellow oil (40 mg, 48%). 
Specific rotation [ =  -5.6⁰ (c = 1.0, CHCl3).   
121 
 
CHAPTER II 
 
DISCOVERY OF NOVEL PHOSPHOLIPASE D INHIBITORS 
 
2.1 Phospholipase D: a brief overview of its clinical relevance and chemical inhibition 
2.1.1 Introduction to phospholipase D and phosphatidic acid signaling 
Phosphatidic acid (PA) is an essential phospholipid component of cell membranes 
and accounts for 1-5% of the total lipid content in mammalian cells.1 PA can be generated de 
novo from glycerol-3-phosphate through sequential enzyme catalyzed acylations of the 
hydroxyl groups, or it can also be formed through hydrolysis of phosphatidyl choline (PC). 
PA is involved in the cell structurally as a component of different membrane lipid bilayers, 
and it is a critical lipid species involved in metabolic pathways to different signaling 
chemicals including diacylglycerol (DAG) and lysophosphatidic acid (LPA). While only a 
minor constituent of lipid bilayers, PA has a major impact on the curvature of membranes 
and is involved in important membrane fusion events facilitating endo and exocytosis.2,3 
Additionally, PA is an important second messenger involved in the recruitment and 
regulation of different proteins. Specifically, PA can act as a node in membranes to interact 
with proteins facilitating translocation of these species across the bilayer (eg. Raf-1),4,5 or 
binding of PA can directly regulate signaling proteins (eg. mTOR).6 Aberrant PA signaling, 
which would result in abnormal regulation of its protein binding partners, is proposed to have 
major roles in many types of cancer,7 neurodegenerative disorders,8 and clotting disorders.9 
Since dysregulated PA signaling is considered to have a role in these various debilitating 
diseases, controlling PA biosynthesis could have an effect on these disease states. Proteins 
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that modulate PA concentrations, therefore, are being studied to determine whether they have 
a role in aberrant PA signaling.  
 Phospholipase D (PLD) is an enzyme that catalyzes the hydrolysis of PC, which 
accounts for 40-55% of phospholipid cellular mass, to PA. Thus, PLD could be responsible 
for abnormal levels of PA that could cause irregularities in cellular signaling, which warrants 
further investigation of PLD.  PC is a glycerol with two esters and a phosphate containing a 
choline (Figure 2.1.1.1). The prevailing theory for an enzymatic mechanism of PC 
hydrolysis involves PLD facilitating choline cleavage from PC with concomitant formation 
of a histidine—phosphate bond. At this point, the substrate is activated for nucleophilic 
addition of water or a primary alcohol. This addition will occur with simultaneous cleavage 
of the newly formed histidine—phosphate bond to generate PA or a phosphatidyl alcohol 
(depending on the nucleophile).10  The catalytic pocket is involved in a proton shuttle, and 
the side chains involved in these actions are depicted in Figure 2.1.1.1.  
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While over 4,000 PLD enzymes have been reported, the homology between most of 
these PLDs is minimal. To be considered a PLD, an enzyme only needs to catalyze the 
hydrolysis of PC to PA, but a more specific PLD superfamily of enzymes share a similar set 
of residues.3 Namely, they share a conserved HxKxxxxDx6GSxN motif (commonly called 
HKD), which is consistently found within the catalytic domain. Based on that similarity, 
PLDs in this superfamily are proposed to catalyze PC hydrolysis following a similar reaction 
mechanism.11 Mammals have two prominent isoforms of PLD (PLD1 and PLD2), and they 
share close to 50% sequence homology, mainly from semi conserved HKD, PX and PH 
regions (Figure 2.1.1.2). The enzymes are around 1,000 amino acids in length, and contain 
regions of phox homology (PX) and pleckstrin homology (PH), which are hypothesized to be 
essential for trafficking PLDs to lipid bilayers. The PX domains bind polyphosphoinositides 
with high specificity and both PX and PH domains bind anionic lipids with low specificity. 
Additionally, the PH regions contain two cysteine residues and the sulfide R-group can be 
palmitoylated resulting in additional favorable interactions with the plasma membrane. 
 
 Since PLDs are major contributors to the overall PA content of the cell, their activity 
is tightly controlled by a number of molecular regulators.3 Despite the relative similarity 
between the primary sequence of PLD1 and PLD2, they have different localization patterns, 
expression levels, and regulatory mechanisms depending on the cell type. Standard 
124 
 
regulation of PLD enzymes is important because their regulation and activity is directly 
related to PA concentrations and overall signaling levels. Regarding cellular localization, 
PLD1 is concentrated at the Golgi complex, secretory granules, and endosomes while PLD2 
is largely present at the plasma membrane with smaller concentrations of PLD2 at the Golgi 
apparatus, caveolae, and endosomes.12–15 A single consistency between PLD1 and PLD2 
regulation is the need for phosphatidylinositol(4,5)biphosphate (PIP2), which is an essential 
cofactor for the catalytic activity of both enzymes.3,16 There is a large amount of evidence 
implicating phosphorylation as a means of activating and inhibiting PLD function, but data 
regarding the actual sites of phosphorylation and the kinases involved are conflicted.3,7,8  
Protein—protein interactions also play a large role in PLD activation, and while enormous 
amounts of data surround distinct proteins and their impact on the PLDs, the general 
accepted principles are that PLD1 activation requires protein kinase C (PKC) or small GTP 
binding proteins as allosteric activators while PLD2 may require small GTP binding proteins 
but is more often thought to be constitutively active.3,16 While tight regulatory mechanisms 
exist for mammalian PLDs, it is recognized that dysregulated PLD could result in abnormal 
concentrations of PA. PLD activation and atypical PA signaling have been linked to short 
term responses such as secretion and cytoskeletal rearrangement and long term cellular 
responses including proliferation, differentiation, apoptosis, and cell survival.3,16,17 These 
cellular phenotypes, and various in vivo studies have implicated aberrant PLD as a probable 
cause of many diseases. Recently, small molecule inhibitors of both PLD isoforms have 
emerged, and those tool compounds should allow PLD to be fully evaluated as a therapeutic 
target.  
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2.1.2 PLD as a therapeutic target 
Subsection A—PLD signaling and Alzheimer’s disease (AD) 
PLD is proposed to have a major role in neurophysiology based on its high expression 
levels in the brain and its role in cytoskeletal rearrangement, membrane trafficking, and 
signal transduction.18–20 The first reported evidence linking PLD to AD was discovered when 
investigating PLD activity in brain homogenates of AD patients. These studies found 
increased PLD activity compared to that of control subjects, showing the first correlation 
between PLD activity and AD.21 More recently, vast amounts of data have highlighted the 
fact that PLD activity increases when cells are in contact with Aβ, the pathogenic protein 
constituent of the amyloid β plaques that form in patients with AD.8 More evidence has 
implicated PLD as having an essential role during the trafficking of amyloid precursor 
protein (APP) throughout the cell, especially a role in budding the vesicles used to move APP 
from the Golgi to the plasma membrane. These studies, however, have been inconclusive, but 
it is clear that PLD is involved in significant crosstalk with other regulatory factors important 
in amyloidogenesis and the progression of AD.8 
 While the biochemical signaling pathways implicating PLD1 and PLD2 in AD are not 
fully understood, it is clear that the different PLD isoforms have distinct roles during the 
pathogenesis of AD. Recent in vitro and in vivo studies have validated PLD2’s impact on AD 
progression.22 The study suggests that PLD2 is involved in signal transduction downstream 
of Aβ. For in vitro analysis of PLD2, Oliveira and coworkers created a PLD2—green 
fluorescent protein (GFP) fusion protein, which allowed for PLD2 cell localization to be 
monitored by fluorescence. Since PLD2 is typically localized at the plasma membrane, cells 
treated with vehicle retained basal activity and their plasma membrane cellular localization 
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was confirmed by fluorescence microscopy. Conversely, when cells were stimulated with Aβ 
oligomers, PLD2 was observed throughout the cell, showing a regulatory role of Aβ on 
PLD2 activity. This suggests that PLD2 is active in the signal transduction pathway resulting 
in AD pathogenesis. Furthermore, they ensured that this effect was solely related to PLD2 by 
running the same study with a PLD1—GFP fusion protein resulting in no difference in 
cellular localization between vehicle and Aβ oligomer stimulation.22 
Synaptic dysfunction is an additional symptom of AD, and neurons with significant 
Aβ load show reduced synaptic plasticity compared to healthy neurons when comparing long 
term potentiation (LTP). To test PLD2’s effect on LTP, hippocampal slices were harvested 
from PLD2+/+ and PLD2-/- mice. The study showed no difference in LTP comparing slices 
from wild type mice and PLD2 knockout mice treated with vehicle, demonstrating that a lack 
of PLD2 alone should have no impact on LTP. Wild type slices, when treated with Aβ 
oligomers, resulted in LTP impairment, which is consistent with the synaptotoxic impact of 
Aβ oligomers.23–25 Conversely, LTP in PLD2 knockout slices was unaffected by Aβ oligomer 
treatment, giving LTP statistically identical to the samples that were treated with vehicle. 
This evidence validates PLD2’s impact in Aβ mediated synaptotoxicity, implying a role for 
PLD2 downstream in the signal transduction pathway from Aβ.22 
  To further validate PLD2’s role in AD progression, Oliveira and coworkers 
performed in vivo  studies with an AD mouse model. PLD2+/+, PLD2+/-, and PLD2-/- Tg2576 
transgenic mice, which contain the Swedish APP (SwAPP) mutation, were tested alongside 
PLD2+/+, PLD2+/-, and PLD2-/- wild type mice to look for impairments in memory. They 
utilized a contextual fear conditioning paradigm where mice are alerted to an aversive 
stimulus by an innocuous tone. Mice with unimpaired memory then react to the tone with a 
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freezing behavior that can be quantified. While all mice from the six separate genotypes 
showed no significant difference in the baseline testing, only one genotype (SwAPP, 
PLD2+/+) displayed little contextual fear response when tested 24 hours later, showing the 
Alzheimer’s mouse model with a full complement of Pld2 to lack the contextual learning 
ability. Conversely, the AD mouse model, when lacking Pld2, exhibited contextual learning 
statistically identical to wild type mice, suggesting PLD2 is necessary for Aβ signal 
transduction leading to learning and memory deficits.22    
 These researchers performed one additional memory test with the six genotypes of 
mice to again investigate learning and memory as they relate to PLD2 and AD.22 They used 
the radial arm water maze (RAWM) paradigm, which forces the mice to find a hidden 
platform while annotating mistakes by the mice to test spatial working memory. Again, 
SwAPP/PLD2+/+ mice performed statistically worse than all other mouse genotypes, and the 
five other genotypes were statistically non-distinguishable (Figure 2.1.2.4). It must be noted, 
once more, that the AD mouse model when lacking copies of Pld2 performed equally well 
compared to wild type mice, which indicates PLD2 must have a joint role with Aβ in AD 
progression.8,22  
Subsection B—PLD signaling and cancer 
 While the myriad cancer signaling processes are quite complex, PLD overexpression 
and increased enzymatic activity have been observed in a large number of cancer types.16,26 
On a molecular signaling level, PLD has been implicated in a number of oncogenic pathways 
that promote cell growth, proliferation, and invasiveness, and these pathways involve the 
epidermal growth factor receptor,27 matrix metalloproteinase expression,28,29 p53,30,31 
mTOR,32 and Ras.33 Essentially, PLD has been implicated in oncogenic signaling through its 
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known protein—protein interactions and additionally through PAs ligand—protein 
interactions. The signaling networks involving PLD’s contribution to tumorigenesis, 
invasion, and metastasis are expansive, but a recent provocative in vivo study involving Ras 
demonstrates PLD1 and PA’s role in cancer.34 
 To give a brief overview of Ras, it is the given name of a superfamily of proteins that 
are present in many cell types. Since Ras is a small GTPase enzyme, it canonically facilitates 
signal transduction pathways started by G-proteins. It switches between binding GDP in a 
non-productive state, and binding GTP which promotes the active form of Ras.35 While 
activated, Ras stimulates its downstream partners resulting in mitogenic signaling, provoking 
cell survival mechanisms. In healthy cells, active GTP-Ras quickly hydrolyzes to inactive 
GDP-Ras, ending the signal transduction pathways coding for proliferation and survival. 
Frequently, mutations in the ras gene cause the Ras protein to permanently adopt the 
“switched on” conformation without needing to bind GTP. This mutation can result in 
unchecked cell division leading to tumorigenesis and cancer.35 The ras oncogene is the most 
prevalent cause of all known cancers, and the mutations that permanently activate Ras cause 
20-25% of all human tumors, and this mutation is much more prevalent in other cancer 
subtypes (90% in pancreatic cancer).36 While Ras itself has proven to be a difficult drug 
target, other members of the signal transduction pathway could be targeted to potentially 
generate the same chemotherapeutic effect. For instance, Raf-1 kinase is trafficked to the 
plasma membrane during the Ras induced signal cascade, the ability of Raf-1 kinase to 
translocate to the membrane is dependent on a direct interaction between the kinase and 
PA.5,37 Therefore, one can reason that chemical inhibition of Raf-1 kinase or PLD may 
prevent that translocation event, ending the oncogenic signaling cascade. 
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 This theory was tested in vivo by Exton and coworkers in a nude mice xenograft 
model.34 In their study, they transformed Rat-2 fibroblasts with a catalytically inactive 
variant of PLD1 that was constitutively expressed (PLD1-). This gave them a line of Rat-2 
fibroblasts that they could compare in studies against cells that were wild type (PLD1+). In 
essence, PLD1+ cells would have a normal complement of the enzymes generating normal 
volumes of PA, while the modified PLD1- strain was inactive and would therefore have less 
PA. They transfected those cell lines with a mutant form of Ras (HRasV12), which was 
mutated to be permanently active leading to tumor formation. These cells were injected into 
nude mice to observe potential tumorigenesis. When cells with catalytically active PLD1 and 
mutant HRas were injected, a large tumor formed after 10 days. Essentially, the HRas 
oncogenic signaling cascade was uninterrupted in these cells, which led to proliferation and 
tumor formation. When cells with catalytically inactive PLD1 and mutant HRas were 
injected, no tumor formed in mice during the same period of time. This illustrates that either 
PLD1 or PA are involved in the HRas induced oncogenic signaling which led to 
tumorigenesis, but the two variables are indistinguishable with these experiments alone. An 
additional experiment injected cells with catalytically inactive PLD1 and mutant HRas into 
cells, which is identical to the former example that produced no tumor. However, PA was 
injected into the mouse with the cells, and that mixture restored tumorigenesis.34 These data 
demonstrate that PA formed by PLD1 was necessary for the HRas oncogenic signaling 
pathway.  
 While this striking example illustrates the importance of PLD in cellular signaling 
and cancer, the role of the two PLD isoforms is still under investigation as a therapeutic 
target. Since PLD activity and expression levels are heightened in clinical tissue samples of 
130 
 
tumors, that data further validates the need for additional research investigating the role of 
PLD activity in cancer progression. 
2.1.3 Assaying for PLD Activity 
The most direct measurement of PLD activity would be to monitor the direct 
conversion of PC to PA by PLD.  Since (i) there are multiple pathways for biosynthesis of 
PA and (ii) PA is a metabolic intermediate that can be readily converted to DAG or LPA, 
however, a direct measurement of the amount of PA cannot correlate to PLD activity (Figure 
2.1.3.1).  
 
If PLD catalyzed a reaction forming a product that was stable in vivo, that product could be 
quantified and directly related to PLD activity. Fortunately, PLD not only catalyzes the 
hydrolysis of PC to PA. Instead, it also catalyzes the transphosphatidylation reaction of PC 
with primary alcohols to generate phosphatidyl alcohols, which are stable molecular entities 
that can be quantified to determine PLD activity (Figure 2.1.3.2).  
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Additionally, most PLD enzymes in the superfamily catalyze the transphosphatidylation 
reaction 1,000-fold faster than the hydrolysis reaction, which allows the reaction to occur at 
very low, non-toxic concentrations of primary alcohol.38 This cellular PLD assay system, 
therefore, allows n-butanol to be added to the cellular mixture to participate in the 
transphosphatidylation reaction, and the product—phosphatidylbutanol (PtdBuOH)—can be 
detected by quantitative mass spectrometry. Since various alkyl side chains of PC exist, that 
gives way to a variety of PtdBuOH species that require measurement. Additionally, many of 
these PtdBuOH species are isobaric with different PAs; therefore, an additional experiment 
must be performed to accurately quantify PtdBuOH and correlate it to PLD activity. To shift 
the mass of the PtdBuOH species to an open region of the mass spectrum, deuterated n-
butanol is added to a different cellular mixture making PtdBuOH-d9, which results in a 9 
dalton shift in mass to a non-isobaric region of the mass spectrum.  
 A typical experiment to quantify PLD activity consists of four experiments and is 
depicted below (Figure 2.1.3.3).39 Experiment 1 (spectra A) contains no primary alcohol, so 
this is the control experiment resulting in no PtdBuOH. Experiment 2 (spectra B) 
corresponds to a sample where tert-butanol was added. Since PLD only catalyzes the 
transphosphatidylation reaction with primary alcohols, this experiment serves to prove that 
an alcohol is not causing a side reaction altering the mass spectral data. The spectrum for 
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experiment 2, therefore, should look very similar to experiment 1. In experiment 3 (spectra 
C), n-butanol was added to the reaction resulting in formation of PtdBuOH. The new peaks 
in the mass spectrum, therefore, should correspond to PtdBuOH species that were not present 
in experiments 1 or 2. The PtdBuOHs will overlap with some PA species, however, so this 
spectrum alone cannot be used to quantify total PtdBuOH formed. Experiment 4 (spectra D) 
will contain deuterated n-butanol, which will result in formation of PtdBuOH-d9. All 
PtdBuOH-d9 species will be shifted 9 Daltons in the mass spectrum, and can be measured 
against PtdBuOH-d9 standards to quantify the amount of PtdBuOH-d9, which can then be 
directly related to quantify PLD activity (Figure 2.1.3.3).39 
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Figure 2.1.3.3 Measuring PLD activity by quantifying PtdBuOH. Figure adapted from ref
39.  
 
2.1.4 Known Chemical Modulators of PLD 
While genetic knockout studies have provided strong proof of concept that PLD 
inhibition is a therapeutically relevant strategy, these methods do not give temporal control of 
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PLD activity, nor are genetic methods therapeutically viable options for treating disease.3,17 
Small molecule chemical inhibitors, on the other hand, provide the ability to modulate a 
biological system in a time-based manner and are readily applied to biological systems 
compared to the tedious process of generating genetically modified organisms. Prior to recent 
discoveries of influential PLD inhibitors, n-butanol was often used in studies to “inhibit” 
PLD (Figure 2.1.4.1). It is known, however, that n-butanol is not a PLD inhibitor; instead, n-
butanol is a competitive substrate taking part in the transphosphatidylation reaction forming 
PtdBuOH. While treating a system with n-butanol will serve to prevent formation of PA, 
PtdBuOH serves some of the same structural roles as PA, and directly inhibiting PLD 
catalysis is advantageous compared to this n-butanol paradigm. Prior to 2007, however, small 
molecule inhibitors of PLD were mainly indirect, very large concentrations were required to 
affect PLD, and the many of the known inhibitors lacked drug-like properties. These 
inhibitors include diethylstilbestrol, resveratrol, honokiol, presqualene diphosphate, 
raloxifene, tamoxifen, and SCH420789 (Figure 2.1.4.1).40–46 
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One common characteristic shared by all of these inhibitors is their inability to inhibit PLD 
isoforms selectively. Since PLD1 and PLD2 have differential cell localizations, regulatory 
mechanisms, and roles in diseases, selective inhibition of a single PLD isoform would allow 
for modulation of the specific isoenzyme involved in each disease state, which would likely 
result in a more direct treatment of a disease with fewer side effects.  
  In 2007, scientists from Novartis published halopemide 2.1, a compound previously 
dosed in clinical trials for neuroscience indications, to be a potent PLD inhibitor.47 Through 
standard medicinal chemistry, the group reported an additional 14 structures that had 
enhanced inhibitory activity. FIPI 2.2, their best compound with a reported PLD2 IC50 of 200 
nM, was a significant improvement compared to known PLD inhibitors, and 2.2 had good 
physiochemical properties in rats. These compounds represented the first potent PLD 
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inhibitors that could be used as in vivo tool compounds, but minimal SAR was reported in the 
initial letter (Figure 2.1.4.2).  
 
 The brief letter that reported the activity of these benzimidazolone scaffolds did not 
describe the assay methods, but they reported the compounds as PLD2 selective inhibitors. 
This caught the attention of the Brown and Lindsley groups as they knew potent and 
selective small molecule ligands would be invaluable tools to further probe PLD function. 
They were additionally encouraged by this new finding because halopemide was known to be 
involved in five separate clinical trials with over 100 patients in the 1970s and 1980s. This 
was encouraging because data from those trials showed halopemide reaching plasma 
concentrations between 100-360 ng/mL in these patients, and no adverse side effects or 
toxicities were noted.48 Since PLD was likely inhibited at these concentrations of 
halopemide, therefore, it stands to reason that PLD inhibition is a therapeutically viable and 
safe mechanism. With these data noted, the Brown and Lindsley groups launched a medicinal 
chemistry campaign to probe the structure activity relationships (SAR) of this scaffold, and 
that effort—using the cell based assay described above—led them to reclassify halopemide 
and FIPI as PLD1 and PLD2 dual inhibitors that are slightly selective for PLD1 (halopemide 
PLD1 IC50 = 21 nM, PLD2 IC50 = 300 nM; FIPI PLD1 IC50 = 1 nM, PLD2 IC50 = 44 nM).17  
 In the medicinal chemistry effort to flesh out the SAR of the benzimidazolone 
scaffold, the Brown and Lindsley labs prepared a 3 X 3 X 30 matrix library of close to 270 
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analogs. To do this, they modified the headgroup with the des-chloro benzimidazolone and a 
triazaspirone, which is isosteric to the benzimidazole. They tested diversity in the linker 
region by adding groups containing chiral methyl substituents or a spiro cyclopentyl. Lastly, 
they used a large variety of acid chlorides to add in the aryl amide region to generate 
maximal diversity (Figure 2.1.4.3). 
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Figure 2.1.4.3 Library design to generate maximal SAR. Figure adapted from ref 17.
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By preparing these analogs, they hoped to generate (i) more potent PLD inhibitors, (ii) 
selective PLD1 inhibitors, and (iii) selective PLD2 inhibitors. This large library was intended 
to sample vast quantities of chemical space by modifying the steric and electronic 
components of each region.  
 This process produced potent dual inhibitors, highly selective PLD1 inhibitors, and 
slightly selective PLD2 inhibitors.17 Specifically, benzimidazolone 2.3 is a slightly PLD1 
preferring dual inhibitor (PLD1 IC50 = 21 nM; PLD2 IC50 = 380 nM), chloro-
benzimidazolone 2.4 is a selective PLD1 inhibitor (PLD1 IC50 = 11 nM; PLD2 IC50 = 1800 
nM), and triazaspirone 2.5 is a marginally PLD2 preferring inhibitor (PLD1 IC50 = 1000 nM; 
PLD2 IC50 = 110 nM) (Figure 2.1.4.4). 
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The SAR from those compound libraries was informative when developing new molecules. 
For instance, the methyl group on the linker region always conferred enhanced PLD1 activity 
compared to the des-methyl compound. Additionally, the triazaspirone headgroup 
consistently provided compounds with a moderate PLD2 preference.17  
 In order to increase PLD1 selectivity, additional work was done with the 
benzimidazolone scaffold. By maintaining the benzimidazolone headgroup, alternating 
halogens in place of the chlorine of 2.4, changing between the ethyl linker and the chiral 
methyl linker, and modifying those scaffolds with the most potent aryl amides, compounds 
with unprecedented PLD1 selectivity and potency were generated (Figure 2.1.4.5). 2.6 was 
discovered during those efforts and is the most selective PLD1 inhibitor known.49 
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2.6 combines aspects of the SAR greatly biasing compounds toward PLD1 selectivity 
including (i) the bromo-benzimidazolone, (ii) the (S)-methyl group in the linker region, and 
(iii) the trans-cyclopropyl phenyl amide. Since a highly selective (1,700-fold) and potent 
(PLD1 IC50 = 3.7 nM) PLD1 inhibitor was now available, work in the Brown and Lindsley 
labs now turned to development of a selective PLD2 inhibitor. 
 Efforts focused on the triazaspirone scaffold since previous work resulted in 10-fold 
selective PLD2 inhibitor 2.5. Initially, they focused on varying the aryl amide while keeping 
the aniline moiety constant (Figure 2.1.4.6). This resulted in 2.7, which was only slightly 
more PLD2 selective than 2.5 from the initial medicinal chemistry efforts.17,50 However, 2.7 
only had a modest improvement in selectivity (21-fold compared to 10-fold), and the 
quinolone ring favorably increased compound solubility compared to 2.5. Instead of aryl 
amide modifications, Brown, Lindsley, and coworkers added halogens to the aniline ring in a 
similar fashion to the work that generated 1,700-fold PLD1 selective compound 2.6. This 
effort resulted in 3-fluoroaniline triazaspirone VU0364739 2.8, which was 75-fold selective 
for PLD2 with a PLD2 IC50 of 20 nM. This quite selective PLD2 inhibitor, however, is still 
relatively potent at PLD1 (IC50 = 1,500 nM). Nevertheless, it was a large improvement 
compared to previous compounds since it increased both potency and selectivity (Figure 
2.1.4.6).51  
140 
 
 
 The newly developed inhibitors were invaluable for those who studied PLD. 
Previously, chemical inhibition of a single isoenzyme was impossible, but these new 
compounds made cellular assays examining PLD’s role in various phenomena easy. In fact, 
in many of the communications regarding these newly developed inhibitors, the compounds 
were shown to be active against many cancer cell types.17,51 While the new inhibitors 
represent a large step forward for those studying PLD, substantial improvements are still 
possible regarding PLD1 selective, PLD2 selective, and dual PLD inhibitors.  
2.2 Discovery of phospholipase D inhibitors ML298 and ML299 
2.2.1 Envisioned improvements to known PLD inhibitors 
Considering the attributes of the known PLD inhibitors, we attempted to discover 
novel tool compounds with (i) enhanced PLD2 selectivity, (ii) DMPK profiles to 
complement the existing inhibitors, and (iii) reduced ancillary pharmacology compared to the 
known molecules. Examining the most useful tool compounds from previous efforts, our lab 
had discovered the 1,700-fold selective PLD1 inhibitor 2.6, a potent dual inhibitor 2.3, and 
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75-fold selective PLD2 inhibitor 2.8 (Figure 2.2.1.1). Looking at additional properties of 
PLD1 selective compound 2.6, it was not CNS penetrant and had some off target effects, 
exerting binding affinities for 7 targets in a screen of 68 common molecular targets that 
include GPCRs, ion channels, and transporters. To improve our ability to target PLD1 
selectively, compounds are needed that maintain this level of selectivity while addressing 
CNS penetrance and limit the off target liabilities of 2.6. For dual inhibition of PLD1 and 
PLD2, 2.3 is potent, peripherally restricted, and has substantial off target binding. Lastly, for 
selective PLD2 inhibition, 2.8 is potent, quite selective, and CNS penetrant. It, like the other 
two compounds, also has off target liabilities affecting 11 of the common molecular targets 
(Figure 2.2.1.1).  
 
While PLD1 selective 2.6 can still be improved upon, there are more substantial 
improvements necessary when PLD2 selective compound 2.8 is considered. While this 
molecular probe is potent (PLD2 IC50 = 20 nM) and 75-fold selective, many of the assays 
this compound has been used in require concentrations above 1,500 nM (the PLD1 IC50) to 
achieve a statistically significant effect. At those high concentrations, PLD1 may also be 
inhibited, and if this is the case the assay result cannot be linked to PLD2 alone based on 
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chemical inhibition. For instance, breast cancer cell proliferation was analyzed compared to 
vehicle, and when 75-fold selective PLD2 inhibitor 2.8 was used in the assay, a significant 
effect was seen only at 10 μM.51 Since 10 μM is almost 7-times the PLD1 IC50 of 2.8, it is 
unknown whether that significant decrease in cell growth is exclusively related to PLD2 or 
PLD1. Additionally, when an assay examining Caspase activity was performed to look at 
PLD2’s contribution to apoptosis, 10 μM concentrations of 2.8 were again necessary to elicit 
a significant effect (Figure 2.2.1.2).51 
 
2.2.2 Synthesis of 3-fluoro aniline triazaspirone scaffold  
With the limitations of 2.8 noted, it was clear that selective PLD2 inhibitors that 
elicited significant cellular effects at concentrations less than the PLD1 IC50 would greatly 
impact the field. Work began, therefore, using the triazaspirone scaffold as a starting point, 
since its chemical properties had always promoted modest PLD2 selectivity. Additionally, 
only four compounds had been synthesized and tested with the 3-fluoroaniline ring, and since 
that halogenated aniline conferred PLD2 selectivity, we thought it prudent to maintain that 
core scaffold and alternate the aryl amide to generate maximal molecular diversity. To that 
end, synthesis of the triazaspirone core began with Strecker reaction of N-benzyl 
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piperidinone 2.9 and 3-fluoroaniline to afford crude nitrile 2.10, which was hydrolyzed to the 
carboxylic amide 2.11 with concentrated sulfuric acid in a 68-74% two-step yield. Forcing 
microwave assisted conditions were required to close the spirocyclic five-membered ring 
using trimethyl orthoformate followed by sodium borohydride reduction to provide benzyl 
triazaspirone 2.12 in 12-20% yield. Hydrogenolysis allowed for benzyl cleavage furnishing 
free piperidine 2.13 in 89-96% yield. To install the ethyl linker, reductive amination with 
tert-butyl 2-oxoethylcarbamate was performed providing Boc-amine 2.14, and the Boc-group 
was successively cleaved with acid to generate free amine 2.15 in 58% yield over two-steps 
(Scheme 2.2.2.1).  
 
This synthetic route allowed for the preparation of monosubstituted amine 2.15 on a gram 
scale, which provided ample material to be used in acylations or amide couplings to generate 
large numbers of amide analogs.52 
144 
 
2.2.3 Library synthesis with 3-fluoroaniline triazaspirone 
Using monosubstituted amine 2.15 with various acid chlorides in DMF, acylation to 
amide triazaspirone resulted in various amide subtypes including alkyl amides, aryl amides, 
and methylene linked aryl amides. Generally, aryl amides were active inhibitors of PLD 
while the alkyl amides were inactive. Table 2.2.3.1 highlights the compounds that were 
involved in this screen. 
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The compounds were screened at a single-point concentration of 200 nM in cell lines 
specifically characterized for PLD1 or PLD2 expression.17 In this single-point assay, DMSO 
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is added as a negative control and a known PLD1/2 dual inhibitor is used as a positive 
control. Single-point at 200 nM is a low enough concentration to highlight any interesting 
compounds without directing us towards compounds that would ultimately be far less 
interesting than known inhibitors (Figure 2.2.3.1). From the single-point data, compounds 
2.16G, 2.16H, and 2.16V were considered interesting enough to warrant further 
characterization.  
 
Therefore, concentration response curves (CRCs) were generated from these three 
compounds, and difluoro amide 2.16G was found to be a potent and selective PLD2 inhibitor 
(PLD2 IC50 = 355 nM, >53-fold selective) with no measurable PLD1 inhibition at the upper 
end of the assay (PLD1 IC50 > 20,000 nM). This PLD2 inhibitor was later declared a 
molecular libraries probe center network (MLPCN) probe and assigned ML298.  From this 
first scan, a 3-fluoro amide 2.16H and aryl anhydride 2.16V were also PLD2 selective 
compounds but were less selective than ML298 (Figure 2.2.3.2).52 
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Compound PLD1 IC50 PLD2 IC50 Fold Selectivity
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20,000 nM 355 nM 53
22,000 nM 2,025 nM 11
5,550 nM 265 nM 21
Figure 2.2.3.2 (a) CRC of ML298. (b) PLD selectivity data from first amide
scan. Figure adapted from ref 52.
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 We were pleased to have found 3,4-difluoro compound ML298 from this first amide 
scan, which remained potent at PLD2 while almost ablating PLD1 activity. While ML298 
was not as selective as naphthyl amide 2.8 (75-fold selectivity, PLD1 IC50 = 1.5 μM), we 
reasoned the decreased PLD1 potency could give rise to a more useful PLD2 selective 
compound since ML298 does not impact PLD1 activity until concentrations over 20 μM. To 
test this hypothesis, ML298 was taken into some cancer invasive migration assays while 
medicinal chemistry efforts continued on this scaffold.  
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Since we had success discovering a PLD2 selective probe from the triazaspirone 
scaffold, we reasoned that some additional modifications that were previously done to the 
benzimidazolone scaffold may facilitate similar bioactive properties on the triazaspirone 
scaffold. Specifically, when a methyl group was added to the linker region on the 
benzimidazolone, it consistently made the compounds more potent and/or selective for PLD1 
compared to the des-methyl compound.17,50 Therefore, we envisioned adding a methyl group 
to the linker region to potentially discover PLD1/2 dual inhibitors with properties to 
complement the known dual inhibitors based on the benzimidazolone scaffold. 
 Synthetically, we were able to add the chiral methyl group through the same 
chemistry that facilitated preparation of the des-methyl compound.52 We then prepared a 
variety of aryl amides containing the methyl group, ensuring that compounds prepared with 
the chiral methyl group had a des-methyl congener with which the activity could be 
compared (Figure 2.2.3.3). 
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Single-point data was generated for this set of compounds, and the methyl group—as 
predicted—had a large effect on compound activity. The effect on PLD2 potency was 
modest, generally slightly increasing potency. The effect on PLD1 potency, however, was 
enormous (Figure 2.2.3.4).52 When considering the 3,4-difluoro, 4-bromo, and 4-fluoro 
amides, addition of the (S)-methyl group increased PLD1 potency 233-fold, 257-fold, and 
590-fold respectively. Addition of methyl substitution to biologically active scaffolds is 
commonly accompanied by enormous gains in potency, and the field has termed this 
phenomenon “the magic methyl effect.”53 Essentially, the methyl group on the 
benzimidazolone and triazaspirone is leading to conformational effects that are greatly 
increasing the binding affinity of the compounds. 2.17, the 4-bromo compound containing 
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the (S)-methyl, was declared an MLPCN probe (ML299) since it is the most potent PLD1/2 
dual inhibitor. It also has other benefits compared to the previous dual inhibitor, and those 
advantages will be discussed later. 
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2.17/ML299
PLD1 IC50 PLD2 IC50 Selectivity
6 nM 20 nM nonselective
Figure 2.2.3.4 The magic methyl effect  
 This methyl effect prompted us to question whether the enhanced bioactivity would 
be enantiospecific in nature. Specifically, if it were an (R)-methyl instead of the opposite 
configuration, would the effect be as pronounced? This led us to synthesize an additional 
library of compounds with the opposite configuration at the methyl stereocenter, followed by 
single point screening and generation of CRCs.52 Interestingly, enantiospecific activity 
existed that did not track between isoenzymes. To summarize the data, any configuration 
methyl group on the linker resulted in enhanced potency at PLD1. At PLD1, the (R)-methyl 
increased potency 14 to 20-fold whereas the (S)-methyl increased potency 232 to 590-fold. 
For PLD2, however, an (R)-methyl always resulted in decreased potency while an (S)-methyl 
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led to enhanced potency. Three congeners with this bioactivity pattern are illustrated in 
Table 2.2.3.2.52 
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2.2.4 Anticancer activity of ML298 and ML299 
 With that SAR trend outlined, we next looked at the biological activity of these 
inhibitors. Previous work in the Brown and Lindsley labs had shown PLD1 and dual PLD1/2 
inhibitors can block invasive migration of a triple negative breast cancer cell line (MDA- 
MB-231) and a U87-MG glioblastoma cell line, but siRNA studies showed PLD2 to likely be 
playing the dominant role in this phenomenon.17 Therefore, the Transwell assay was 
performed to investigate invasive migration in the presence of the two new probe compounds 
(Figure 2.2.4.1). Dual inhibitor ML299 showed a dose dependent decreasing invasion 
phenotype with statistical significance at 1 and 10 μM doses. This experiment does not 
distinguish which PLD isoform is responsible for the invasion phenotype, since the IC50 for 
both PLD1 and PLD2 inhibition is 6 and 20 nM respectively. When the assay was performed 
with PLD2 selective inhibitor ML298, however, a similar dose dependent decrease in 
invasion was observed gaining statistical significance at a 10 μM concentration.  
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Since 10 μM is close to half of the necessary 20 μM concentration ML298 needs to inhibit 
PLD1, this result suggests invasive migration to be a PLD2 controlled phenomenon.52 
Understandably, ML299 shows a larger decrease in invasion compared to ML298, but that 
could be PLD2 related since ML299’s PLD2 IC50 is roughly 17-fold lower than ML298.  
2.2.5 Physiochemical and DMPK properties 
 Now that our dual PLD1/2 inhibitor ML299 and selective PLD2 inhibitor ML298 
were validated using cellular cancer models, we intended to compare them to previous 
inhibitors regarding their DMPK. One thing all PLD probes have in common is a high 
clearance rate, and these new compounds were not an exception to that trend.49–51 While 
ML299 and ML298 possessed low but acceptable free fraction in rat and human plasma and 
acceptable CYP profiles, both compounds had rates of clearance in line with hepatic blood 
flow, rendering them impractical for oral administration.52  To circumvent first pass 
metabolism, therefore, the compounds were dosed intraperitoneally (IP). This route of 
administration provided excellent plasma levels for both ML299 and ML298 (Figure 
2.2.5.1). Additionally, IP dosing gave the compounds access to the lung, and ML299 seemed 
to deposit in that tissue. Moreover, this dosing paradigm allowed us to calculate CNS 
penetrance of our two probes, and while ML299 was observed to enter the nervous system 
and reach concentrations  24 to 80-fold higher than the compound’s IC50’s, only trace 
amounts of ML298 were detected in the CNS. Peripherally restricted probe ML298, 
therefore, is a good addition to the other PLD2 selective inhibitor 2.8, since that compound 
has good CNS penetrance.  
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The final comparison between ML299, ML298, and the previous probes involves the 
off target liabilities that each compound possesses. When ML299 and ML298 were screened 
against a panel of 68 common molecular targets including GPCRs, ion channels, and 
transporters, both were only active at 3 targets (compared to 12 and 11 targets from the 
previous dual and PLD2 selective inhibitors). To summarize, therefore, this medicinal 
chemistry campaign was focused on generating a selective PLD2 inhibitor with decreased off 
target effects and increased selectivity. By discovering ML298, we developed a compound 
that (i) had reduced ancillary pharmacology, (ii) had excellent PLD2 selectivity (no PLD1 
inhibition @ >20 μM), and (iii) was restricted to the peripheral nervous system, an attribute 
complementing the previously existing isoform selective PLD2 inhibitor (Figure 2.2.5.2). 
Additionally, we desired a dual PLD1/2 inhibitor with decreased off target effects, increased 
potency, and CNS penetration. ML299 provided us with a compound that met all of those 
criteria.52  
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2.3 Discovery of 80-fold phospholipase D inhibitor with enhanced physiochemical 
properties 
2.3.1 Plans to establish novel SAR for the triazaspirone scaffold 
The addition of ML298 and ML299 to the existing complement of PLD inhibitors 
provided compounds with valuable attributes compared to what was available; however, 
there were still notable improvements that could be made. Namely, compounds with 
improved DMPK and physiochemical properties are desirable, and we are still in search for a 
greater than 1000-fold selective PLD2 inhibitor. As many SAR of the benzimidazolone and 
triazaspirone scaffolds have already been noted throughout previous studies, there was one 
segment of the compounds that was relatively unexplored. Throughout all previous studies, 
the N-aryl portion of the triazaspirone (previously called the aniline region vide supra) was 
underexplored with only a phenyl ring substituent (sometimes containing halogens) tested for 
biological activity. Therefore, we began a medicinal chemistry campaign surrounding that N-
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aryl substitution planning to test a range of R-groups to evaluate SAR and potentially 
develop compounds with enhanced selectivity, DMPK, and physiochemical properties 
(Figure 2.3.1.1).  
 
2.3.2 Synthesis of triazaspirone advanced intermediate 
To develop SAR for the amine of the imidazolone, a novel synthetic route for 
preparation of the fully elaborated structure without amine substitution would be ideal. If 
possible, that would allow for one step library synthesis from the penultimate intermediate. 
Therefore, we considered that a minor modification to the previous route, involving a 
Strecker reaction with ammonia, would allow for preparation of this penultimate intermediate 
after some minor protecting group modifications (Scheme 2.3.2.1). Beginning with N-benzyl 
piperidinone 2.9, Strecker reaction followed by sulfuric acid hydrolysis delivered 
monosubstituted amine 2.25. Treatment of 2.25 with formamide under thermal conditions 
promoted condensation, then sodium borohydride treatment facilitated reduction to 
imidazolone 2.26 in 20-25% yield. Subsequent Boc protection of the disubstituted amine and 
benzyl cleavage under reductive conditions delivered free piperidine, which was used in a 
reductive amination with (2-oxoethyl)carbamate 2.27 to deliver bis-Boc 2.28 in 55% yield 
over three steps. Acid mediated cleavage of the Boc protecting groups and selective acylation 
of the monosubstituted amine provided penultimate intermediate 2.29 in 51% over two steps, 
which we could then use in acylations, alkylations, reductive aminations, nucleophilic 
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aromatic substitution, and Pd catalyzed N-arylation chemistry. We chose the naphthyl aryl 
amide derivative since that substituent had historically promoted the highest degree of 
potency and selectivity.51,52 
 
2.3.3 Synthesis of non N-aryl triazaspirone analogs 
With penultimate intermediate 2.29 in hand, we wanted to immediately develop SAR 
trends from this region of the molecule. Therefore, we began acylations and alkylations of 
the disubstituted amine in an attempt to understand whether amides or methylene linked 
groups would confer potency and/or selectivity. It should be noted that the amine was quite 
unreactive. We reasoned this to be an effect of its sterically hindered space. Specifically, it is 
vicinal to a spiro center, which is similar to a tert-butyl group. Additionally, it is flanked on 
the other side by a methylene. Electronically, it is in a 5-membered ring system containing an 
amide, which inductively withdrawals from the amine, lowering its HOMO and decreasing 
its nucleophilicity. Essentially, acylations and alkylations of the amine were sluggish and 
gave low yields compared to primary amines, but we were able to prepare enough of the 
desired compounds to assay them for activity. Therefore, we made a library of ten 
compounds for a single point screen prior to designing future libraries (Table 2.3.3.1). 
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 When a major modification to the scaffold is accomplished, the single point screening 
is done at a larger concentration of compound, compared to the 200 nM concentrations used 
in the single-point shown vide supra. Since no non N-aryl species had been screened for PLD 
activity before, this was considered a major scaffold change. We performed the single-point 
screen, therefore, at 20 μM to ensure that no subtle activity of these compounds was missed. 
Gratifyingly, at this concentration, we were able to see major trends from the data (Figure 
2.3.3.1). Methylene linked aryl groups appeared to be more potent than the amide variants, 
and amide linked small saturated rings appeared to be more potent compared to aryl amides. 
Additionally, the changes appeared to confer a preference for PLD2 inhibition for all but 
2.30I. 
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 This data encouraged us to design and synthesize an additional focused library of ten 
compounds focusing on methylene linked aryl groups. We wanted to flesh out additional 
SAR involving halogenation of the rings, and we hoped to add polar surface area by 
incorporating methylene linked pyridyl rings. Additionally, since the cyclopropyl amide 
looked promising from the single point data, we synthesized a methylene linked 
cyclopropane to further flesh out the SAR involving the amide (Table 2.3.3.2). 
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 These compounds were single-point screened at 20 μM. Delightfully, the SAR trend 
of PLD2 preference continued, and all but one of the compounds screened at this 
concentrations fully ablated PLD2 activity (Figure 2.3.3.2).  
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These data confirmed our suspicions that methylene linked aryl rings could confer 
PLD2 selective inhibition. Since the single-point data was generated at 20 μM, however, the 
relative potencies of these compounds were unknown. Therefore, CRCs of many of them 
were generated to develop a more thorough understanding of the SAR (Table 2.3.3.3). 
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 From the CRCs, we found that a number of trends could describe the SAR. 
Specifically, halogenation of the ring, unless in the para-position, increased potency and/or 
selectivity for PLD2 compared to the naked phenyl ring. Additionally, the methylene linked 
aryl rings had enhanced potency compared to their amide congeners. The cyclopropane and 
cyclobutane rings, whether amide or methylene linked, were potent but only ~10-fold 
selective. The most interesting SAR was seen with regioisomeric methylene linked pyridyl 
rings. Namely, the 2-pyridyl analog 2.30P was 18-fold selective for PLD2 inhibition (PLD2 
IC50 = 145 nM), 3-pyridyl analog 2.30S was >80-fold selective for PLD2 (PLD2 IC50 = 360 
nM), and 4-pyridyl analog 2.30T was 28-fold selective (PLD2 IC50 = 850 nM). We had, 
therefore, uncovered the most selective PLD2 isoform selective inhibitor known, to the best 
of our knowledge, with this 3-pyridyl benzyl amine 2.30S replacing the N-aryl substitution. 
Compared to our recently developed PLD2 selective inhibitor ML298 (PLD1 IC50 = 20,000 
nM, PLD2 IC50 = 355 nM, 53-fold selective), by changing the 3-fluoroaniline substitution to 
a 3-pyridyl benzyl amine, we retained close to identical potency at PLD2 while decreasing 
PLD1 potency 10 μM—a significant decrease.  
2.3.4 Focused library of N-pyridyl triazaspirone analogs 
 Since the new pyridyl group conferred such an exciting increase in selectivity, we 
contemplated whether the methylene linker was necessary. Essentially, we wondered if 
switching back to the N-aryl substitution with a pyridyl instead of a halogenated phenyl ring 
would confer enhanced potency or selectivity. We could synthesize those analogs through 
nucleophilic aromatic substitution or Pd-catalyzed coupling chemistry following our previous 
route; therefore, we prepared a small sampling of pyridyl rings with various substituents. We 
made two core structures with a 3-pyridyl fluoro aryl group 2.31 and a 3-pyridyl group 2.32 
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and added six of the historically most potent aryl amides to determine whether directly linked 
N-pyridyl group would confer potency and/or selectivity (Figure 2.3.4.1).  
 
Additionally, five analogs were made where the aryl amide was held constant as a naphthyl 
group while the N-aryl group was modified with different pyridyl substitutions (Figure 
2.3.4.2). 
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Figure 2.3.4.2 Analogs testing pyridyl
N-aryl derivatives  
These compounds were screened in a single-point assay at 2 μM. Since we expected them to 
be somewhat active, we assumed that 20 μM concentrations would be too high to produce 
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interpretable SAR. Unfortunately, however, none of the compounds with the direct N-pyridyl 
substitution gave rise to inhibitors showing >75% inhibition at 2 μM. Therefore, we decided 
to move forward with the methylene linked 3-pyridyl ring system that conferred 80-fold 
selectivity.  
2.3.5 Aryl amide libraries containing the 3-pyridyl benzylamine triazaspirone 
 Next, we wanted to understand whether retention of the 3-pyridyl group and analog 
synthesis of the aryl amide could result in a more potent and selective compound. 
Modification to the synthetic procedure, again, was necessary for facile library synthesis with 
formation of the aryl amide in the last step. While we initially worked on routes that would 
have provided our necessary penultimate intermediate 2.33 more directly (but ultimately 
were unsuccessful for a variety of reasons), we ultimately returned to our previous route 
using some slight procedural modifications and protecting group manipulations to obtain 
2.33 (Scheme 2.3.5.1). We began with previously disclosed intermediate 2.26, and again 
formed bis-Boc intermediate 2.28 through a Boc protection, hydrogenolysis, and reductive 
amination sequence. At this point, we needed to remove the Boc protecting groups and 
functionalize the more hindered and generally less nucleophilic amine chemoselectively over 
the primary amine to allow for easy synthesis of aryl amide analogs. While this was not 
possible directly, we decided to take advantage of the primary amine’s comparatively high 
nucleophilicity by addition of an electrophilic protecting group that the more nucleophilic 
amine would react with preferentially. Therefore, bis-Boc 2.28 was treated with acid to 
cleave the Boc groups, and the triamine was then treated with phthalic anhydride, which 
reacted with the primary amine to form phthalamide 2.34. After extensively screening 
reductive amination conditions, the reaction of 2.34 with 3-pyridine carboxaldehyde was 
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found to proceed only when neat acetic acid was used as the solvent. The product of that 
reaction was then treated with hydrazine to cleave the phthalamide and form free amine 2.33, 
our penultimate intermediate for aryl amide library synthesis. 
 
 With 2.33 in hand, we performed acylation and amide coupling chemistry on the 
monosubstituted amine to generate maximal diversity in the aryl amide region. Our first 
expansive library included mainly substituted phenyl rings to furnish a library of compounds 
with similar amides compared to what was prepared while discovering ML298 and ML299. 
Specifically, different regioisomers of fluorinated and/or chlorinated phenyl rings had 
significant impacts on the biological activity of previous PLD inhibitors; therefore, we 
synthesized many of the possible fluorinated and chlorinated ring permutations. Additionally, 
we added other substituents including a few heterocycles and a bicyclic ring that was 
previously of interest (Figure 2.3.5.1). 
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Figure 2.3.5.1 Analogs alternating aryl amides with pyridyl
benzyl amine  
These analogs were screened at 2 μM for inhibition of PLD1 and PLD2. Unfortunately, only 
two novel compounds from this library showed >50% inhibition of PLD2 at this 
concentration. Concentration response curves were generated for these compounds to obtain 
IC50 values, but the data was not superior to any of the known compounds. Fluoro-indole 
2.35A was potent (PLD2 IC50 = 120 nM), but was less selective than other equipotent 
compounds (26-fold PLD2 selective, PLD1 IC50 = 3,100 nM). Additionally, 3,4-dichloro 
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amide 2.35B was found to be 16-fold selective for PLD2 inhibition, but it lacked potency 
(PLD2 IC50 = 1,250 nM) (Figure 2.3.5.2).  
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Figure 2.3.5.2 CRCs of fluoro-indole and dichloro inhibitors  
 This substituted phenyl ring library of compounds illustrated shallow SAR involving 
the aryl amide region. This group of compounds, however, propelled us to ask whether larger 
aromatic rings would provide robust SAR that could lead to more selective and potent PLD 
inhibitors. Essentially, we noted that fluoro-indole 2.35A and naphthyl derivative 2.30S 
provided potency at PLD2, and those were the only larger ring systems tested with this 
alternative non N-aryl pyridyl group. Additionally, the chlorine atoms of the 3,4-dichloro 
compound 2.35B could be filling the spatial region of PLD enzymes that the larger ring 
systems occupy while binding PLD2, which would explain why that chlorinated variant 
showed modest PLD2 potency while other halogenated phenyl rings were largely inactive. 
To test the hypothesis that larger ring sizes of aryl amides could lead to enhanced PLD2 
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potency and/or selectivity, we generated an additional library of twenty bicyclic aryl amide 
ring systems (Table 2.3.5.1).  
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We used a single-point screen at 2 μM to evaluate these compounds’ ability to inhibit 
PLD1 and/or PLD2. While we thought the size of a ring system would impact its ability to 
bind PLD, we observed that the electronics of the ring, heteroatom positioning, and 
halogenation also had large effects on biological activity. For instance, while previously 
discussed 80-fold selective naphthyl ring containing compound 2.30S was potent and 
selective for PLD2, bromination or fluorination drastically decreased PLD potency (2.35H 
and 2.35I), nitrogen incorporation (making it a quinolone, 2.35D) almost ablated PLD 
potency, and regioisomeric quinolone rings also lacked potency (2.35S, 2.35T, and 2.35U). 
Indole containing compounds also showed this large variability in bioactivity. While 
regioisomer 2.35L appeared potent and selective based on the single-point data, regioisomer 
2.35M and indoles with additional substituents (2.35O, 2.35R, and 2.35V) lacked potency at 
PLD1 and PLD2 (Figure 2.3.5.3).  
  
The single-point data propelled us to generate CRCs for 2.35C, 2.35H, and 2.35L. 
Benzofuran 2.35C and indole 2.35L have the steric potential to adopt the same conformation, 
which explains why both were active as inhibitors. Indole 2.35L, however, was much more 
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potent and selective than benzofuran 2.35C, which only showed moderate potency at PLD2. 
Bromo-naphthyl compound 2.35H was also a modest PLD2 selective inhibitor (Figure 
2.3.5.4). 
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 To summarize the chemistry efforts using iterative parallel synthesis to develop a 
more selective PLD2 inhibitor, we began looking at the underexplored region from previous 
inhibitors, which previously was a 3-fluoroaniline. By modifying that region with various 
groups, we found a methylene linked 3-pyridyl ring that conferred unprecedented selectivity 
and similar PLD2 potency to ML298. By holding the 3-pyridyl portion constant and 
performing a large amide scan, unfortunately, we did not discover any compounds with 
enhanced selectivity compared to the initial lead 2.30S. Those modifications did allow us to 
understand the SAR of the aryl amide region on a deeper level, however, and it provided 
indole 2.35L that had similar selectivity to naphthyl 2.30S with a 7-fold boost in potency. All 
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things considered, we decided to move forward with biological characterization of 2.30S as 
an antiviral agent and also examine its DMPK and physiochemical properties.  
2.3.6 Physiochemical and DMPK properties 
 Inspecting 2.30S as a probe, its atomic mass is less than 500 daltons (443 Da), it has 
less than 5 hydrogen bond donors (2), less than 10 hydrogen bond acceptors (3), and its 
cLogP is less than 5 (2.74). Therefore, 2.30S conforms to all of Lipinski’s rules making it 
“druglike,” which means it is likely orally bioavailable. Solubility and stability in phosphate 
buffered saline (PBS) is an issue that has been problematic for previous generations of PLD 
inhibitors; however, 2.30S was found to be both soluble (95 μM with pH = 7.4 @ 23 °C) and 
stable (~100% of parent compound remaining at 48 hours @ 23 °C) in PBS. Additionally, 
2.30S displayed a favorable cytochrome P450 (CYP) profile with modest inhibition of CYP 
3A4 and CYP 2D6 (CYP3A4 IC50 = 3.9 μM; CYP2D6 IC50 = 16.4 μM; CYP1A2 IC50 > 30 
μM; CYP2C9 IC50 > 30 μM). Another important property is plasma protein binding, and 
while previous PLD inhibitors generally were only 1-5% unbound (meaning only 1-5% of 
administered drug is available for binding of the biological target), 2.30S is 26.3% unbound 
in rat and 8.8% unbound in human, which conveys a considerable advantage compared to 
previous compounds. Although all of these properties have been ideal, one apparent 
weakness of the compound is it clearance rate. In rat and human hepatic microsomes, 2.30S 
exhibited moderate-to-high intrinsic clearance (rat CLint: 82.1 mL/min/kg; human CLint: 43 
mL/min/kg) with predicted hepatic clearance rates near the respective rates of hepatic blood 
flow for each species (rat CLhep: 64.3 mL/min/kg; human CLhep: 17 mL/min/kg). Intravenous 
(IV) administration of 2.30S in Sprague Dawley rats (n = 2) revealed a brain:plasma partition 
coefficient of 1.48, demonstrating 2.30S to have excellent distribution to the CNS. Lastly, 
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2.30S has minimal ancillary pharmacology. 2.30S, like all PLD inhibitors developed by our 
laboratory, was sent through a panel of common molecular targets including GPCRs, ion 
channels, and transporters. While the previously discussed PLD2 selective compounds (2.8 
and ML298) at 10 μM gave > 75% inhibition of 12 and 3 of the common molecular targets 
respectively, 2.30S only inhibited 2 of those common molecular targets, demonstrating it to 
be a clean compound with minimal off target liabilities (Figure 2.3.6.1).  
 
2.3.7 Antiviral activity of novel PLD inhibitors 
Recently, the Brown, Lindsley, and Thomas Labs have implicated PLD2 in viral 
infection and proliferation. PLD2 selective inhibitor 2.8 and PLD2 RNA interference have 
delayed viral entry and reduced viral titers in vitro. Additionally, treatment of infected mice 
with 2.8 led to reduced viral titer, increased survival, and significant increases in 
transcription of innate antiviral effectors. Unfortunately, however, higher concentrations of 
2.8 were cytotoxic to the cells in vitro, and concentrations far exceeding the PLD1 IC50 of 2.8 
were used in both the in vitro and in vivo studies. Since that was the case, the antiviral results 
from chemical inhibition cannot be conclusively tied to the sole inhibition of PLD2. With the 
novel 80-fold selective inhibitor 2.30S in hand, we were anxious to evaluate its antiviral activity.  
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 Initially, 2.30S was evaluated alongside 75-fold selective inhibitor 2.8 to examine 
cytotoxicity with both inhibitors. In the assay, cells were treated with different concentrations 
of compound or vehicle ranging from 1 nM to 50 μM. The cells were allowed to grow for 24 
hours, and then the number of dead cells was counted (Figure 2.3.7.1). Cells treated with 2.8 
showed a slight increase in cytotoxicity at 10 μM, but that was followed by an enormous 
increase at 20 μM and an additionally large increase at 50 μM. Inhibitor 2.30S, conversely, is 
indistinguishable from cells treated with DMSO or with growth media only. Using 2.30S in 
vitro and in vivo, therefore, offers a considerable advantage when compared to the 
pronounced cytotoxicity of 2.8.  
 
 To examine the antiviral effect of 2.8 versus 2.30S, a standard TCID50 assay was used 
to assess viral reproduction in vitro. A549 cells were treated with 10 μM concentrations of 
either DMSO, 2.8, or 2.30S, and the cells were infected with 0.01 multiplicity of infection 
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(MOI) with four distinct strains of influenza (A/California/04/2009 (H1N1), 
A/Brisbane/10/2007 (H3N2), rg-A/Vietnam/1203/2004 (H5N1), and A/Anhui/01/2013 
(H7N9)). After 24 hours of treatment with the viruses, the viral supernatant is removed and 
titrated on MDCK cells to measure viral replication, and change in viral titer can be 
correlated to antiviral activity. Across all four viral strains, both 2.8 and 2.30S significantly 
lowered viral replication (Figure 2.3.7.2).  
Figure 2.3.7.2 Effect of 2.8 (10 M) and 2.30S (10 M) on viral replication and titer.
DMSO 2.8 2.30S 2.8 2.30SDMSO
DMSO 2.8 2.30S 2.8 2.30SDMSO
 
In these viral proliferation assays, the improved physiochemical properties of 2.30S 
translated into comparable potency to 2.8, despite a ~20-fold reduction in PLD2 potency. 
Notably, the antiviral activity of 2.30S can be explicitly tied to PLD2 inhibition since 10 μM 
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concentrations were used and 2.30S does not inhibit PLD1 until ~30 μM. Conversely, when 
2.8 is used in this assay at 10 μM, it inhibits both PLD isoforms so the antiviral effect cannot 
be linked to either PLD isoform. Importantly, both PLD inhibitors displayed pan-anti-
influenza activity across seasonal influenza (H1N1), low pathogenicity influenza (H3N2), 
highly pathogenic avian influenza (H5N1), and recently emergent influenza with pandemic 
potential (H7N9). Since Tamiflu has no efficacy against H7N9, PLD inhibition could 
represent an exciting new mechanism to combat pathogenic influenza. 
 In summary, we developed 2.30S, a potent (PLD2 IC50 = 360 nM) and selective (80-
fold selective, PLD1 IC50 > 30,000 nM) PLD2 inhibitor. Compared to previous generations 
of PLD inhibitors, compound 2.30S has unprecedented selectivity, improved physiochemical 
properties, no cytotoxicity to cells, high CNS penetration, and a favorable DMPK profile that 
will be improved once the metabolic soft spots are addressed. In developing this molecule, 
we addressed portions of the triazaspirone scaffold that had never been altered, and in doing 
so we charted SAR that could be useful in future efforts. 2.30S was used in cell-based 
antiviral assays and was found to inhibit infection and viral replication of not only H1N1 and 
H3N2, but also the highly virulent bacterial strains H5N1 and H7N9. Medicinal chemistry 
efforts to address the metabolic liabilities of this compound are underway to develop a 
compound that could be delivered orally, and results of those studies will be reported in due 
course. 
2.4 PLD inhibitors: overview of our efforts and future directions 
2.4.1 PLD inhibitors prior to my efforts 
Prior to the Brown and Lindsley efforts toward the discovery of novel isoform 
selective PLD inhibitors, genetic knock outs, siRNA, and adding n-butanol as a competitive 
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substrate were the only means of modulating PLD activity and phosphatidic acid levels. 
Since genetic knock outs are extremely labor intensive, siRNA cannot be used effectively on 
an organismal level, and n-butanol is not a relevant in vivo strategy, small molecule inhibitors 
provide a considerable benefit to the field allowing more effective and facile modulation of 
these biological systems. After halopemide 2.1 was discovered to inhibit PLD1 and PLD2, 
efforts in our labs facilitated the discovery of potent and isoform selective inhibitors (2.6 and 
2.8). These compounds provided the ability to modulate in vitro systems and methodically 
evaluate each isoenzyme in different cellular phenotypes. In many assay systems, however, 
the most selective inhibitors still required compound concentrations that should affect both 
PLD1 and PLD2. Any effect in these assays, therefore, could not be directly attributed to 
selective inhibition of either isoenzyme. The major goal of my research, as I began this 
project, was to develop inhibitors of PLD2 that could provide statistically significant effects 
in assays at concentrations below the PLD1 IC50. Additionally, the known PLD inhibitors 
had other limitations. Specifically, (a) their in vivo DMPK profiles were suboptimal and (b) 
they had ancillary pharmacology profiles where significant off target activity was noted.  
2.4.2 Novel PLD inhibitors and their advantages 
In an attempt to increase selectivity of the PLD2 inhibitors, three major regions were 
modified iteratively to annotate the impact on biological activity. Initially, the amide region 
was varied with substituted aryl compounds, and this effort resulted in the discovery of 
ML298. This compound was less selective than 2.8 in the cellular reporter assay, but ML298 
had considerably decreased potency at PLD1 compared to 2.8. Additionally, when ML298 
was used in a cancer cell invasive migration assay, it was shown to decrease that phenotype 
when used at 10 μM concentrations, which allows the invasive migration phenotype to be 
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directly linked to PLD2 inhibition. Compared to 2.8, therefore, ML298 can sometimes be 
advantageous when used in vitro if the effort is intended to probe the effect of single PLD 
isoform inhibition on a specific phenotype. Additionally, ML298 complements 2.8’s DMPK 
profile. Both compounds have very similar low free fraction and high clearance rates, but IV 
or IP dosing allow the compounds to circulate in therapeutically relevant concentrations. 
Considering CNS penetration, 2.8 and ML298 are CNS penetrant and peripherally restricted, 
respectively, which provides complementary tools if in vivo dosing was required. Moreover, 
ML298 has fewer off target effects when compared to 2.8. In the ancillary pharmacology 
screen, ML298 only bound three common molecular targets at 10 μM compared to 2.8 
binding eleven of those same molecular targets.51,52 
After varying the amide region of the triazaspirone scaffold, the linker region was 
modified with addition of an (R) or (S) methyl group. After surveying some of the most 
selective and potent PLD2 scaffolds with these methyl group modifications, we found that 
methylation of these scaffolds had an enormous impact on the biological activity. Essentially, 
an (S)-methyl increased PLD1 potency 200 to 590-fold depending on the substrate while an 
(R)-methyl also increased PLD1 potency, but to a lesser extent. These modifications provided 
ML299, our most potent PLD dual inhibitor. ML299 has an attractive in vivo profile with IP 
dosing, which showed the compound to get into the lungs, plasma, and central nervous 
system in concentrations far exceeding its IC50. Additionally, ML299 was selective and only 
bound three of the common molecular targets that were screened for ancillary pharmacology. 
After fully evaluating ML299, it is our most potent PLD1/2 inhibitor with acceptable DMPK 
properties and decreased ancillary pharmacology when compared to previous dual PLD 
inhibitors.52 
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In an effort to discover more selective PLD2 inhibitors, the N-aryl region of the 
compound was next modified with an assortment of substituents. This led to the discovery of 
2.30S, which is the most selective PLD2 inhibitor known. The pyridyl group, which took the 
place of the 3-fluorophenyl group, adds extra polarity to the compound, and that change 
resulted in enhanced solubility. Upon analysis of the physiochemical and DMPK properties 
of 2.30S, the added solubility seems to have had an effect on other compound characteristics. 
Namely, compared to previous PLD inhibitors, 2.30S gained a sizeable increase in free 
fraction, had excellent CNS penetrance (B:P = 1.48), and had less ancillary pharmacology 
than any previous PLD inhibitor. Its only blemish was a high rate of hepatic clearance, which 
can likely be addressed by modification of the piperidine ring to halt the major metabolic 
pathway. Additionally, this compound provides a large concentration window before PLD1 
is inhibited (PLD1 IC50 = 30 μM), and 2.30S and 2.8 were used at 10 μM concentrations in 
vitro to determine their ability to decrease viral proliferation. Importantly, both compounds 
decreased viral proliferation, but 2.30S’s effect could be directly linked to PLD2 inhibition 
while 2.8 would be inhibiting both PLD1 and PLD2 at 10 μM concentrations. 2.30S offers a 
considerable advantage, therefore, while attempting to relate the activity of PLD1 and PLD2 
to viral proliferation.54 
2.4.3 Future studies to evaluate PLD 
While the PLD inhibitors recently discovered provide the field with considerable 
advantages while studying PLD, large discoveries are required to provide the field with a 
better platform to evaluate PLD inhibitors and a better understanding of the mechanism of 
inhibition. Moving forward to study PLD and develop novel inhibitors with enhanced 
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potency and selectivity, various discoveries will facilitate more rapid discovery on an 
assortment of fronts.  
In probe discovery—or drug discovery—organic synthesis can often be the slowest 
step to evaluate structure activity relationships of various compound classes. With PLD, 
however, the speed at which compounds can be biologically characterized limits the 
discovery efforts. One place that would enhance probe or drug discovery efforts, therefore, is 
development of an assay to decrease the labor necessary to evaluate compound libraries. 
While the current methods are effective,39 I frequently wondered if we could be missing 
valuable SAR by not biologically evaluating enough of the compounds past a single-point 
screen. To make a high-throughput PLD screening paradigm, I have pondered methods to 
make the assay produce a reporter such as fluorescence or absorbance that can be measured 
using a plate reader. To do this, one potential option would be to link a PA signal cascade to 
the production of a reporter that could be quantified at the assay end-point. This will be 
difficult to develop since PA is a fleeting intermediate in the cell, but it may be possible if the 
cell line was extensively characterized. If completed, this assay could boost PLD medicinal 
chemistry efforts and allow vast SAR to be charted in record times. 
An additional complication for those studying PLD is the inability to purify large 
quantities of the enzymes. Because a protocol is lacking for expression of large quantities of 
PLD1 or PLD2, this decreases our abilities for in vitro characterization of our compounds in 
a cell-free environment. Moreover, without large quantities of PLD, efforts to solve the 
structure of PLD—through crystallography—are deterred. To improve the understanding of 
the PLD structure, and how that structure relates to our inhibition efforts, protocols for 
purification of larger quantities of PLD are necessary. Once larger quantities of the PLD 
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isoforms can be purified, solving the structure of PLD can explain how our inhibitors exert 
their effects. This effort is paramount to developing more selective and potent PLD 
inhibitors. That structure could explain where our compounds are binding, which will 
improve efforts to design potent and selective probes in the future. 
While the former two goals are long term and will enhance any effort to study PLD, 
short term goals to evaluate PLD and validate its importance in different disease states are 
also necessary. The most recent PLD2 selective probe compound (2.30S) looks like it could 
be effective as an in vivo probe after its metabolic hotspot is addressed. The recent data 
linking PLD2 to AD are provocative,22 and the Brown and Lindsley labs are uniquely poised 
to evaluate this using chemical inhibition instead of genetic knock out studies. A congener of 
2.30S with decreased clearance may be orally bioavailable, and this compound—and the 
result of this study—could increase interest in PLD as a therapeutic target in CNS disorders.  
An additional short term goal would be to evaluate the added methyl group’s effect 
on potency.52 As data is available for many congeners with the des-methyl, (S)-methyl, and 
(R)-methyl, in silico evaluation of each compound’s low energy conformation coupled to the 
known potency data could provide insight into what is causing the conformational effect. 
After studying the modeling, there could likely be a way to modify the compounds into a 
more rigid conformation, which could bias them toward the conformation the modeling 
predicted. To rigidify the compounds, enantioselective cyclopropanation reactions could lock 
the linker region into a more defined conformational arrangement, and the methylene of the 
cyclopropane would serve to provide similar lipophilicity to that region as the initial methyl 
group. These experiments would be designed to provide a better explanation of the 
conformational effects that the methyl group is inducing. 
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Experimental for the discovery of PLD2 selective and PLD1/2 dual inhibitors ML298 
and ML299 
All reagents were purchased from Sigma-Aldrich Corp., TCI America, Rieke Metals, Inc. 
and were used without purification. Analytical thin-layer chromatography (TLC) was 
performed on 250 µm silica plates from Sorbent Technologies.  Visualization was 
accomplished via UV light, and/or the use of ninhydrin, iodine, and potassium permanganate 
solutions followed by application of heat.  Chromatography was performed using Silica Gel 
60 (230-400 mesh) from Sorbent Technologies or Silica RediSep Rf flash columns on a 
CombiFlash Rf automated flash chromatography system.  All 1H and 13C NMR spectra were 
recorded on a Bruker AV-400 (400 MHz) instrument.  Chemical shifts are reported in ppm 
relative to residual solvent peaks as an internal standard set to δ 7.26 and δ 77.16 (CDCl3).  
Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, 
q = quartet, p = pentet, br = broad, dd = doublet of doublets, dq = doublet of quartets, td = 
triplet of doublets, pd = pentet of doublets, m = multiplet), coupling constat (Hz), integration. 
Low resolution mass spectra (LCMS) were recorded on an Agilent 1200 LCMS with 
electrospray ionization.  High resolution mass spectra (HRMS) were recorded on a Waters 
Qtof-API-US plus Acuity system with ES as the ion source. Analytical high performance 
liquid chromatography (HPLC) was performed on an Agilent 1200 analytical LCMS with 
UV detection at 214 nm and 254 nm along with ELSD detection.  Chiral separations were 
performed on a Thar Investigator II supercritical fluid chromatograph (SFC) utilizing 
Chiralcel® OD, OD-Cl, OJ, and Chiralpak® IA columns. Optical rotations were acquired on a 
Jasco P-2000 polarimeter at 23 ⁰C and 589 nm.  The specific rotations were calculated 
188 
 
according to the equation [α]23/D = 100α/l x c where l is the path length in decimeters and c 
is the concentration in g/100 mL.   
 
 
1-(3-fluorophenyl)-1,3,8-triazaspiro[4.5]decan-4-one (2.13). To a solution of 1-
benzylpiperidin-4-one 2.9 (13.25 g, 70 mmol) in glacial acetic acid (70 mL) and water (12 
mL) cooled to 0 °C was added 3-fluoroaniline (8.55 g, 77 mmol) and potassium cyanide 
(4.55 g, 70 mmol). The reaction was allowed to warm to room temperature and agitated for 
approximately 12 hours. The reaction was then cooled to 0 °C and ammonium hydroxide (18 
M) was added dropwise until the solution pH was 11 or greater. The mixture was then 
extracted into dichloromethane and dried under reduced pressure to yield the crude product 
as a tan oil (20.5 g). The crude product was then immediately cooled to 0 °C and 
concentrated sulfuric acid (18 M, 120 mL) was added dropwise with vigorous stirring. The 
reaction was allowed to warm to room temperature and agitated for approximately 12 hours. 
The reaction was then cooled to 0 °C and ammonium hydroxide (18 M) was added dropwise 
until the solution pH was 11 or greater. The mixture was then extracted into dichloromethane 
and dried under reduced pressure to afford a tan solid (15.78 g, 48.25 mmol, 68%). 1H NMR 
(400.1 MHz, CDCl3) δ (ppm): 7.51 - 7.37 (m, 7H), 6.67 - 6.47 (m, 4H), 4.27 (s, 1H), 3.64 (s, 
2H), 2.95 - 2.87 (m, 2H), 2.53 - 2.44 (m, 2H), 2.29 - 2.21 (m, 2H), 2.07 (d, J = 13 Hz, 2H); 
13C NMR (100.6 MHz, CDCl3) δ (ppm): 178.0, 162.6, 145.7, 138.3, 130.5, 129.1 (2C), 
128.4 (2C), 127.2, 111.8, 106.1, 103.1, 63.1, 58.5, 48.7 (2C), 34.8, 31.5; HRMS (TOF, ESI) 
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C19H23N3OF [M+H]+ calculated 328.1825, found 328.1827; LC-MS: rt (min) = 1.855; 
LRMS (ESI) m/z = 328.2. 1-Benzyl-4-((3-fluorophenyl)amino)piperidine-4-carboxamide 
(15.78 g, 48.25 mmol), trimethyl orthoformate (80 mL), and glacial acetic acid (40 mL) were 
combined and subjected to microwave irradiation at 150 °C for 15 minutes. The mixture was 
adjusted to pH 12 with ammonium hydroxide (18 M) and extracted into dichloromethane and 
dried under reduced pressure. This material was then added to a suspension of sodium 
borohydride (4.56 g, 120.6 mmol) in methanol (150 mL) and stirred for about 3 hours. The 
reaction was quenched with water, extracted into dichloromethane, and dried under reduced 
pressure. The material was then chromatographed on a 330 g flash column (Teledyne) as 
follows: (1) a gradient from 0-80% ethyl acetated in hexanes over 10 minutes was run, and 
on the same column (2) a gradient from 0-10 % methanol in dichloromethane was run. The 
purity of the isolated intermediate was established via LCMS, rt (min) 1.723; LRMS (ESI) 
m/z = 340.1. This intermediate (1.94 g) was immediately dissolved in methanol (40 mL) and 
glacial acetic acid (10 mL), and treated with palladium on carbon (cat., 80 mg) under an 
atmosphere of hydrogen. After about 36 hours the reaction mixture was filtered through 
celite, concentrated under reduced pressure, diluted with water, made alkaline with saturated 
sodium bicarbonate and extracted 8 times into dichloromethane to afford 2.13 as a white 
solid (1.37 g, 5.49 mmol, 11 %). 1H NMR (400.1 MHz, DMSO-d6) δ (ppm): 8.67 (s, 1H), 
7.20 (q, J = 8 Hz, 1H), 6.73 (d, J = 8 Hz, 1H), 6.62 (d, J = 13 Hz, 1H), 6.52 - 6.46 (m, 1H), 
4.57 (s, 2H), 3.20 - 3.09 (m, 3H), 2.91 - 2.82 (m, 2H), 2.46 - 2.36 (m, 2H), 1.48 (d, J = 14 
Hz, 2H); 13C NMR (100.6 MHz, DMSO-d6) δ (ppm): 176.0, 164.3, 145.0, 130.1, 109.3, 
103.1, 100.2, 58.8, 58.6, 42.1 (2C), 28.9 (2C); HRMS (TOF, ESI) C13H17N3OF [M+H]+ 
calculated 250.1356, found 250.1351; LC-MS: rt (min) = 1.394; LRMS (ESI) m/z = 250.1. 
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tert-Butyl-(2-3-fluorophenyl)-4-oxo-1,3,8-triazasprio[4.5]decan-8-yl)ethyl)carbamate 
(2.14). 1-(3-fluorophenyl)-1,3,8-triazaspiro[4.5]decan-4-one 2.13 (1370 mg, 5.49 mmol) and 
tert-butyl (2-oxoethyl)carbamate (961 mg, 6.03 mmol) were combined and dissolved in 
dichloromethane (25 mL) and methanol (10 mL) and stirred for about 30 minutes at room 
temperature. After about 30 minutes macroporous triacetoxyborohydride (3 g, 7.26 mmol) 
was added to the reaction and after 14 hours an additional amount of tert-butyl (2-
oxoethyl)carbamate (200 mg, 1.25 mmol) was added to drive the reaction to completion. 
After about 24 hours the reaction mixture was filtered through celite and concentrated under 
reduced pressure. The crude compound was chromatographed on an 80 g flash column 
eluting in a gradient of 0-10 % methanol in dichloromethane to afford 2.14 as a white solid 
(1.64 g, 4.18 mmol, 76 %). 1H NMR (400.1 MHz, DMSO-d6) δ (ppm): 8.69 (s, 1H), 7.22 (q, 
J = 8 Hz, 1H), 6.72 - 6.63 (m, 2H), 6.60 - 6.49 (m, 2H), 4.58 (s, 2H), 2.83 - 2.75 (m, 2H), 
2.74 - 2.65 (m, 2H), 2.61 - 2.48 (m, 2H), 2.42 - 2.35 (m, 2H), 1.91 (s, 2H), 1.55 (d, J = 13 
Hz, 2H), 1.39 (s, 9H); 13C NMR (100.6 MHz, DMSO-d6) δ (ppm): 175.8, 161.9, 155.6, 
145.0, 130.4, 109.4, 103.2, 100.3, 77.5, 58.7, 58.1, 57.4, 49.3 (2C), 37.6, 28.3 (3C), 28.1 
(2C); HRMS (TOF, ESI) C20H30N4O3F [M+H]+ calculated 393.2302, found 393.2301; LC-
MS: rt (min) = 1.966; LRMS (ESI) m/z = 393.2. 
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That starting material (1 eq.)  was dissolved in DCM (0.1 M) and a solution of HCl in 
Dioxane (4 M, 30 eq.) was added to the mixture. It was allowed to stir until consumption of 
starting material was determined by LC-MS.  The crude mixture was then concentrated in 
vacuo, and was then redissolved in DMF (0.1 M). Triethylamine (5 eq.) followed by acid 
chloride (1.5 eq.) were added to this stirred mixture and the reaction was quenched in less 
than ~10 minutes, determined by consumption of starting material seen via LC-MS. The 
reaction was quenched with water/brine and was extracted 3X with ethyl acetate.  The 
organic extract was concentrated and the product was purified via reverse phase HPLC 
eluting with MeCN/H2O/TFA to afford the product as a white solid trifluoroacetic acid salt 
(50-80%). 
 
 
1H NMR (400.1 MHz, MeOD (D4)) δ (ppm): 7.86-7.79 (m, 1H); 7.77-7.72 (m, 1H); 7.43-
7.35 (m, 1H); 7.25 (q, J = 7.5 Hz, 1H); 6.76 (dd, J1 = 11.4 Hz, J2 = 2.2 Hz, 1H); 6.67 (dt, J1 = 
12.4 Hz, J2 = 2.3 Hz, 1H); 6.58 (td, J1 = 8.3 Hz, J2 = 1.5 Hz, 1H); 4.74 (s, 2H); 3.95-3.86 (m, 
2H); 3.83-3.72 (m, 4H); 3.44 (t, J = 5.9 Hz, 2H); 2.97 (td, J1 = 13.6 Hz, J2 = 3.8 Hz, 2H); 
2.05 (d, J = 15.2 Hz, 2H). 13C NMR (100.6 MHz, MeOD (D4)) δ (ppm): 176.9, 168.9, 165.3 
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(d, J = 243 Hz), 154.0 (dd, J1 = 253 Hz, J2 = 13 Hz), 151.4 (dd, J1 = 248 Hz, J2 = 13 Hz), 
145.8 (d, J = 11 Hz), 132.1-131.9 (m), 131.8 (d, J = 10 Hz), 125.7 (dd, J1 = 7 Hz, J2 = 4 Hz), 
118.6 (d, J = 18 Hz), 118.1 (d, J = 18 Hz), 111.8, 106.6 (d, J = 22 Hz), 103.0 (d, J = 28 Hz), 
60.6, 58.5, 58.0, 51.0, 36.4, 28.1. HRMS (TOF, ES+) C22H24N4O2F3 [M+H]+ calc. mass 
433.1851, found 433.1849.   
 
 
1H NMR (400.1 MHz, MeOD (D4)) δ (ppm): 7.81 (d, J = 8.5 Hz, 2H); 7.67 (d, J = 8.6 Hz, 
2H); 7.27 (q, J = 7.4 Hz, 1H); 6.76 (dd, J1 = 8.4 Hz, J2 = 2.1 Hz, 1H); 6.69 (dt, J1 = 12.3 Hz, 
J2 = 2.3 Hz, 1H); 6.59 (td, J1 = 8.3 Hz, J2 = 1.6 Hz, 1H); 4.47 (s, 2H); 3.96-3.86 (m, 2H); 
3.84-3.72 (m, 4H); 3.44 (t, J = 5.8 Hz, 2H); 2.96 (td, J1 = 14.9 Hz, J2 = 3.8 Hz, 2H); 2.07 (d, 
15.1 Hz, 2H). 13C NMR (100.6 MHz, MeOD (D4)) δ (ppm): 176.9, 170.4, 165.3 (d, J = 243 
Hz), 145.8 (d, J = 10 Hz), 133.6, 132.9, 131.8 (d, J = 10 Hz), 130.4, 127.8, 111.9, 106.7 (d, J 
= 22 Hz), 102.1 (d, J = 27 Hz), 60.6, 58.5, 58.2, 51.1, 36.5, 28.2. HRMS (TOF, ES+) 
C23H27N4O2BrF [M+H]+ calc. mass 475.1145, found 474.1142.   
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1H NMR (400.1 MHz, MeOD (D4)) δ (ppm): 7.99-7.93 (m, 2H); 7.30-7.18 (m, 3H); 6.77 (dd, 
J1 = 8.3 Hz, J2 = 2.3 Hz, 1H); 6.68 (dt, J1 = 12.4 Hz, J2 = 2.3 Hz, 1H); 6.58 (td, J1 = 8.3 Hz, 
J2 = 1.5 Hz, 1H); 4.74 (s, 2H); 3.95-3.85 (m, 2H); 3.84-3.72 (m, 4H); 3.44 (t, J = 5.8 Hz, 
2H); 2.98 (td, J1 = 14.8 Hz, J2 = 3.7 Hz, 2H); 2.06, (d, J = 15.2 Hz, 2H). 13C NMR (100.6 
MHz, MeOD (D4)) δ (ppm): 176.9, 170.2, 166.6 (d, J = 252 Hz), 165.3 (d, J = 243 Hz), 
145.8 (d, J = 11 Hz), 131.8 (d, J = 10 Hz), 131.2 (d, J = 9 Hz), 130.9 (d, J = 3 Hz), 116.5 (d, 
J = 22 Hz), 111.8, 106.6 (d, J = 22 Hz), 103.0 (d, J = 27 Hz), 60.6, 58.5, 58.2, 51.0, 36.4, 
28.1. HRMS (TOF, ES+) C23H27N4O2BrF [M+H]+ calc. mass 415.1946, found 415.1943.   
 
 
The starting material (1 eq.)  was dissolved in DCM (0.1 M) and a solution of HCl in 
Dioxane (4 M, 30 eq.) was added to the mixture. It was allowed to stir until consumption of 
starting material was determined by LC-MS.  The crude mixture was then concentrated in 
vacuo, and was then redissolved in DMF (0.1 M). Triethylamine (5 eq.) followed by acid 
chloride (1.5 eq.) were added to this stirred mixture and the reaction was quenched in less 
than 30 minutes, determined by consumption of starting material seen via LC-MS. The 
reaction was quenched with water/brine and was extracted 3X with ethyl acetate.  The 
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organic extract was concentrated and the product was purified via reverse phase HPLC 
eluting with MeCN/H2O/TFA to afford the product as a white solid trifluoroacetic acid salt 
(50-80%). 
 
N
F
HN
O
N
NH
O F
F
(S)-3,4-difluoro-N-(1-(1-(3-fluorophenyl)-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)propan-2-yl)benzamide
2.18
 
1H NMR (400.1 MHz, MeOD (D4)) δ (ppm): 7.92-7.83 (m, 1H); 7.81-7.76 (m, 1H); 7.39 (q, 
J = 7.6 Hz, 1H); 7.25 (d, J = 7.2 Hz, 1H); 6.75 (d, J1 = 8.4 Hz, 1H); 6.68 (d, J1 = 12.3 Hz, 
1H); 6.62-6.53 (m, 1H); 4.73 (s, 2H); 4.68-4.58 (m, 1H); 4.05-3.78 (m, 3H); 3.65-3.51 (m, 
1H); 3.45-3.32 (m, 2H); 3.04-2.85 (m, 2H); 2.04 (dd, J1 = 24.6 Hz, J2 = 16.4 Hz, 2H); 1.38 
(d, J = 6.8 Hz, 3H). 13C NMR (125 MHz, MeOD (D4)) δ (ppm): 176.9, 168.7, 165.3 (d, J = 
242 Hz), 154.1 (dd, J1 = 253 Hz, J2 = 13 Hz), 151.4 (dd, J1 = 248 Hz, J2 = 13 Hz), 145.8 (d, J 
= 10 Hz), 132.1, 131.8 (d, J = 10 Hz), 125.9 (dd, J1 = 7 Hz, J2 = 3 Hz), 118.5 (d, J = 18 Hz), 
118.3 (d, J = 21 Hz), 112.0, 106.8 (d, J = 22 Hz), 103.2 (d, J = 26 Hz), 63.8, 60.6, 58.6, 52.3, 
50.4, 43.6, 28.2, 18.7. HRMS (TOF, ES+) C23H27N4O2BrF [M+H]+ calc. mass 447.2008, 
found 447.2009.  Specific rotation [ߙሿ ଶଷ஽  = +26 (c = 0.5, MeOH). 
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1H NMR (400.1 MHz, MeOD (D4)) δ (ppm): 7.92-7.83 (m, 1H); 7.81-7.76 (m, 1H); 7.44-
7.36 (m, 1H); 7.25 (q, J = 7.2 Hz, 1H); 6.75 (dd, J1 = 8.4 Hz, J2 = 2.3 Hz, 1H); 6.68 (dt, J1 = 
12.3 Hz, J2 = 2.3 Hz, 1H); 6.59 (td, J1 = 8.2 Hz, J2 = 2.0 Hz, 1H); 4.73 (s, 2H); 4.68-4.58 (m, 
1H); 3.99-3.78 (m, 3H); 3.58-3.50 (m, 1H); 3.41-3.32 (m, 2H); 2.98-2.85 (m, 2H); 2.04 (dd, 
J1 = 24.6 Hz, J2 = 16.4 Hz, 2H); 1.38 (d, J = 6.8 Hz, 3H). 13C NMR (125 MHz, MeOD (D4)) 
δ (ppm): 176.9, 168.7, 165.3 (d, J = 242 Hz), 163.1 (d, J = 34 Hz), 154.1 (dd, J1 = 253 Hz, J2 
= 13 Hz), 151.4 (dd, J1 = 248 Hz, J2 = 13 Hz), 145.8 (d, J = 10 Hz), 132.1, 131.8 (d, J = 10 
Hz), 125.9 (dd, J1 = 7 Hz, J2 = 3 Hz), 118.4 (t, J = 20 Hz), 112.0, 106.8 (d, J = 22 Hz), 103.2 
(d, J = 26 Hz), 63.8, 60.6, 58.6, 52.3, 50.4, 43.6, 28.2, 18.7. HRMS (TOF, ES+) 
C23H27N4O2BrF [M+H]+ calc. mass 447.2008, found 447.2009.  Specific rotation [ߙሿ ଶଷ஽  = -34 
(c = 0.5, MeOH). 
 
 
1H NMR (400.1 MHz, MeOD (D4)) δ (ppm): 7.84 (d, J = 8.6 Hz, 2H); 7.67 (d, J = 8.7 Hz, 
2H); 7.25 (q, J = 7.1 Hz, 1H); 6.76 (dd, J1 = 8.4 Hz, J2 = 2.3 Hz, 1H); 6.68 (dt, J1 = 12.4 Hz, 
J2 = 2.3 Hz, 1H); 6.59 (td, J1 = 8.3 Hz, J2 = 2.0 Hz, 1H); 4.73 (s, 2H); 4.68-4.59 (m, 1H); 
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4.01-3.83 (m, 3H); 3.60-3.52 (m, 1H); 3.44-3.33 (m, 2H); 3.00-2.86 (m, 2H); 2.04 (dd, J1 = 
24.3 Hz, J2 = 15.6 Hz, 2H); 1.38 (d, J = 6.9 Hz, 3H). 13C NMR (125 MHz, MeOD (D4)) δ 
(ppm): 176.9, 170.2, 165.25 (d, J = 242 Hz), 145.7 (d, J = 10 Hz), 133.8, 132.8, 131.8 (d, J = 
10 Hz), 130.6, 127.7, 112.0, 106.8 (d, J = 22 Hz), 103.2 (d, J = 26 Hz), 63.9, 60.6, 58.5, 52.3, 
50.5, 43.7, 28.2, 18.7. HRMS (TOF, ES+) C23H27N4O2BrF [M+H]+ calc. mass 489.1301, 
found 489.1299.  Specific rotation [ߙሿ ଶଷ஽  = +36 (c = 0.5, MeOH). 
 
 
1H NMR (400.1 MHz, MeOD (D4)) δ (ppm): 7.84 (d, J = 8.6 Hz, 2H); 7.67 (d, J = 8.7 Hz, 
2H); 7.25 (q, J = 7.1 Hz, 1H); 6.76 (dd, J1 = 8.4 Hz, J2 = 2.3 Hz, 1H); 6.68 (dt, J1 = 12.4 Hz, 
J2 = 2.3 Hz, 1H); 6.59 (td, J1 = 8.3 Hz, J2 = 2.0 Hz, 1H); 4.73 (s, 2H); 4.68-4.59 (m, 1H); 
4.01-3.83 (m, 3H); 3.54 (dd, J1 = 12.1 Hz, J2 = 3.8 Hz, 1H); 3.44-3.33 (m, 2H); 3.00-2.86 (m, 
2H); 2.04 (dd, J1 = 24.3 Hz, J2 = 15.6 Hz, 2H); 1.38 (d, J = 6.9 Hz, 3H). 13C NMR (125 MHz, 
MeOD (D4)) δ (ppm): 176.9, 170.2, 165.25 (d, J = 242 Hz), 145.7 (d, J = 10 Hz), 133.8, 
132.8, 131.8 (d, J = 10 Hz), 130.6, 127.7, 112.0, 106.8 (d, J = 22 Hz), 103.2 (d, J = 26 Hz), 
63.9, 60.6, 58.5, 52.3, 50.5, 43.7, 28.2, 18.7. HRMS (TOF, ES+) C23H27N4O2BrF [M+H]+ 
calc. mass 489.1301, found 489.1302.  Specific rotation [ߙሿ ଶଷ஽  = -52 (c = 0.5, MeOH). 
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1H NMR (400.1 MHz, MeOD (D4)) δ (ppm): 8.11-7.92 (m, 2H); 7.32-7.14 (m, 3H); 6.76 (d, 
8.2 Hz, 1H); 6.69 (d, J = 12.3 Hz, 1H); 6.59 (t, J = 7.5 Hz, 1H); 4.73 (s, 2H); 4.69-4.57 (m, 
1H); 4.04-3.81 (m, 3H); 3.56 (d, J = 9.9 Hz, 1H); 3.45-3.32 (m, 2H); 3.03-2.85 (m, 2H); 2.05 
(dd, J1 = 26.3 Hz, J2 = 14.9 Hz, 2H); 1.38 (d, J = 6.6 Hz, 3H). 13C NMR (125 MHz, MeOD 
(D4)) δ (ppm): 176.9, 170.2, 166.6 (d, J = 251 Hz), 165.3 (d, J = 242 Hz), 145.8 (d, J = 10 
Hz), 131.8 (d, J = 10 Hz), 131.4 (d, J = 9 Hz), 131.0, 116.4 (d, J = 23 Hz), 112.01, 106.7 (d, 
J = 22 Hz), 103.2 (d, J = 26 Hz), 64.0, 60.6, 58.5, 52.3, 50.5, 43.7, 28.2, 18.7. HRMS (TOF, 
ES+) C23H27N4O2BrF [M+H]+ calc. mass 429.2102, found 429.2099.  Specific rotation [ߙሿ ଶଷ஽  
= +37 (c = 0.5, MeOH). 
 
 
1H NMR (400.1 MHz, MeOD (D4)) δ (ppm): 8.026-7.96 (m, 2H); 7.29-7.19 (m, 3H); 6.75 
(dd, J1 = 8.4 Hz, J2 = 2.3 Hz, 1H); 6.69 (dt, J1 = 12.3 Hz, J2 = 2.4 Hz, 1H); 6.59 (td, J1 = 8.3 
Hz, J2 = 2.2 Hz, 1H); 4.73 (s, 2H); 4.68-4.58 (m, 1H); 3.96-3.78 (m, 3H); 3.58-3.47 (m, 1H); 
3.39-3.32 (m, 2H); 2.98-2.86 (m, 2H); 2.03 (dd, J1 = 24.7 Hz, J2 = 15.4 Hz, 2H); 1.38 (d, J = 
6.8 Hz, 3H). 13C NMR (125 MHz, MeOD (D4)) δ (ppm): 176.9, 170.2, 166.6 (d, J = 251 Hz), 
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165.3 (d, J = 242 Hz), 145.8 (d, J = 10 Hz), 131.8 (d, J = 10 Hz), 131.4 (d, J = 9 Hz), 131.0, 
116.4 (d, J = 23 Hz), 112.01, 106.7 (d, J = 22 Hz), 103.2 (d, J = 26 Hz), 64.0, 60.6, 58.5, 
52.3, 50.5, 43.7, 28.2, 18.7. HRMS (TOF, ES+) C23H27N4O2BrF [M+H]+ calc. mass 
429.2102, found 429.2103.  Specific rotation [ߙሿ ଶଷ஽  = -47 (c = 0.5, MeOH). 
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Experimental for discovery of 80-fold selective phospholipase D2 inhibitor with 
enhanced physiochemical properties and antiviral activity 
All reagents were purchased from Sigma-Aldrich Corp., TCI America, Rieke Metals, Inc. 
and were used without purification. Analytical thin-layer chromatography (TLC) was 
performed on 250 µm silica plates from Sorbent Technologies.  Visualization was 
accomplished via UV light, and/or the use of ninhydrin, iodine, and potassium permanganate 
solutions followed by application of heat.  Chromatography was performed using Silica Gel 
60 (230-400 mesh) from Sorbent Technologies or Silica RediSep Rf flash columns on a 
CombiFlash Rf automated flash chromatography system.  All 1H and 13C NMR spectra were 
recorded on a Bruker AV-400 (400 MHz) instrument.  Chemical shifts are reported in ppm 
relative to residual solvent peaks as an internal standard set to δ 7.26 and δ 77.16 (CDCl3).  
Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, 
q = quartet, p = pentet, br = broad, dd = doublet of doublets, dq = doublet of quartets, td = 
triplet of doublets, pd = pentet of doublets, m = multiplet), coupling constat (Hz), integration. 
Low resolution mass spectra (LCMS) were recorded on an Agilent 1200 LCMS with 
electrospray ionization.  High resolution mass spectra (HRMS) were recorded on a Waters 
Qtof-API-US plus Acuity system with ES as the ion source. Analytical high performance 
liquid chromatography (HPLC) was performed on an Agilent 1200 analytical LCMS with 
UV detection at 214 nm and 254 nm along with ELSD detection.  Chiral separations were 
performed on a Thar Investigator II supercritical fluid chromatograph (SFC) utilizing 
Chiralcel® OD, OD-Cl, OJ, and Chiralpak® IA columns. Optical rotations were acquired on a 
Jasco P-2000 polarimeter at 23 ⁰C and 589 nm.  The specific rotations were calculated 
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according to the equation [α]23/D = 100α/l x c where l is the path length in decimeters and c 
is the concentration in g/100 mL.   
 
 
(a) To an oven dried round-bottomed flask equipped with a magnetic stir bar under argon 
was added triazaspirone 2.26 starting material (1.00 g, 4.08 mmol, 1.00 eq.), diisopropyl 
ethyl amine (2.63 g, 3.55 mL, 20.38 mmol, 5.00 eq.), 4-dimethylaminopyridine (0.25 g, 2.04 
mmol, 0.50 eq.), and those contents were dissolved in THF (41 mL). Di-tert-butyl 
dicarbonate (0.98 g, 4.48 mmol, 1.10 eq) was added, as a liquid, to the mixture at room 
temperature, and the reaction was stirred for 1.5 hours at room temperature. The solvent was 
then removed under reduced pressure, and the residual material was dissolved in diethyl ether 
(150 mL). That organic layer was washed with saturated brine (2 X 100 mL), dried with 
magnesium sulfate, filtered, and concentrated under reduced pressure to provide 1.487 g of 
crude 2.36 that was used in the next reaction without further purification. 
 
 
(b) Crude 2.36 (1.49 g), in a round-bottomed flask equipped with a magnetic stir bar, from 
the previous reaction was dissolved in methanol (82 mL), and 10% palladium on carbon 
(0.22 g, 0.20 mmol, 0.05 eq) was added to the solution under argon. The reaction was purged 
with hydrogen gas and was stirred under a hydrogen atmosphere for 15 hours. The reaction 
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was filtered through a celite pad to remove the palladium on carbon, and the filtrate was 
concentrated under reduced pressure to provide 1.10 g of crude 2.37, which was used in the 
next reaction without further purification.  
 
 
(c) Crude 2.37 (1.10 g), in a flame dried round-bottomed flask equipped with a magnetic stir 
bar, from the previous reaction was dissolved in DMF (8.2 mL). Potassium carbonate (2.82 
g, 20.39 mmol, 5.00 eq) followed by tert-butyl (2-bromoethyl) carbamate (1.325 g, 4.91 
mmol, 1.45 eq) were added to the reaction mixture at room temperature and it was stirred for 
22 hours. The reaction was then partitioned between with ether (50 mL) and water (50 mL). 
The reaction mass was extracted with ether (3 X 50 mL), the combined organic was dried 
with magnesium sulfate, filtered, and concentrated under reduced pressure. The crude 
material was purified using flash column chromatography (0-20% methanol (w/ 10% 
NH4OH) in ethyl acetate, stain with KMnO4) to yield 1.01 g (62% over 3 steps) of the 
desired product 2.28. 1H NMR (400.1 MHz, MeOD) δ (ppm): 4.58 (s, 2H); 3.20 (t, J = 6.7 
Hz, 2H); 2.83 (dt, J1 = 11.8 Hz, J2 = 3.6 Hz, 2H); 2.50 (t, J = 6.8 Hz, 2H); 2.39 (td, J1 = 12.0 
Hz, J2 = 2.2 Hz, 2H); 1.91 (td, J1 = 13.7 Hz, J2 = 4.2 Hz, 2H); 1.65 (d, J = 13.1 Hz, 2H); 1.52 
(s, 9H); 1.44 (s, 9H). 13C NMR (100.6 MHz, MeOD) δ (ppm): 178.67, 158.39, 150.64, 84.45, 
80.06, 62.41, 61.57, 58.73, 49.92, 38.44, 31.66, 28.75, 28.19. HRMS (TOF, ES+) 
C19H35N4O5 [M+H]+ calc. mass 399.2607, found 399.2605. 
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(d) To a solution of starting material 2.28 (0.94 g, 2.36 mmol, 1.00 eq) in dichloromethane 
(24 mL) was added 4 M HCl in dioxane (17.7 mL, 70.84 mmol, 30.00 eq), at room 
temperature all at once. The reaction was stirred for 18 hours at room temperature at which 
point the reaction was concentrated under reduced pressure to afford the tris-HCl salt 2.38 
(0.726 g, quantitative yield). The product 2.38 was used in the next reaction without further 
purification. 
 
 
(e) The crude starting material 2.38 (0.726 g, 2.36 mmol, 1.00 eq) from the previous reaction, 
phthalic anhydride (0.524 g, 3.54 mmol, 1.50 eq), and diisopropyl ethyl amine (1.52 g, 2.06 
mL, 11.80 mmol, 5.00 eq) were added to a microwave vial and dissolved in DMF (11.8 mL). 
The reaction was heated in a microwave reactor at 120 ˚C for 20 minutes. The crude mixture 
in DMF was injected onto a reverse phase HPLC (5-20% acetonitrile in water (0.1% 
trifluoroacetic acid)) for purification monitoring product elution at 221 nm to provide the bis 
trifluoroacetic acid salt 2.34 (956 mg, 73%). 1H NMR (400.1 MHz, MeOD) δ (ppm): 7.93-
7.88 (m, 2H); 7.87-7.81 (m, 2H); 4.57 (s, 2H); 4.13 (t, J = 5.89 Hz, 2H); 3.90-3.41 (m, 6H); 
2.50-2.04 (m, 4H). 13C NMR (100.6 MHz, MeOD) δ (ppm): 168.35, 160.26, 134.20, 131.88, 
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123.03, 57.17, 54.72, 48.38, 31.97, 27.70. HRMS (TOF, ES+) C17H21N4O3 [M+H]+ calc. 
mass 329.1614, found 326.1617. 
 
 
(f) A mixture of starting material 2.34 (0.37 g, 0.66 mmol, 1.00 eq) and 3-pyridine 
carboxaldehyde (0.36 g, 3.32 mmol, 5.00 eq) were stirred in glacial acetic acid (3.3 mL) for 
20 minutes. Sodium triacetoxy borohydride (0.703 g, 3.32 mmol, 5.00 eq) was added to the 
mixture, and it was left to stir at room temperature for an additional 30 minutes. The acetic 
acid was then removed via vacuum distillation, and the dry reaction mass was resuspended in 
methanol (10 mL) and concentrated under reduced pressure to remove boron byproducts as 
trimethyl borate. The crude material was then purified via flash column chromatography (10-
20% methanol in ethyl acetate) to afford the product 2.39 (0.254 g, 91%). 1H NMR (400.1 
MHz, MeOD) δ (ppm): 8.56-8.37 (m, 2H); 7.89-7.76 (m, 5H); 7.40 (dd, J1 = 7.8 Hz, J2 = 4.9 
Hz, 1H); 3.98-3.91 (m, 4H); 3.79 (s, 2H); 3.30-3.23 (m, 2H); 3.17 (td, J1 = 11.7 Hz, J2 = 2.9 
Hz, 2H); 3.02 (t, J = 6.2 Hz, 2H); 2.10- 2.00 (m, 2H); 1.95-1.87 (m, 2H). 13C NMR (100.6 
MHz, MeOD) δ (ppm): 179.37, 169.69, 150.06, 149.05, 138.41, 136.06, 135.27, 133.48, 
125.23, 124.15, 62.24, 60.14, 56.20, 50.30, 48.72, 35.09, 28.90. HRMS (TOF, ES+) 
C23H26N5O3 [M+H]+ calc. mass 420.2036, found 420.2034. 
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HN
N
N
O
N
O
O
N
g
HN
N
N
O
NH2
N
2.39 2.33
 
(g) To a mixture of starting material 2.39 (0.471 g, 1.12 mmol, 1.00 eq) in acetonitrile (9.4 
mL) was added hydrazine (0.360 g, 11.23 mmol, 10.00 eq). The reaction was stirred for 15 
hours before the acetonitrile was removed under reduced pressure. The solid material was 
redissolved in methanol and was passed through a cation exchange cartridge. The product 
2.33 was eluted from the column with 2 M NH4OH in methanol, and the filtrate was 
concentrated under reduced pressure to afford the product 2.33 as a crude solid (0.322 g, 
99%) that was used without further purification. 
 
HN
N
N
O H
N
N O
2.30S
HN
N
N
O
NH2
N
h
2.33
 
(h) Crude starting material 2.33 (0.12 g) and diisopropyl ethyl amine (0.266 g, 0.364 mL, 
2.06 mmol, 5.00 eq), in a flame dried round-bottomed flask equipped with a magnetic stir 
bar, were dissolved in DMF (4.1 mL). To that flask was added naphthoyl chloride (0.10 g, 
0.49 mmol, 1.20 eq), and the reaction was stirred for 30 minutes. The crude mixture was 
injected onto a reverse phase HPLC (5-80% acetonitrile in water (0.1% NH4OH)) for 
purification monitoring product elution at 215 nm to provide the solid product 2.30S (137 
mg, 75%). 1H NMR (400.1 MHz, MeOD) δ (ppm): 8.53-8.36 (m, 3H); 8.01-7.72 (m, 6H); 
7.56-7.47 (m, 2H); 7.34 (dd, J1 = 7.7 Hz, J2 = 4.9 Hz, 1H); 3.88 (s, 2H); 3.72 (s, 2H); 3.61 (t, 
J = 6.8 Hz, 2H); 3.35 (s, 1H); 2.92-2.79 (m, 4H); 2.69 (t, J = 6.8 Hz, 2H); 1.89 (td, J1 = 13.5 
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Hz, J2 = 5.0 Hz, 2H); 1.82-1.73 (m, 2H). 13C NMR (100.6 MHz, MeOD) δ (ppm): 179.96, 
169.99, 150.08, 149.00, 138.37, 136.23, 136.14, 133.96, 132.81, 129.97, 129.29, 128.79, 
128.77, 128.74, 127.81, 125.19, 124.87, 62.19, 60.88, 58.03, 50.48, 48.85, 38.34, 29.66. 
HRMS (TOF, ES+) C26H30N5O2 [M+H]+ calc. mass 444.2400, found 444.2402. 
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